The effect of colonic propionate and the acetate : propionate ratio on risk markers for cardiovascular disease in westernised African men by De Wet, Martie
  
 
 
 
By  
MARTIE DE WET 
B.Sc Dietetics (UFS) 
M.Sc Dietetics (UFS) 
 
Thesis submitted in fulfillment of the requirements for the Degree 
 
DOCTOR TECHNOLOGIAE: BIOMEDICAL TECHNOLOGY 
In the 
School of Health Technology 
Faculty of Health and Environmental Sciences 
at the 
CENTRAL UNIVERSITY OF TECHNOLOGY, FREE STATE 
BLOEMFONTEIN 
 
Promotor:    Prof FJ Veldman  
Co-Promotor: Prof Corinna Walsh 
Co-Promotor: Dr Marina Brand 
 
BLOEMFONTEIN 
October 2009 
 
THE EFFECT OF COLONIC PROPIONATE AND THE 
ACETATE:PROPIONATE RATIO ON RISK MARKERS FOR 
CARDIOVASCULAR DISEASE IN WESTERNISED 
AFRICAN MEN  
i 
TABLE OF CONTENTS PAGES 
 
 
DECLARATION OF INDEPENDENT WORK xii 
ACKNOWLEDGEMENTS xiii 
LIST OF FIGURES xv 
LIST OF TABLES xvi 
LIST OF ABBREVIATIONS xviii 
LIST OF APPENDICES xxi 
SUMMARY xxii 
OPSOMMING xxvi 
 
 
CHAPTER 1 1 
INTRODUCTION 1 
1.1 BACKGROUND 1 
1.2 MOTIVATION 5 
1.3 HYPOTHESIS 6 
1.4 AIM AND OBJECTIVES 7 
1.4.1 AIM 7 
1.4.2 Objectives                7 
 
1.5 STRUCTURE OF THE THESIS 8 
CHAPTER 2 9 
LITERATURE REVIEW 9 
2.1 INTRODUCTION 9 
2.2 TERMS AND DEFINITIONS 12 
2.2.1 Atherosclerosis 13 
ii 
 
2.2.2 Thrombosis 13 
2.2.3 Coronary Heart Disease 13 
2.2.4 Stroke 13 
2.2.5 Myocardial Infarction (MI) 14 
2.2.6 Cerebrovascular Disease (CVD) 14 
2.2.7 Dietary fibre 14 
2.2.8 CHD Risk Factor versus CHD Risk Marker 15 
2.2.9 Urbanisation 15 
2.2.10 Westernisation 15 
2.2.11 Metabolic Syndrome 16 
2.3 METABOLIC RISK MARKERS FOR ATHEROSCLEROSIS 
AND THROMBOSIS 16 
2.3.1 Introduction 16 
2.3.2 Haemostatic Risk Markers 17 
2.3.2.1 Plasma Fibrinogen 18 
Urbanisation and Diet as risk factor for raised plasma 
fibrinogen levels 19 
2.3.2.2 Fibrin Network Formation  and Architecture 20 
Urbanisation and Diet as risk factor for altering fibrin 
network structure 25 
2.3.2.3 Factor VII-activity 26 
Urbanisation and Diet as Risk Factor for raised Factor 
VII-activity  27 
2.3.2.4 Factor VIII 28 
iii 
 
Urbanisation and Diet as Risk Factor for raised Factor 
VIII-activity 29 
2.3.2.5 Plasminogen activator inhibitor (PAI-1) 30 
Urbanisation and Diet as Risk Factor for raised PAI-1 
activity  31 
2.3.2.6 Blood Platelets 31 
Urbanisation and Diet as Risk Factor for raised Blood 
Platelet levels 32 
2.3.3 Blood Lipids 33 
Urbanisation and Diet as Risk Factor for abnormal Blood 
Lipid Profiles 35 
2.3.4 Possible Relationship between Haemostatic and Other 
Risk Markers 38 
2.3.5 Other cardiovascular risk factors 40 
2.4 DIETARY FIBRE 41 
2.4.1 Introduction 41 
2.4.2 Classification, chemistry and sources of dietary fibre 42 
2.4.3 Production of Short-Chain Fatty Acids 43 
2.4.4 Absorption and functions of SCFAs 46 
2.4.5 SCFAs Metabolism 47 
2.4.5.1 Acetate metabolism 48 
2.4.5.2 Butyrate metabolism 49 
2.4.5.3 Propionate  metabolism 50 
2.4.6 Biological Effects of SCFAs 50 
2.4.6.1 Acetate 51 
iv 
 
2.4.6.2 Propionate 52 
2.4.6.3 Butyrate 53 
2.5 SUMMARY 54 
CHAPTER 3 56 
METHODOLOGY 56 
3.1 INTRODUCTION 56 
3.2 STUDY DESIGN 56 
3.3 SUBJECT SELECTION 59 
3.4 ETHICAL CONSIDERATION 59 
3.5 OPERATIONAL DEFINITIONS 60 
3.5.1 GENERAL HEALTH PROFILES 60 
3.5.1.1 Anthropometric measurements 60 
3.5.1.2 Blood Pressure 61 
3.5.1.3 Biochemical parameters 61 
3.5.2 Lipid profiles 63 
3.5.2.1 Serum total cholesterol (TC) 63 
3.5.2.2 Serum Low-Density Lipoprotein Cholesterol (LDL-C) 63 
3.5.2.3 Serum High Density Lipoprotein Cholesterol (HDL-C) 64 
3.5.2.4 Serum Triglycerides 64 
3.5.3 Haemostatic profiles 65 
3.5.3.1 Plasma fibrinogen 65 
3.5.3.2 Factor VII and VIII activity 65 
3.5.3.3 Antithrombin III (AT III) 65 
3.5.3.4 Fibrin monomer and D-Dimer 66 
3.5.3.5 Fibrin network architecture 66 
v 
 
3.5.3.6 C-reactive protein 66 
3.5.4 Glycometabolic indicators 67 
3.5.4.1 Fasting Serum Glucose 67 
3.5.4.2 Fasting Serum Insulin 67 
3.6 MATERIALS 68 
3.6.1 Study population 68 
3.6.2 Sample size 69 
3.6.3 Supplements 69 
3.6.4 Specimen collection 71 
3.6.5 Apparatus 71 
3.6.6 Standards and controls 72 
3.6.7 Reagents and consumables 72 
3.7 METHODS AND TECHNIQUES 73 
3.7.1 Metabolic risk markers 73 
3.7.1.1  Specimen preparation 73 
3.7.1.2 Fibrin network architecture variables 73 
3.7.1.2.1 Network fibrin content 74 
3.7.1.2.2 Mass-length ratio from turbidity (µT) 75 
3.7.1.2.3 Fibrin network compaction 75 
3.7.1.2.4 Fibrin network lysis rate 76 
3.7.1.3 Coagulation factor determinations 77 
3.7.1.4 Blood Chemistry analyses 77 
3.7.1.5 Full blood counts and C–reactive protein 
measurements 78 
3.7.2 Anthropometric Measurements 78 
vi 
 
3.7.3 Blood Pressure 79 
3.7.4 Questionnaires 80 
3.7.4.1 Screening questionnaire 80 
3.7.4.2 Food Frequency Questionnaire (FFQ) 81 
3.7.4.3 Tolerance questionnaire 82 
3.8 FIELDWORKERS AND STANDARDISATION OF 
TECHNIQUES 82 
3.8.1 Pilot Study 83 
3.8.2 Fieldworkers 83 
3.9 VALIDITY AND RELIABILITY OF MEASUREMENTS 84 
3.9.1 Anthropometric measurements 84 
3.9.1.1 Validity 85 
3.9.1.2 Reliability 85 
3.9.2 Questionnaires 85 
3.9.2.1 Validity 86 
3.9.2.2 Reliability 86 
3.10 MANAGEMENT OF THE STUDY AND ROLE OF THE 
RESEARCHER 87 
3.11 STATISTICAL ANALYSES 90 
CHAPTER 4 92 
RESULTS 92 
4.1 INTRODUCTION 92 
4.2 BASELINE RESULTS OF THE ENTIRE STUDY GROUP 93 
4.2.1 Demographic characteristics of the study group as a 
whole 93 
vii 
 
4.2.2 Dietary intake of the entire study group 93 
4.2.3 General health profiles of the entire study group for 
both baseline 1 and 2 (Table 4.1) 95 
4.2.4 Haemostatic profiles of the entire study group for both 
baseline 1 and 2 (Table 4.2) 97 
4.2.5 Lipid profiles of the entire study group for both 
baseline 1 and 2 (Day 0 and 8) 98 
4.2.6 Glycometabolic profiles of the entire study group for 
both baseline 1 and 2 (Day 0 and 8) 99 
4.3 RESULTS OF THE INTERVENTION STUDY 100 
4.3.1 The Placebo Supplement Study Group Results 101 
4.3.1.1 Changes in the general health profiles within the 
placebo supplement study group 101 
4.3.1.2 Changes in the haemostatic profiles within the 
placebo supplement study group 102 
4.3.1.3 Changes in the lipid profiles within the placebo 
supplement study group 104 
4.3.1.4 Changes in the glycometabolic profiles within the 
placebo supplement study group 105 
4.3.2 The Acetate-Propionate (50%/50%) Supplement Study 
Group Results 106 
4.3.2.1 Changes in the general health profiles within the 
acetate-propionate supplement study group 106 
4.3.2.2 Changes in the haemostatic profiles within the 
acetate-propionate supplement study group 107 
viii 
 
4.3.2.3 Changes in the lipid profiles within the acetate-
propionate supplement group 109 
4.3.2.4 Changes in the glycometabolic profiles within the 
acetate-propionate supplement group 110 
4.3.3 The High Acetate Supplement Group Results 110 
4.3.3.1 Mean changes in the general health indicators of the 
high acetate supplement study group 111 
4.3.3.2 Changes in the haemostatic profiles within the high 
acetate supplement study group 112 
4.3.3.3 Changes in the lipid profiles within the high acetate 
supplement group 114 
4.3.3.4 Mean changes in the glycometabolic profiles within 
the high acetate supplement group 114 
4.4 COLLECTIVE SUMMARY 115 
CHAPTER 5 116 
DISCUSSION 116 
5.1 INTRODUCTION 116 
5.2 BASELINE RESULTS OF THE ENTIRE STUDY GROUP 117 
5.2.1 Baseline general health indicators of the entire study 
group 117 
5.2.2       Dietary intake of the entire study group           117 
 
5.2.3 Anthropometric measurements of the entire study 
group 120 
5.2.4 Haemostatic profile of the entire study group at 
baseline 120 
ix 
 
5.2.5 Baseline lipid variables of the entire study group 123 
5.2.6 Glycometabolic indicators of the entire study group 125 
5.3 INTERVENTION STUDY 126 
5.3.1 The Placebo Supplement Study group 126 
5.3.1.1 Anthropometric and general health changes of the 
placebo supplement study group 126 
5.3.1.2 The haemostatic profiles of the placebo supplement 
study group 127 
5.3.1.3 The lipid profiles of the placebo supplement study 
group 127 
5.3.1.4 The glycometabolic indicators of the placebo 
supplement study group 127 
5.3.2 The Acetate/Propionate (50/50) Supplement Group 128 
5.3.2.1 Changes in anthropometric and general health 
indicators of the acetate-propionate (50/50) 
supplement study group 128 
5.3.2.2 The haemostatic profiles of the acetate-propionate 
(50/50) supplement study group 128 
5.3.2.3 The lipid profiles of the acetate-propionate (50/50) 
supplement study group 129 
5.3.2.4 The glycometabolic indicators of the acetate-
propionate (50/50) supplement group 130 
5.3.3 The High Acetate Supplement Study Group Results 131 
 
5.3.3.1 Haemostatic profiles of the high acetate supplement study 
group                            131 
x 
 
5.3.3.2 Haemostatic profiles of the high acetate supplement 
study group 131 
5.3.3.3 Lipid profiles of the high acetate supplement study 
group 133 
5.3.3.4 Glycometabolic profiles of the high acetate 
supplement study group 134 
5.4 COLLECTIVE DISCUSSION 135 
5.5 LIMITATIONS OF THE STUDY 142 
 
CHAPTER 6 143 
CONCLUSION 143 
6.1 INTRODUCTION 143 
6.2 BASELINE CHARACTERISTICS OF THE ENTIRE STUDY 
GROUP 144 
6.3 INTERVENTION STUDY 145 
6.3.1 The Placebo Supplement Study group 145 
6.3.2 The Acetate-Propionate (50/50) Supplement Study 
Group 146 
6.3.3 The High Acetate Supplement Study Group 146 
6.3.4 Conclusion 147 
6.4 RECOMMENDATIONS 148 
6.4.1 General recommendations 148 
6.4.2 Further research 149 
REFERENCES 152 
  
 
xi 
 
 
Appendix A  Information leaflet and consent form    
Appendix B Recruitment Questionnaire  
Appendix C Food Frequency Questionnaire  
Appendix D Questionnaire for subjects who completed the study (Tolerance 
Questionnaire) 
 
 
xii 
 
DECLARATION OF INDEPENDENT WORK 
 
 
I, MARTIE MARGARETHA DE WET, identity number and 
student number, 20044941, do hereby declare that this research project 
submitted to the Central University of Technology, Free State for the degree 
DOCTOR TECHNOLOGIAE: BIOMEDICAL TECHNOLOGY is my own 
independent work and complies with the Code of Academic Integrity, as well 
as other relevant policies, procedures and regulations of the Central 
University of Technology, Free State; and has not been submitted before to 
any institution by me or any other person in fulfilment of the requirements for 
the attainment of any like or other qualification. 
 
 
 
 
 
 
_______________________________                               _____________ 
SIGNATURE OF STUDENT                DATE 
 
 
 
 
 
xiii 
 
ACKNOWLEDGEMENTS 
 
I would like to express my gratitude and sincere appreciation to the following 
individuals and organisations for their valued assistance, support and 
contributions to the successful completion of this study: 
 
 My supervisor, Prof Derick Veldman‘s expert guidance, assistance, 
encouragement, patience and support during the execution of this study.  
Thank you for sacrificing your time; 
 My co-promoter, Prof Corina Walsh:  Department Nutrition and Dietetics, 
University of the Free State, for your professional contribution, valuable 
input, guidance and encouragement; 
 Dr Marina Brand, School of Health Technology, Central University of 
Technology, Free State, for your support, guidance and assistance, 
especially with the administrative duties; 
 My family. Huge thanks to my husband, Eli for his endless patience, 
encouragement and support. You kept me focused.  My three precious 
girls- Kate, Karla and Donna, thank you for your willingness to sacrifice our 
precious time together; 
 Henry Gleimius, Francis Mogongoa and Anette van Onselen, for their 
partnership in the execution of this project;  
 NESTEC LTD PTY., Lausanne, for funding the project, as well as for the 
special production of supplement material; 
xiv 
 
 The School of Health Technology, Central University of Technology, Free 
State and for making available their laboratory facilities, as well as for the 
opportunity to further my career; 
 QuatroMed, Bethlehem, who supplied and prepared the supplement 
capsules; 
 The enthusiastic study population, who followed the protocol without any 
complaints; 
 Staff of the South African National Defence Force, for their support; 
 My Heavenly Father, for giving me the courage and strength to undertake 
and complete this work.  
 
 
 
 
 
 
 
xv 
 
LIST OF FIGURES 
   
Page 
Figure 2.1 SCFA production in the colon 45 
Figure 3.1 Schematic representation of the study design    57 
Figure 4.1 A turbidimetric presentation of the mean fibrin network lysis 
rate of the entire study group at baseline one and two (Day 
0 and 8) 
 
 
98 
Figure 4.2 A turbidimetric presentation of the mean fibrin network lysis 
rates of the placebo group for the entire study period  
 
104 
Figure 4.3 A turbidimetric presentation of the mean fibrin network lysis 
rate of the acetate-propionate group for the entire study 
period 
 
 
109 
Figure 4.4 A turbidimetric presentation of the mean fibrin network lysis 
rate of the high acetate group for the entire study period 
 
113 
 
 
 
 
 
 
 
 
 
 
xvi 
 
LIST OF TABLES 
  Page 
Table 3.1 Classification of BMI 61 
Table 3.2 Classification of Blood Pressure 62 
Table 3.3 Classification of serum Total Cholesterol 63 
Table 3.4 Classification of serum LDL-Cholesterol 64 
Table 3.5 Classification of serum HDL-Cholesterol 64 
Table 3.6 Classification of serum Triglycerides 65 
Table 3.7 Normal ranges for haemostatic profiles 67 
Table 3.8 Ratio of SCFAs in the different supplements 70 
Table 3.9 The apparatus used for laboratory analyses of blood 
specimens  
71 
Table 3.10 Standards and controls used for different laboratory 
investigations  
72 
Table 3.11 Reagents and consumables used during the study  73 
Table 3.12 Methods used for coagulation factor determination  77 
Table 3.13 Methods used for chemical variables determination  77 
Table 4.1 General health profiles of the entire study group for both 
baseline 1 and 2  
 
96 
Table 4.2 Haemostatic profiles of the study group as a whole for both 
baseline 1 and 2 
 
97 
Table 4.3 Blood lipid profiles of the study group as a whole for both 
baseline 1 and 2 
 
99 
Table 4.4 Glycometabolic indicators of the study group as a whole for 
both baseline 1 and 2 
 
100 
Table 4.5 Changes in the general health profiles within the placebo 
supplement study group  
 
102 
xvii 
 
  Page 
 Table 4.6 Changes in the haemostatic profiles within the placebo 
supplement study group  
 
103 
Table 4.7 Changes in the lipid profiles within the placebo supplement 
study group 
 
105 
Table 4.8 Changes in the glycmetabolic profiles within the placebo 
supplement study group   
 
105 
Table 4.9 Changes in the general health profiles within the acetate-
propionate (50%-50%) supplement group 
 
107 
Table 4.10 Changes in the haemostatic profiles within the acetate-
propionate (50%-50%) study group 
 
108 
Table 4.11 Changes in the lipid profiles within the acetate-propionate 
(50%-50%) supplement group  
 
110 
Table 4.12 Changes in the glycometabolic indicators of the acetate-
propionate (50%-50%) supplement group  
 
110 
Table 4.13 Changes in the general health profiles within the high acetate 
supplement group 
 
111 
Table 4.14 Changes in the haemostatic profiles within the high acetate 
supplement group 
 
112 
Table 4.15 Changes in the lipid profiles within the high acetate 
supplement study group 
 
114 
Table 4.16 Changes in the glycometabolic profiles within the high acetate 
supplement study group 
 
115 
 
 
 
 
xviii 
 
LIST OF ABBREVIATIONS 
 Alpha 
 Beta 
 Gamma 
 Micro 
T Mass length ratio from turbidity 
Acetyl-CoA Acetyl coenzyme A 
ADA American Diabetes Association 
ADP Adenosine diphosphate 
AIDS Acquired Immunudificiency Syndrome 
ATIII Antithrombin III 
ATP Adult treatment panel  
BMI Body Mass Index 
CAD Coronary artery disease 
CDC Centers for disease control and prevention 
CHD Coronary heart disease 
CH4 Methane 
cm centimetre 
CO2 Carbon dioxide 
CoA Co-enzyme A 
CRP C-reactive protein 
CVD Cerebrovascular disease 
DBP Diastolic blood pressure 
EDTA Ethylenediaminetetraacetic acid 
FBC Full blood count 
FFQ Food frequency questionnaire 
FM Fibrin monomer 
xix 
 
FVII Factor VII 
FVIII Factor VIII 
g gram 
g/L gram per litre 
H+ ionic hydrogen 
H2O2 hydrogen peroxide  
HCT Haematocrit 
HDL-C High-density lipoprotein cholesterol  
HIV Human immunodeficiency virus 
Hb Haemoglobin 
IFG Impaired fasting glucose 
IHD Ischaemic heart disease 
JNC Joint National Committee 
kg Kilogramme 
KKV Kort ketting vetsure 
LDL-C Low-density lipoprotein cholesterol 
Max Maximum 
m meter 
Min Minimum 
MI Myocardial infarction 
ml millilitre 
mmHg millimetre mercury 
mmol/L Millimole per litre 
MS Metabolic syndrome 
NaOH Sodium hydroxide 
NCEP National Cholesterol Education Programme 
NEFA Non-esterified fatty acids 
NFC Network fibrin content 
xx 
 
NSP Non-starch polysaccharides 
PAI-1 Plasminogen activator inhibitor-1 
pH Percentage hydrogen 
PLT Platelets 
RBC Red blood cells 
SANDF South African National Defence Force 
SBP Systolic blood pressure 
SCFA Short-chain fatty acid 
SCFAs Short-chain fatty acids 
SD Standard deviation 
THUSA Transition and Health during Urbanisation in South Africa 
TC Total cholesterol 
TG Triglycerides 
TP Total Protein 
tPA Tissue plasminogen activator 
UFS University of the Free State 
USDA United States Department of Agriculture 
VLDL Very low-density lipoprotein 
WBC White blood cells 
WHO World Health Organisation 
X Mean 
xxi 
 
APPENDICES 
 
Appendix A  Information leaflet and consent form  
Appendix B Recruitment Questionnaire  
Appendix C Food Frequency Questionnaire  
Appendix D Questionnaire for subjects who completed the study 
(Tolerance Questionnaire) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxii 
 
SUMMARY 
 
Historically, coronary artery disease (CAD) has been remarkably rare in the 
black South African population.  However, in recent years, major social and 
demographic changes have taken place in Africa. Large sections of rural black 
populations migrate to the cities, adopting a more western style of life, with the 
consequent emergence of a variety of degenerative western diseases. A diet 
low in saturated fat and high in fibre is regarded as one of the few controllable 
factors in the prevention of degenerative diseases.  Long-term epidemiological 
and clinical intervention studies indicate that the addition of dietary fibre to the 
daily diet can be used as a promising therapeutic agent for the control of 
known coronary risk factors. The exact mechanism through which dietary fibre 
influences human metabolism, is not yet known. However, it is suspected that 
the metabolic effects of dietary fibre in humans are significantly influenced by 
the degree to which the fibre is fermented in the colon.  Fermentation of 
dietary fibre results in the production of the short-chain fatty acids (SCFAs)- 
acetate, propionate and butyrate. These SCFAs are absorbed in the large gut 
where they enter the hepatic blood circulation and contribute to a number of 
metabolic processes, especially in the liver. It has been hypothesised that 
these SCFAs contribute, at least in part, to the beneficial effects of dietary 
fibre on human metabolism. 
The main objective of the study was to measure the possible effects of the 
long-term intake of different combinations of colonic release SCFA 
supplements on lipid, carbohydrate and haemostatic risk markers in 
westernised African men.  The concentration of SCFAs was equivalent to that 
normally generated by the natural fermentation of 15g of mixed fibres.  It is 
xxiii 
 
important to acknowledge that the ratio in which the different acids are 
produced, differ from fibre to fibre. This aspect was the focus of this study. 
Two supplements, with diferent acetate:propionate:butyrate ratios, in addition 
to a placebo supplement were employed for standardisation and control 
purposes. 
The study design composed of a randomised, placebo-controlled, double 
blinded, clinical research trial.  Seventy-five black male volunteers were 
recruited from the Military Base at Tempe Defence Force, Bloemfontein, and 
randomly assigned to three different supplementation groups.  All subjects 
received a placebo supplement, sustained for a period of one week after the 
collection of baseline information and blood samples.  A second baseline 
blood sample was collected from each individual at the end of this period to 
secure a stable baseline.  Subjects were then randomly assigned to three 
different intervention groups.  The three groups included a placebo 
supplement, an acetate(70%), propionate (15%) and butyrate (15%) 
supplement, as well as an acetate (50%) and propionate (50%) supplement, 
sustained for a period of four weeks, following the second baseline.  
Measurements included that of the general health status (anthropometric 
measurements, some biochemical parameters and blood pressure), lipid 
profiles (total cholesterol or TC, low-density lipoprotein cholesterol or LDL-C, 
high-density lipoprotein cholesterol, or HDL-C, and triglycerides), haemostatic 
profiles (the plasma fibrinogen concentration, factor VII & VIII activity, fibrin 
monomer concentrations, and some fibrin network architecture variables), as 
well as glycometabolic indicators (fasting serum-glucose and -insulin).  The 
experimental supplementation phase was followed by a wash-out period of 
xxiv 
 
one week, during which all subjects consumed placebo supplements. 
At baseline, the study group represented a group of black African men without 
any apparent metabolic or physical abnormalities.  All measured variables fell 
within the normal range.  Results from the experimental phase showed that 
the placebo supplement caused no significant changes in any of the 
measured variables.  The acetate-propionate (50/50) supplement caused a 
statistically significant decrease in the factor VII activity (from102 ± 7 to 97 ± 
7%), ATIII  activity (from 114 ± 13 to 108 ± 10 %), the fasting serum-glucose 
(from 6.65 ± 0.98 to 5.65 ± 0.42 mmol/L), a significant increase in the HDL-C 
(from 1.21 ± 0.24 to 1.35 ± 0.34 mmol/L) concentration, as well as a clinically 
insignificant, but statistically significant increase in plasma fibrinogen 
concentrations (from 2.98 ± 0.96 to 3.04 ± 0.89 g/L) from baseline to the end 
of supplementation.  The high-acetate supplement induced a beneficial 
decrease in factor VII (from 103 ±14 to 101 ± 6 %) and factor VIII (from 93 ± 
13 to 88 ± 6%) activity, ATIII activity (from 109.2 ± 16.0 to 103.0 ± 10%), the 
network compaction (from 14.2 ± 5 to 13.7 ± 4.0%), as well as the fibrin 
monomer concentrations (from 13.9 ± 2.2 to 12.1 ± 4 mg/L), during the 
experimental phase.  This group also experienced a beneficial and statistically 
significant decrease of the LDL-C levels of 16% (from 3.10 ± 0.78 to 2.61 ± 
0.94 mmol/L) the fasting serum-glucose concentrations (from 5.41 ± 0.52 to 
4.96 ± 0.85 mmol/L), and a concomitant significant decrease in the circulating 
serum-insulin levels (5.80 ± 0.77 to 1.70 ± 0.36 mmol/L). 
Results from this study show that supplementation with different combinations 
of SCFAs affect human metabolism, and more specific, the metabolism of 
those markers that are generally associated with the development of 
xxv 
 
cardiovascular disease. In addition, it is also evident that the specific 
combination (and respective ratios) in which these SCFAs are used as a 
supplement, play a significant role in the way it affects human metabolism. It 
therefore becomes clear that it is not only the presence of a single one of the 
SCFAs that mediate the overall metabolic effects of dietary fibre on human 
metabolism, but also the ratio in which they occur relative to each other, that 
collectively affects human metabolism. 
The specific combinations of SFCAs, as applied in this study, did not affect 
human metabolism to the extent that it could be advised that they be used as 
therapeutic agents. Further research to establish the most appropriate 
combination in which these acids can be used to the benefit of cardiovascular 
disease prevention in human subjects is recommended. 
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OPSOMMING 
 
Hartvatsiekte was aansienlik ongewoon onder die swart Suid-Afrikaanse 
populasie.  Geweldige sosiale en demografiese verandering in Afrika het 
onlangs plaasgevind.  Groot groepe landelike swart gemeenskappe het na 
stede migreer en sodoende ook ‗n meer verwesterse lewenstyl aangeleer, wat 
aanleiding daartoe gee dat verskeie degeneratiewe westerse siektes ook nou 
in hierdie populasiegroep voorkom.  Langtermyn epidemiologiese en kliniese 
intervensiestudies dui daarop dat die inname van dieetvesel tot ‗n mate 
gebruik kan word as ‗n belowende terapeutiese middel vir die voordelige 
beheer van die algemene koronêre risikofaktore. Die presiese meganisme 
waardeur dieetvesel menslike metabolisme voordelig beïnvloed is egter 
onbekend.  Daar word wel vermoed dat die metaboliese effek van dieetvesel 
betekenisvol beïnvloed word deur die mate waartoe die vesel in die kolon 
mikrobies fermenteer. Fermentasie van dieetvesel lei tot die produksie van die 
kortkettingvetsure (KKVs) – asetaat, propionaat en butiraat. Hierdie KKVs 
word in die kolon absorbeer waar dit vervolgens die hepatiese bloedsirkulasie 
binnegaan en deelneem aan verskeie metaboliese prosesse, veral in die 
lewer. Die hipotese bestaan dat hierdie KKVs, ten minste gedeeltelik, ‗n 
bydrae lewer tot die voordelige effek van dieetvesel by die menslike 
metabolisme. 
Die doel van hierdie studie was om die moontlike effek van die langtermyn 
inname van verskillende kombinasies KKV-aanvullings op die lipied-, 
hemostatiese- en koolhidraat risikomerkers in verwesterse swart mans te 
toets. Die konsentrasie KKVs in die supplemente was soortgelyk aan dit wat 
produseer sou word deur die natuurlike fermentasie van 15g gemengde vesel.   
xxvii 
 
Dit is belangrik om waar te neem dat die verhouding vaarin die vetsure 
produseer word, verskil van vesel tot vesel. Dit is hierdie eienskap wat in die 
studie aangespreek is. Twee supplemente, waarvan die verhouding van 
asetaat:propionaat en butiraat verskil, asook ‗n plasebo supplement, vir 
kontrole- en standardisasiedoeleindes, is aan die respondente toegedien. 
Hierdie studie was ‗n willekeurige, plasebo-gekontroleerde, dubbelblinde, 
kliniese proef.  Vyf en sewentig vrywillige Afrikaan mans was by die Tempe 
Militêre Basis lukraak geselekteer en in drie groepe verdeel.  Alle respondente 
het aanvanklik vir ‗n tydperk van een week die plasebo aanvulling geneem.  
Bloedmonsters en ander inligting is ingesamel aan die begin en einde van 
hierdie tydperk om sodoende ‗n meer betroubare basislyn te verseker. 
Respondente is vervolgens lukraak in drie groepe verdeel.  Die drie groepe is 
onderskeidelik vir ‗n tydperk van vier weke blootgestel aan ‗n plasebo-
supplement, ‗n asetaat (70%), propionaat (15%) en butiraat (15%)- 
supplement, asook ‗n asetaat (50%) en propionaat (50%)- supplement.  
Veranderlikes wat gemeet is, sluit in die algehele gesondheidstatus 
(antropometrie, biochemiese  veranderlikes en bloeddruk), lipiedprofiele 
(totale cholesterol of TC, laedigtheidslipoproteïen-cholesterol of LDL-C, 
hoëdigtheidslipoproteïen-cholesterol, of HDL-C, asook die trigliseriedes), 
hemostatiese  profiele (die plasmafibrinogeen konsentrasie, faktor VII & VIII 
aktiwiteit, fibrienmonomeer konsentrasie, asook sommige fibriennetwerk 
struktuur veranderlikes), asook glikometaboliese veranderlikes (vastende 
serum-glukose en -insulien).  Die eksperimentele fase is gevolg deur ‗n een-
week uitwasfase.  Gedurende hierdie fase is al die respondente aan plasebo 
supplementasie ondewerp.  
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Met aanvangs van die studie was die studiegroep verteenwoordigend van ‗n 
groep swart mans sonder enige metaboliese of fisieke abnormaliteite. Al die 
veranderlikes wat gemeet is, was binne die normale reikwydte vir die gegewe 
veranderlike.  Volgens die resultate van die eksperimentele fase het 
volgehoue supplementasie met die plasebo geen betekenisvolle veranderinge 
in enige van die gemete veranderlikes aangebring nie.  Die asetaat-
propionaat (50/50)- aanvulling het gepaard gegaan met ‗n statisties 
betekenisvolle verlaging in faktor VII aktiwiteit (van 102 ± 7 tot 97 ± 7%), ATIII 
aktiwiteit (van 114 ± 13 tot 108 ± 10%), vastende serum-glukose konsentrasie 
(van 6.65 ± 0.98 tot 5.65 ± 0.42 mmol/L), asook ‗n betekeninsvolle verhoging 
in die HDL-C konsentrasie (van 1.21 ± 0.24 tot 1.35 ± 0.34 mmol/L), asook ‗n 
statisties betekenisvolle, maar klinies nie-betekenisvolle verhoging in die 
plasmafibrinogeen konsentrasies (van 2.98 ± 0.96 tot 3.04 ± 0.89 g/L) vanaf 
die aanvang tot aan die einde van die vier weke intervensie.  Die hoë-asetaat 
aanvulling het ‗n voordelige verlaging in faktor VII (van 103 ±14 tot 101 ± 6%) 
en faktor VIII (van 93 ± 13 tot 88 ± 6%) aktiwiteit, ATIII aktiwiteit (van 109.2 ± 
16.0 tot 103.0 ± 10%), die netwerk kompaksie (van 14.2 ± 5 tot 13.7 ± 4.0%), 
asook die fibrienmonomeer konsentrasies (van 13.9 ± 2.2 tot 12.1 ± 3.6 
mg/L), gedurende die eksperimentele fase tot gevolg gehad.  Hierdie groep 
het ook ‗n voordelige en statisties betekenisvolle verlaging van 16% in die 
LDL-C konsentrasie (van 3.10 mmol/L ± 0.78 tot 2.61 ± 0.94 mmol/L), die 
vastende serum-glukose konsentrasies (van 5.41 mmol/L ± 0.52 tot 4.96 ± 
0.85 mmol/L), en ‗n gepaardgaande betekenisvolle verlaging in die 
sirkulerende serum-insulienvlakke (5.80 mmol/L ± 0.77 tot 1.70 ± 0.36 
mmol/L) getoon.   
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Volgens die resultate van hierdie studie is dit beduidend dat aanvulling met 
verskillende kombinasies van KKVs wel die menslike metabolisme beïnvloed.  
Dit kan veral die metabolisme van daardie merkers wat in die algemeen met 
kardiovaskulêre siektes geassosieer word, voordelig beïnvloed.  Verder is dit 
ook duidelik dat beide die aanwesigheid van een or meer van die KKVs, 
asook die spesifieke kombinasie waarin hierdie KKVs as ‗n supplement 
aangewend word, ‗n beduidende rol speel in die wyse waarop dit menslike 
metabolisme beïnvloed.  Dit spruit dus duidelik hieruit dat dit nie net die 
teenwoordigheid van ‗n enkele KKV is wat die algehele metaboliese effek van 
KKVs bemiddel nie, maar ook die verhouding waarin dit relatief tot mekaar 
voorkom wat gesamentlik die menslike metabolisme beïnvloed.   
Die spesifieke kombinasies van KKVs, soos in die studie aangewend, het nie 
menslike metabolisme in so ‗n mate beïnvloed dat dit aanbeveel kan word om 
as ‗n terapeutiese middel gebruik te word nie.  Verdere navorsing om die 
mees geskikte kombinasie te vind waarin hierdie vetsure tot voordeel vir die 
voorkoming van kardiovaskulêre siektes in mense aangewend kan word is 
nodig. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 BACKGROUND 
 
Cerebrovascular disease (CVD) and coronary heart disease (CHD) are 
among the most important causes of morbidity and mortality amongst 
South Africans and the people of the western world (Bradshaw et al., 
2005).  Cardiovascular disease is the leading cause of disability and 
death in developed nations and is increasing in prevalence throughout 
the developing world (WHO, 2002).  Murray & Lopez (1996) reported 
that, world-wide, Ischemic Heart Disease (IHD) was the highest cause 
of death in 1990 and estimated that it will remain the highest cause to 
2020, while CVD was and will be the second highest cause (WHO, 
2002).  The South African National Burden of Disease study for the 
year 2000 estimated that 17% of all deaths were due to cardiovascular 
disease (Bradshaw et al., 2003).  Cardiovascular disease is a major 
health problem in all population groups of South Africa, contributing 
23%, 41%, 31% and 52% of the total age-standardised death rates in 
the African, white, coloured an Indian population groups, respectively 
(Bradshaw et al., 2006). 
In recent years, major social and demographic changes have taken 
place in Africa, with large sections of rural African populations migrating 
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to the cities, adopting a more western style of life, and being exposed 
to vascular risk factors with respect to diet and level of physical activity, 
with the consequent emergence of a variety of degenerative ―first-
world‖ diseases (Steyn et al., 1991; Seedat et al., 1992; Bourne et al., 
1993; Mollentze et al., 1995; Solomons & Gross, 1995; Murray & 
Lopez, 1997; Kruger, Venter & Vorster, 2003;  Ntyintyane et al., 2008).   
The health status of black South Africans, compared to other middle-
income countries, is poor (Bradshaw, Masiteng & Nannen, 2000).   The 
incidence of the western diseases, atherosclerosis, CHD and CVD is 
progressively rising in black populations in South Africa (Mollentze et 
al., 1995; Kahn & Tollman, 1999; Bourne, Lambert & Steyn, 2002; 
Schutte et al., 2004; Vorster et., 2007). 
Prevention and cost-effective management of risk factors for CVD and 
CHD patients require an appropriate modification of life-style: 
avoidance of tobacco smoking, participating in regular exercise, and a 
health-promoting diet (Third Report of the National Education Program 
(NCEP) on detection, evaluation, and treatment of high blood 
cholesterol in adults, 2002; Erhardt, 2007).  
A diet low in saturated fat and high in fibre is regarded as protective 
against the  onset of degenerative diseases.  It is suspected that the 
mechanism throught which diet acts, is partially mediated by its effect 
on the identified coronary risk factors (hyperinsulinaemia, 
hyperlipidaemia, hypertension, obesity, etc.) as well as raised clotting 
factors (Vorster, Cummings & Veldman, 1997; Ginsberg et al., 1998; 
Anderson & Hanna, 1999; Brown et al., 1999; Chobanian et al., 2003).  
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The hypocholesterolaemic effect of dietary fermentable plant fibres, 
such as oat bran, has been attributed to, in part, to short chain fatty 
acids (SCFAs) generated during gut fermentation of these fibres 
(Bridges et al., 1992; Roberfroid, Gibson & Delzenne, 1993; Anderson, 
1995).  In rats, fermentation derived SCFAs are well absorbed and 
have been suggested to suppress cholesterol synthesis in the liver 
(Hara et al., 1999).  In addition to their hypocholesterolaemic effects, 
absorbed SCFAs have been reported to have a beneficial effect on 
important factors that play a role in the coagulation cascade, including 
plasma fibrinogen and resulting fibrin network structure (Veldman et al., 
1997; Veldman et al., 1999).   
The in vivo mechanisms through which SCFAs affect lipid metabolism 
and haemostasis are poorly understood and in some instances, 
controversial.  In its physical form, it is reported that dietary fibre and 
bile acids chelate and wash out cholesterol from the gut (Anderson et 
al., 1991).  Yet, additional studies suggest that the production and 
absorption of SCFAs, such as propionate, resulting from dietary fibre 
fermentation, would have a direct impact on reducing cholesterol 
synthesis in the liver (Anderson, 1995; Hara et al., 1999).  Some 
authors suggest that it is not the presence of these SCFAs alone, but 
rather the ratio in which they are produced and absorbed that 
determines the impact they have on lipid metabolism (Wolever, 
Fernandes & Rao, 1996).  Serum acetate and -propionate 
concentrations are related to serum total cholesterol levels in men 
(Wolever, Fernandes & Rao, 1996) and the authors also suggest that 
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the ratio of these two products may predict the risk for CVD.  Whether 
this is true for haemostatic risk profiles is yet to be established.  
The effects of both dietary derived SCFAs and food grade SCFA 
supplements on lipids metabolism and haemostatic risk factors have 
previously been examined (Veldman et al., 1997; Veldman et al., 
1999).  Veldman et al. (1999) applied colonic release capsules to 
simulate SCFA release in the large intestine and directly monitored 
their effects on lipid and haemostatic risk markers in human volunteers 
over a period of four weeks. The main shortcoming of this study was 
the absence of propionate and butyrate from the supplement.  In the 
study by Veldman et al (1999), supplementation caused a statistically 
significant reduction in serum cholesterol levels in 
hypercholesterolaemic subjects (Veldman et al., 1999). Yet, the clinical 
significance of the decrease in serum total cholesterol was not 
sufficient to promote the use of acetate supplementation as a 
cholesterol-lowering agent. Yet, these results strongly suggest that the 
beneficial effect of soluble dietary fibre intake could only be partially 
mediated by the production of acetate and  that the addition of both 
butyrate and propionate should be investigated further.  In the present 
study, the effect of the addition of butyrate and propionate, in different 
proportions, to colonic release acetate capsules, was used to measure 
their long-term effects on haemostatic and lipid profiles in westernised 
African men.  It is envisaged that the results from this study  could 
provide information to better understand the protective properties of 
dietary fibre against the  development of both CVD and CHD in 
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humans.  Such information is also likely to be used in future for the 
development of short-chain fatty acid supplements that provide similar 
protection. 
 
1.2 MOTIVATION 
 
Cerebrovascular disease (CVD) and coronary heart disease (CHD) are 
among the most important causes of morbidity and mortality amongst 
South Africans and other people of the western world.  A new political 
and socio-economic environment in South Africa allows for the mass 
movement of individuals from rural to urban and semi-urban areas, 
where they are exposed to factors that we collectively use to define as 
a westernised lifestyle. The westernised lifestyle introduces new 
metabolic abnormalities, such as CHD and CVD, that these population 
groups, in the past, enjoyed protection against through a variety of 
known and unknown mechanisms. Medical intervention for the 
treatment of CHD and CVD is expensive. The development of cheap 
alternative and natural methods for both the treatment and prevention 
of CVD and CHD is therefore, a research priority. 
Previous research shows how the addition of dietary fibre to any diet 
can significantly improve the metabolic risk profiles that are associated 
with a westernised lifestyle. Yet, not all fibres exert exactly the same 
metabolic response. In general, the improvements include changes in 
the lipid, carbohydrate and protein metabolism, as well as weight loss 
and other physico-chemical effects that are suspected to influence 
6 
 
health and disease. It is believed that some of these beneficial effects 
may be mediated, at least in part, by the ratio of SCFAs produced 
during the microbial fermentation of dietary fibre in the large intestine. 
Not all fibres produce the same ratio of short-chain fatty acids.  All  
short-chain fatty acids are absorbed and metabolised in the liver, where 
it partakes in a number of important metabolic cycles and processes, 
including those that affect CHD and CVD risk. 
A typical westernised diet is low in dietary fibre. It is suspected that a 
supplement of short-chain fatty acids could, at least in part, provide 
protection against the development of CHD and CVD in individuals that 
follow a typically western diet, with a low fibre intake. These acids are 
easy to produce, inexpensive and available as a stable powdered 
crystal salt. The development of SCFA supplements would therefore, 
be appropriate if the intake of SCFAs holds any potential clinical benefit 
to human health. Yet, it is important to investigate the most appropriate 
ratio in which these acids should be employed. 
 
1.3 HYPOTHESIS 
 
The hypothesis tested in this study states that:  
H0 - The addition of propionate and butyrate in different quantities to 
colonic release acetate supplements will not significantly affect the 
effects of the supplement on haemostatic,  lipid and 
glycomatebolic profiles   of westernised African men. 
H1 - The addition of propionate and butyrate in different quantities to 
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colonic release acetate supplements will significantly affect  the 
effects of the supplement on haemostatic, lipid and 
glycometabolic profiles of westernised African men. 
 
1.4 AIM AND OBJECTIVES 
 1.4.1 Aim 
The main aim of the study was to measure the possible effects 
of the long-term intake of different combinations of colonic 
release SCFA supplements on lipid, carbohydrate and 
haemostatic risk markers in westernised Black men.  The 
concentration of SCFAs was standardised as equivalent to that 
normally generated by the natural fermentation of 15g of mixed 
fibres. 
 
 1.4.2 Objectives 
  The objectives of the study are: 
 To investigate whether the exposure to different 
combinations of SCFAs orally administered, will have 
beneficial effects on the hamostatic, lipid and carbohydrate 
risk markers in westernised Black men.  One of the 
supplements contained a mixture of acetate, propionate and 
butyrate in a ratio of 70% acetate, 15% propionate and 15% 
butyrate.  The other supplement contained only a mixture of 
acetate and propionate, in a ratio of 50% acetate and 50% 
propionate.   
8 
 
 To investigate whether the ratio of acetate to propionate, as 
well as the absence or presence of butyrate may evoke a 
collaborative physiological response. 
 
1.5 STRUCTURE OF THE THESIS 
 
In Chapter 1 of this thesis, a short discussion is used to elucidate the 
rationale on which the hypothesis of this study is based.   Chapter 2 
provides an extensive literature survey, in which the most critical 
information needed to understand and interpret the hypothesis and the 
results of this study, is examined.  In Chapter 3, a comprehensive 
description of the experimental methods used in the study is provided.  
The results of the study are reported in Chapter 4 and Chapter 5 
discuss the results and compare it to previous relevant studies.   
Finally, in Chapter 6, conclusions and recommendations are made 
based on the findings reported inChapter 5. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
Coronary heart disease (CHD) and stroke are considered as degenerative 
western diseases which in most cases, can be prevented by a change in 
lifestyle, for example diet, physical activity and psychological well-being.  
Today, diet plays an integral position in the control of atherosclerosis, which 
relates to general vascular disease, CHD and stroke, especially in 
westernised cultures with an unhealthy lifestyle (Yussaf et al., 2001).  
It was estimated that approximately 75% of the South Africa population would 
be urbanised by the turn of 2000 (Mollentze et al., 1995).  Richter, Norris & 
Swart (2006) confirmed that South Africa has reached comparatively high 
levels of urbanisation and the African urban and rural metropolitan population 
is projected to more than double between 1990 and 2010.  Of all ethnic 
groups, the Black South African (African) group has the lowest prevalence of 
diseases related to lifestyle, when compared to any other groups, such as the 
Indian and White population groups.  This phenomenon is changing, taking 
into consideration the adaptation of the African population to a westernised 
lifestyle, concomitant to urbanisation. In general, rural African groups followed 
a highly prudent, low-fat, high-fibre diet.   Urbanisation and consequent 
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adoption of a western lifestyle also includes a change in diet.  The western 
diet with its high-fat, low-fibre content already seems to increase the incidence 
of diseases of lifestyle among the African population group (Steyn et al., 1987; 
Steyn, Fourie & Bradshaw, 1992; Mollentze et al., 1995; Jenkins et al., 2001; 
Vorster et al., 2007). In the early 2000s an additional factor brought the reality 
of raised CHD risk into the lives of the South African community. The 
prevalence of HIV and AIDS in the African population is considered to be 
amongst the highest in the world. The treatment of Human immunudifficiency 
virus (HIV) and Acquired immunodeficiency syndrome (AIDS) by means of 
antiretroviral therapy introduces metabolic changes that simulate the 
metabolic profile of those with increased CHD risk, such as 
hypercholesterolaemia, hypertriglyceridaemia and insulin resistance (Carr et 
al., 1999).  Yet, it is unknown whether the cardiovascular side-effects 
associated with the long-term use of these drugs would cause similar effects 
in the presence of the HIV, something which only time would tell (Hadigan et 
al., 2001; Samaras et al., 2007). 
CHD is preventable.  It is important to recognise that CHD is a multi-factorial 
disease and manifest as a single effect with many causes (Krummel, 2008).  
Some of these factors (such as those we associate with lifestyle) can be 
controlled, by either lifestyle changes or medical intervention, others not (such 
as genetic predisposition). In addition, those lifestyle factors that directly affect 
the development of CHD have been well investigated. Prevention of CHD 
therefore, depends mostly upon lifestyle intervention, especially in the early 
phase of its development (Erhardt, 2007; Giugliano, Ceriello & Esposito, 
2008).  This strong link between CHD and lifestyle serves as the major force 
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behind the large amount of research performed to elucidate the interplay 
between lifestyle factors and metabolic profiles in human subjects. The 
National Cholesterol Education Program‘s Adult Treatment Panel III (NCEP 
ATP III) report viewed cardiovascular disease as the primary outcome of 
metabolic syndrome (NCEP, 2002).  Most individuals who develop CHD have 
multiple risk factors.  Mancia (2006) noted that several risk factors (eg. 
dyslipidaemia, hypertension, hyperglycemia, obesity) commonly cluster 
together.  The metabolic syndrome is a particularly well-characterised 
example of co-excisting cardiovascular risk factors that is increasing at an 
alarming rate (Elabassi & Haddad, 2005).  Grundy et al. (2004) reviewed that 
the metabolic syndrome can be identified by six components that relate to 
CHD: abdominal obesity, atherogenic dyslipidaemia, raised blood pressure, 
insulin resistance or glucose intolerance, proinflammatory and prothrombotic 
state (NCEP, 2002).   The ATP III report considered the metabolic syndrome 
an indication for intensive lifestyle change (NCEP, 2002).   
As a facet of lifestyle, dietary intervention has been a major topic of 
investigation. A series of recent scientific statements support this and 
recommend the modification of atherogenic diets as a major lifestyle 
intervention to reduce metabolic risk (Grundy et al., 2005).  The prudent or 
low-fat, high-fibre diet is regarded by some authors as an effective tool in 
exercising control over CHD risk (Vorster, Cummings & Veldman, 1997; 
Jenkins et al., 2002a; NCEP, 2002).  It is important to note that the degree of 
control should have clinical significance, rather than to hold just statistical 
significance.   
Protection against CHD provided by the prudent diet mainly seems to centre 
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on the decrease in saturated fats and on the role of dietary fibre.  Dietary fibre 
is fermented in the large intestine to the short-chain fatty acids, acetate, 
propionate and butyrate (Veldman et al., 1999).  It is not only the individual 
acids, but also the combination in which they are produced and absorbed, that 
is believed to play an integral role in the way they act on human metabolism.  
A number of research trials have reported that a combination of the three 
major SCFAs (acetate, propionate and butyrate) in different ratios may directly 
affect metabolic CHD risk factors (Demignè et al., 1995; Veldman et al., 1997; 
De Wet, 2000). However, in some instances results were controversial and 
could not be compared amongs others differences in study design, route of 
administration, concentrations of the acids used and duration of 
supplementation. These are all factors that have to be taken into 
consideration. 
The following section will  be used as an overview of those metabolic CHD 
risk markers that  respond to lifestyle intervention, with special emphasis on 
diet. Other factors that do not respond to lifestyle intervention, such as genetic 
predisposition, will not be discussed here. In addition, the author provides an 
overview of those mechanisms suggested to link the production of short-chain 
fatty acids and CHD risk.  The literature should supply the reader  with a 
sufficient background to interpret the results of this study and the discussion 
at the end of the thesis. 
2.2 TERMS AND DEFINITIONS 
 
Terminology and operational definitions used in this thesis are explained here 
as a term of reference, for understanding the contents of this thesis. 
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2.2.1 Atherosclerosis 
 Atherosclerosis, a form of arteriosclerosis, is a complex process of 
thickening of the walls of arteries, particularly those of small and 
medium size, reducing their inside diameter and the flow of blood by 
the accumulation of lipids, primarily of oxidised low-density lipoprotein 
cholesterol (LDL-C), in the intimal or inner layer in combination with 
connective tissue and calcification (Meydani, 2001; Krummel, 2008). 
2.2.2 Thrombosis 
Thrombosis is the formation of a blood clot, or thrombus, inside a blood 
vessel. Forming a clump of various blood cells, the clot remains 
attached at its point of formation, partially or completely blocking the 
flow of blood through the vessel (Krummel, 2008). 
2.2.3 Coronary Heart Disease 
Coronary Heart Disease (CHD) or Coronary Artery Disease (CAD) is a 
disease involving the network of blood vessels surrounding and serving 
the heart.  CHD is in most instances caused by the obstruction of these 
vessels by means of the process of atherosclerosis or thrombosis, 
singly or in combination, manifested in clinical end points of myocardial 
infarction, sudden death and angina pectoris (Krummel, 2008). 
2.2.4 Stroke 
Stroke is a localised neurological blood shortage due to a vascular 
lesion, categorised by a sudden loss of cerebral function with coma due 
to bleeding, thrombosis or embolism of a cerebral artery (Edlin, 
Golantly & Brown, 1998).   
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2.2.5 Myocardial Infarction (MI) 
When thrombosis occurs in an artery, the tissues that the artery 
normally supplies with blood suffer infarction — that is, they die from a 
lack of blood-borne nutrients. Coronary thrombosis, the blockage of an 
artery that supplies blood to heart muscle, results in a myocardial 
infarction, or heart attack (Krummel, 2008). 
2.2.6 Cerebrovascular Disease (CVD) 
 A cerebrovascular disease is any disease that affects an artery within 
the brain, or that supplies blood to the brain.  The most common 
cerebrovascular disease is atherosclerosis, where plaques (fatty 
deposits) form, leading to narrowing of the arteries. There may also be 
a defect or weakness in a blood vessel in the brain, which can cause 
an aneurysm (ballooning of an artery) (Kumar, Abbas & Fausto, 2005). 
2.2.7 Dietary fibre 
A variety of systems exists that are used to classify dietary fibre. 
Dietary fibre is the substance that remains after treating plant material 
with human digestive-tract enzymes and reduction with acid and alkali 
(Ettinger, 2004). Carbohydrate rich foods can be classified into 
available carbohydrates which are digesed and absorbed in the small 
intestine and resistant carbohydrates which resist digestion in the small 
intestine or are poorly absorbed or metabolised.  The most prominent 
are the non-starch polysaccharides (NSP) from plant cell walls, which 
are characterised of the largely unrefined plant foods (Englyst, Lui & 
Englyst, 2007). Insoluble fibre is not digested and is found in 
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vegetables, whole-grain products, and bran. It provides roughage that 
speeds the elimination of faeces. Soluble fibre, in contrast, is digested 
in the colon, by means of bacterial fermentation, that result in the 
formation of methane, hydrogen, carbon dioxide, and the respective 
short-chain fatty acids (SCFAs).  These short-chain fatty acids, which 
include acetic, propionic, and butyric acid, are absorbed into the 
hepatic blood circulation.  SCFAs are also known as volatile fatty acids 
(Cummings, Macfarlane & Englyst,  2001). 
2.2.8 CHD Risk Factor versus CHD Risk Marker 
Risk Factors represent both lifestyle and metabolic aspects that are 
believed to contribute to the development of CHD, for example diet and 
diabetes mellitus.  Risk Markers represent those specific measurable 
metabolic variables in the patient‘s blood, generally associated with an 
increased risk of developing CHD and stroke, for example plasma 
fibrinogen and serum total cholesterol (Last, 1988). 
2.2.9 Urbanisation 
Urbanisation represents a shift of people from rural areas to cities and 
the resulting growth of urban areas (Le Roux & Le Roux, 1991). 
2.2.10 Westernisation 
Westernisation is an assimilation of western culture; the social process 
of becoming familiar with or converting to the customs and practices of 
Western civilisation (Oxford Dictionary, 2002). 
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2.2.11 Metabolic Syndrome 
The National Cholesterol Education Program‘s Adult Treatment Panel 
III (ATPIII) identified the metabolic syndrome as a multiplex risk factor 
for cardiovascular disease that is deserving of more clinical attention 
(Grundy et al., 2004).  The core components of the metabolic 
syndrome include abdominal obesity, insulin resistance or glucose 
intollerance, atherogenic dyslipidaemia, prothrombotic state and 
hypertension (Grundy et al., 2004; Alberti, Zimmet & Shaw, 2006).   
 
2.3 METABOLIC RISK MARKERS FOR ATHEROSCLEROSIS AND 
THROMBOSIS 
 
2.3.1 Introduction 
 Cerebrovascular disease (CVD) and coronary heart disease (CHD) are 
important causes of morbidity and mortality in the western world (WHO, 
2002), including South Africa (Bradshaw et al., 2003).  CHD is the 
prime cause of death among the South African white, coloured and 
Indian populations. The South African National Burden of Disease 
study for the year 2000 estimated that 17% of all deaths were due to 
cardiovascular disease (Bradshaw et al., 2003). The recent cause-of-
death statistics show different patterns in the cardiovascular disease 
among population groups, with ischaemic heart disease more common 
among the white and Indian groups and stroke more common among 
black Africans (Statistics South Africa, 2007).  Historically CHD has 
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been remarkably rare in black South Africans (Seftel, 1978).  Although 
the black population still have the lowest CHD mortality rate in South 
Africa, some studies report a change in this phenomenon (Steyn et al., 
1991, Mollentze et al., 1995; Jenkins et al., 2001; Vorster et al., 2007; 
Ntyntyane et al., 2008), as ongoing demographic transition and 
aggressive marketing of unhealthy consumer products diminishes the 
apparent protection against CHD they once experienced.  It is this 
change in lifestyle and associated increase in CHD risk that makes one 
realise the association between them and provides an opportunity to 
elucidate mechanisms based on investigating population groups 
undergoing these changes.  CHD is a multifactorial disease influenced 
by a mixture of genetic factors, physiological factors (such as 
metabolism of the arterial wall), humoral factors (lipids, lipoproteins and 
the complex mechanisms of blood clotting) and those associated with 
lifestyle (stress and similar psychological factors, cigarette smoking, 
diet and exercise) (Kritchevsky, 1994; NCEP, 2002; Greenland et al., 
2003; Krummel, 2008), which will be discussed in the following section. 
2.3.2 Haemostatic Risk Markers 
The haemostatic system is designed to maintain blood in a fluid state 
under physiological conditions, but primed to react to vascular injury in 
an explosive manner to stem blood loss by sealing the defect in the 
vessel wall (Ratnoff & Forbes, 1996).  Rapid, localised haemostasis is 
achieved by complicated systems of activation and inhibition whereby 
excessive bleeding and unwanted thrombosis is minimised (Hutton, 
Laffan & Tuddenham, 1999). 
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2.3.2.1 Plasma Fibrinogen 
The first suggestion that raised plasma fibrinogen levels may 
contribute towards the development of CHD was first voiced in the 
1950s (reviewed by Ernst & Resch, 1993). A prothrombotic state, 
characterised by raised fibrinogen was identified by the ATP III as 
one of the six components of the metabolic syndrome (NCEP, 2002; 
Devaraj, Rosenson & Jialal, 2004).  Fibrinogen is a soluble 
glycoprotein, and is present in high concentrations in both plasma 
and platelet granules (Hutton, Laffan & Tuddenham, 1999; Weisel, 
2005).   It is the main clotting protein. The soluble protein circulating 
in the blood provides the source material from which an insoluble 
fibrin clot is formed during the polymerisation process of blood 
coagulation (Weisel, 2005). A high plasma fibrinogen concentration 
in adulthood is associated with an elevated risk of developing CHD 
and/or stroke (Kannel, 2005; Weisel, 2005; Aleksic et al., 2008).  
Fibrinogen may act through two independent pathophysiologic 
mechanisms such as thrombosis and inflammation (Best et al., 
2008). The prospective fibrinogen-CVD association may even be a 
consequence, rather than a cause, of the disease process, perhaps 
due to an inflammatory response to progressive endothelial damage.  
This is why most authors suggest fibrinogen to be a marker of long-
term pathophysiological changes (Fibrinogen Studies Collaboration, 
2005; Aleksic et al., 2008). 
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Urbanisation and Diet as risk factor for raised plasma fibrinogen 
levels 
The effect of urbanisation and a concomitant change in diet on 
circulating plasma fibrinogen concentrations in human subjects 
remains uncertain (James et al., 2000).  In addition, only a limited 
number of studies have investigated the haemostatic risk profiles of 
black South Africans.  However, some authors do report that 
circulating plasma fibrinogen levels increase as a result of 
urbanisation (Pieters & Vorster, 2008).  Yet, circulating fibrinogen 
concentration is controlled by many demographic, environmental, 
dietary, as well as genetic factors (Vorster, Cummings & Jerling, 
1997; De Maat, 2001) and it is difficult to single out the effect of one 
single factor that encompasses so many other variables.  It is 
suggested that 30-50% of the plasma fibrinogen level is genetically 
determined (De Maat, 2001) while Pieters & Vorster (2008) 
confirmed that high circulating plasma fibrinogen concentrations 
were observed in almost all of the studies that reported on black 
South Africans, despite differences in demographic location.  Yet, 
does this imply that the process of urbanisation and concomitant 
change in lifestyle itself has no impact on the expression of 
fibrinogen production?  Although dietary components have been 
shown to affect fibrinogen concentration, the effect seems modest 
and in some cases, even controversial.  Results from the Transition 
and Health during Urbanisation in South Africa (THUSA) Study 
indicated that individuals following a prudent diet (low intakes of 
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animal protein; trans-fatty acids and higher intakes of plant protein 
and dietary fibre) have lower circulating plasma fibrinogen levels 
(James et al., 2000).   
2.3.2.2 Fibrin Network Formation  and Architecture 
It is suspected that not only fibrinogen concentration, but also the 
quality of fibrin networks may directly be related to CHD risk (Scott, 
2004; Weisel, 2004; Collet et al., 2006).  Patients with an elevated 
plasma fibrinogen concentration have a considerably lower fibrin gel 
permeability compared with normofibrinogenaemic patients. 
Fibrinogen is the main clotting protein.  It forms an insoluble gel on 
conversion to fibrin after activation by the proteolytic enzyme 
thrombin, which itself is activated by a cascade of other enzymatic 
reactions (Sugo et al., 2006).  Some other proteins interact with 
fibrinogen to form an elastic filamentous fibrin, such as factor XIII, 
fibronectin, -2 antiplasmin inhibitor, plasminogen, and plasminogen 
activator (Weisel, 2005; Weisel, 2007). 
When thrombin and fibrinogen interact, fibrin monomers are 
generated according to the relative amounts of the enzyme and the 
substrate (Wolberg, 2007; Wolberg & Campbell, 2008; Weisel & 
Litninov, 2008).  Continuing thrombin-catalysed cleavage of the 
resulting fibrinopeptides from the central domain of fibrinogen leads 
to the formation of two-stranded polymers of fibrin, termed 
protofibrils, in a rapid linear bimolecular polymerisation process.  
This process repeats itself causing an increase in the length of the 
protofibrils. Additional stability of protofibrils is provided by non-
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covalent interactions between the distal D-domains of subsequent 
fibrin molecules that are aligned in an end-to-end fashion within the 
same strand of each individual protofibril (Weisel, 2005a; Weisel, 
2007; Crawley et al., 2007).  Progressive lengthening of the polymer 
chain occurs by a half-overlap, side-to-side approximation of fibrin 
monomer molecules.  Separate protofibrils then interact laterally, 
increasing the thickness of the fibrin fibres.  The first part of the 
polymerisation reaction therefore causes lengthening of the fibrin 
strands (protofibrils), whereas the second part of the reaction causes 
thickening of the strands.  Either this could result in long, thin fibrin 
strands or short, broad sheets of fibrin.  In mature forms, one fibrin 
fibre contains more or less 100 protofibrils, with a somewhat random 
pattern of branching that additionally links different fibres together by 
means of cross-linking (Ratnoff & Forbes, 1996; Weisel, 2007; 
Chernysh & Weisel, 2008). 
Fibrin clot formation, on a molecular level, involves a series of highly 
ordered biochemical reactions (Sugo et al., 2006):  
(i) transition of fibrinogen to fibrin monomers by cleavage of the 
polypeptide fragments fibrinogen peptide A and B by thrombin,  
(ii) construction of half-molecular overlapping linear double-
stranded  fibrin protofibrils, and  
(iii) lateral association of the protofibrils to form thick fibrin fibres, 
bundles and networks (Sugo et al., 2006).  
22 
 
It is suspected that the degree of lateral strand association probably 
contributes to the tensile strength of the clot.  Clot resistance to 
plasmin degradation is believed to depend mainly on the degree of 
cross-linking, a process mediated by Factor XIII (Weisel, 2007). Clot 
rigidity is mainly determined by individual fibre size within the 
network, as well as the amount of cross-linking and branch points 
that form between different fibres within the network (Ryan et al., 
1999). 
The physical and biochemical structure of the fibrin network depends 
upon the polymerisation conditions (Weisel, 2007).  It is known that 
any given network comprises of a major network of thicker fibres and 
a minor network of thinner fibres (Nair, Shats & Dhall, 1986; Wolberg 
& Cambell, 2008).  According to Blombäck et al. (1992) these gel 
structures are determined by kinetic factors and modulating factors. 
Kinetic factors:  The kinetic factors are thrombin and fibrinogen 
concentrations.  Increasing the kinetic factors will result in tighter, 
less porous networks with thinner fibres and a higher density of 
nodes.   These structures are dense, rigid and flow of a liquid 
through it is impaired.  Conversely, low concentrations of kinetic 
factors result in porous networks with thick fibres and fewer nodes.  
These structures are less tightly packed, deformable and plastic and 
consequently fluid easily escapes through the structure.   It is 
evident that the initial fibrin polymers create nuclei for the growth of 
linear polymers in different spatial directions.  A network structure is 
thus formed.  The faster the activation the larger the density of 
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polymeric nuclei and the tighter the network structure .  The rate of 
activation of fibrinogen by thrombin will increase significantly with 
increasing fibrinogen concentration and this leads to a drastic 
change in the fibrin gel structure (Blombäck at al., 1992). 
Modulating factors:  The modulating factors include proteins and 
ions in direct contact with the fibrinogen molecule (Diamond & 
Anand, 1993).  Modulating factors change the architecture of the 
network by either interacting with the surrounding fluid during fibrin 
formation or by binding to either fibrinogen or to the fibrin strands in 
the established network.  Modulating factors include: 
 fibrinogen composition, non-enzymatic glycosylation, 
carbohydrate content, and any factors causing a change in 
primary and/or secondary structure of the molecule (Fatah et al., 
1992); 
 albumin (Carr, 1987); 
 cations, pH and temperature (Blombäck & Okada, 1982); 
 blood platelets (Van Gelder, Nair & Dhall,  1993) ; 
 plasma antithrombin-III (Elgue et al., 1994)  ; 
 homo poly (l-amino acids) (Carr, Cromartie & Gabriel, 1989); 
 dextran (Dhall, Bryce and Dhall,  1976) ; 
 glucose and antidiabetic drugs (Azhar et al., 1990); 
 gamma-globulin (Nair et al., 1991a) ; 
 fibronectin (Nair et al., 1991b); 
 insulin, growth hormone and estrogen (Joubert & Veldman, 2002); 
 acetylsalicylic acid (Fatah, 1995) ; and 
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 a variety of long- and short-chain fatty acids (Mogongoa & 
Veldman, 2002). 
Fibrin network structures can vary, and specific structural types are 
considered to be associated with an increased risk of CHD.  Altered 
fibrin network architecture has been observed in patients with 
premature CAD (Collet et al., 2006), myocardial infarction (MI) 
(Fatah et al., 1996), and diabetes mellitus (De Maat, 2001; Dunn, 
Ariens & Grant, 2005), as well as in obese patients (Malan, 1999), 
when compared to those found in apparently healthy patients.  In 
general, fibrin clots with thinner fibres, more branch points and 
smaller intrinsic pores are more dense and resistant to lysis and are 
associated with a raised athero-thrombotic risk (Collet et al., 2000).  
Clots consisting of thicker fibres generally have larger pore sizes 
making the clots more permeable to those enzymes that control the 
breakdown of the clots, in addition to having more plasminogen 
binding sites, compared to networks having thin and dense fibres 
(Kemball-Cook, Tuddenham &  McVey, 2004; Pieters & Vorster, 
2008).  
In addition, circulating LDL-C correlates inversely with permeability 
and the mass-to-length ratio of the fibers (Blombäck at al., 1992).  
Significant inverse relations, which are independent of plasma 
fibrinogen or lipoprotein concentrations, are detected between the 
permeability of plasma generated fibrin networks and mass-to-length 
ratio within the fibrin fibres and the severity of coronary artery 
stenosis as determined by angiography (Fatah, 1995).  Also, 
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Blombäck et al. (1992) indicated that a grossly abnormal gel 
structure rather than simply the tightness and rigidity of the 
architecture is associated with progression of the atherosclerotic  
process.  Since these patients often have elevated plasma 
fibrinogen levels, an association can be found between tight and 
rigid fibrin networks in vitro and the process in vivo.  Further 
research is required to elaborate on these associations. 
Urbanisation and Diet as risk factor for altering fibrin network 
structure 
The effect of diet on the fibrin network structure is not well 
investigated.  Pectin, a soluble dietary fibre, was shown to increase 
the permeability and lysability of the fibrin network and to decrease 
tensile strength of the fibrin fibres (Veldman et al., 1997; Veldman et 
al., 1999).  A number of authors investigated the effect of specific 
molecules on the fibrin network structure, such as albumin (Nair & 
Dhall, 1991), anti-thrombin III (Nair & Dhall, 1991), glucose (Nair et 
al., 1991a; Dunn, Ariens & Grant, 2005; Pieters et al., 2008), etc. by 
means of short-term clinical intervention studies. Yet, no 
epidemiological data is available to support the hypothesis that those 
factors that influence CHD risk, also affect fibrin network structure.  
Studies like these are complex and costly.  In addition, methods 
used to establish fibrin network structure are not well standardised 
and results could differ due to the lack of external quality control 
samples.  No published information on the role of urbanisation on 
fibrin network structure is available.  Urbanisation is a complex 
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process that affects lifestyle.  It is therefore suspected that dietary 
changes related to urbanisation may have indirect or direct effects 
on fibrin network structure, mediated through its effect on circulating 
fibrinogen concentration and the main kinetic or modulating factors 
affecting fibrin network structure (Pieters & Vorster, 2008).  It is 
important to investigate the nature through which these mechanisms 
act.  Further studies are also required to investigate the relationship 
between diet and network structure. 
2.3.2.3 Factor VII-activity 
Smith et al. (2005) reported that factor VII has the potential to 
increase the prediction of CHD and stroke in middle-aged men. A 
high blood factor VII-activity predisposes patients to the onset of 
CHD (Kannel, 2005; Miller et al., 2008).  Karatela & Sainani (2009) 
found that raised factor VII levels in patients with CHD were 
independently associated with the metabolib syndrome. Factor VII 
forms part of the cascade that results in the activation of prothrombin 
to thrombin and thus, the eventual conversion of fibrinogen to fibrin 
(Swales & de Bono, 1993).  It seems that hypercoagulability, 
especially raised plasma fibrinogen levels and factor VII-activity, may 
play an important role, not only in thrombosis, but also in the 
development of atherosclerosis and is therefore considered to be an 
important independent risk factor for the development of CHD 
(Buzzard et al., 1996; Wang et al., 2007; Miller et al., 2008).  Higher 
levels of Factor VII-activity tend to cluster with additional 
independent CHD risk factors and is therefore, more pronounced 
27 
 
with increased age, obesity, high serum total cholesterol (TC), high 
low-density lipoprotein cholesterol (LDL-C), high serum triglycerides 
(TG), low high-density lipoprotein cholesterol (HDL-C), smoking, a 
family history of MI, high fasting insulin levels and high fibrinogen 
levels (Gliksman & Wilson, 1992; Cushman et al., 1996; Junker et 
al., 1997; Ishikawa et al., 1997; Wang et al., 2007). Surgue et al. 
(1985) demonstrated that in a series of patients with heterozygous 
familial hypercholesterolaemia, the age adjusted mean plasma 
fibrinogen level and factor VII-activity were significantly higher in 
patients with symptomatic evidence of CHD, when compared to 
patients without CHD.  Serum-lipid concentration did not differ 
significantly between the two groups. 
Urbanisation and Diet as Risk Factor for raised Factor VII-activity 
Very limited data is available on the effect of urbanisation on factor 
VII-activity.  Vermaak et al. (1991) compared black and Caucasian 
subjects who had been exposed to the same environment and 
western diet for at least 2 years. The authors reported factor VII-
activity to be significantly lower (26.6%) in adult Black Africans, 
compared to the Caucasian study group.  Bowman et al. (2009) 
postulated that a strong association between dietary fat intake and 
dietary cholesterol intake and factor VII-activity (Miller et al., 1986).    
Accordingly, dietary intake of fats could influence the risk of 
ischaemic heart disease via both long-term chronic (atherogenic) 
and short-term (thrombogenic) pathways.  Factor VII activation leads 
to an increase in thrombin concentration, which intensifies platelet 
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activation and promote a procoagulatory state.  Conversely, it can be 
assumed that cholesterol-lowering measures also reduce the 
thrombotic risk associated with a high activity of factor VII-activity 
(Miller et al., 2008).  Furthermore, Tracey et al. (1995) and Cushman 
et al. (1996) suggested that factor VII-activity could be modifiable 
through lifestyle changes, which includes dietary modification, weight 
reduction and lipid lowering, in both men and women.  
2.3.2.4 Factor VIII 
Factor VIII and fibrinogen are both required for the cascade of 
biochemical reactions leading to fibrin formation (Aleksic et al., 
2008).  Since factor VIII is a coagulant favouring clot formation and 
platelet adhesion, high level might be accepted to be a risk factor for 
thrombosis and atherosclerosis. Factor VIII is therefore a key 
procoagulant and like fibrinogen, a plasma protein that participates 
in the inflammation response (Tracey et al., 1995). However, at 
present there are limited data from prospective studies of factor VIII 
as a risk factor for the development of CHD or stroke.  Conlan et al. 
(1993) reported a strong association of factor VIII with a number of 
known cardiovascular disease risk factors.  The authors suggested 
that the association might not be indendent.  In the Northwich Park 
Heart Study, the individuals in the highest tertile group of factor VIII 
levels were associated with a 44% increase risk for CHD (Meade et 
al., 1986a).      Furthermore, a number of studies also report a strong 
association between factor VIII and a number of established CHD 
risk markers, such as glucose, insulin, LDL-cholesterol, serum total 
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cholesterol and serum triglycerides (Gliksman & Wilson, 1992; 
Conlan et al., 1993; Cushman et al., 1996).  Pan et al. (1997) 
reported a positive association between factor VIII concentration and 
atherosclerosis of the carotoid in the Chinese population.   
Meade et al. (1986b) found that factor VIII was higher in Africans 
than Caucasians as observed in other studies (Conlan et al., 1993).  
It is suggested that factor VIII levels may be determined 
predominantly by genetic (ethnic group and ABO bloodgroup status) 
rather than environmental characteristics. 
Urbanisation and Diet as Risk Factor for raised Factor VIII-activity 
The effect of urbanisation and the accompanied westernised diet on 
factor VIII-activity is not well investigated.  Van Wyk et al. (1998) 
determined that almost all the haemostatic variables, including factor 
VIII of San (Bushmen) who were relocated from Namibia to South 
Africa were statistically significantly lower than those of a Western 
reference group.   In another study, Mezzano et al. (2001) found in a 
randomized clinical trial that levels of factor VII and factor VIII were 
reduced in men consuming a Mediterranean-type diet rich in olive 
oil, fish, fruit and vegetables, compared to those on a high saturated 
fat diet.  Nienaber (2006) subdivided a group of 117 black girls and 
78 boys, in transition, into subdivision for gender, physical activity, 
fat percentage and height-for-age.  The author found significant 
changes in some haemostatic variables, but factor VIII showed no 
differences for any of the subdivisions.  
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2.3.2.5 Plasminogen activator inhibitor (PAI-1) 
A variety of fibrinolytic defects has been implicated in the 
pathogenesis of thrombosis.  These include decreased release of 
tissue plasminogen activator (Nilsson, Ljugner & Tengborn, 1985) 
and increased plasminogen activator inhibitor -1 (PAI-1) activity 
(Hamstern et al., 1987). The net effect of each of these 
abnormalities is impaired functional plasmin generation and a 
blunted fibrinolytic response to fibrin formation (De Pergola & 
Pannacciulli, 2002).   
PAI-1 is one of the main inhibitors of the fibrinolytic process and is 
therefore considered to be a potential risk factor for CHD.  High PAI- 
1 activity may especially be used to identify individuals with an 
increased risk of recurrent myocardial infarction (Hamstern et al., 
1987).    Components of the metabolic syndrome are associated with 
both coagulation and fibrinolytic proteins, with a link to an elevated 
PAI-1 being the most consistent (Devaraj, Rosenson & Jialal, 2004). 
PAI-1 activity in black South Africans are low in general but with a 
tendency to increase with urbanisation (Pieters & Vorster, 2008).  
PAI-1 activity is furthermore consistently associated with blood lipids 
(Juhan-Vague et al., 1996; Hoekstra et al., 2004) and black South 
Africans have in general, a favourable lipid profile with low total 
cholesterol and high HDL-cholesterol (Vorster et al., 2005).  
However, it is speculated that PAI-1 activity in black South Africans 
are strongly regulated by genetic factors, although this remains to be 
proven (Pieters & Vorster, 2008). 
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Urbanisation and Diet as Risk Factor for raised PAI-1 activity 
Apart from metabolic risk markers associated with PAI-1, dietary 
factors have also been shown to influence PAI-1 levels.  The intake 
of omega-3 fatty acids and alcohol received much attention in this 
regard.  Most studies show that omega-3 fatty acids increase PAI-1 
levels but the effect is modest and depends on the type of fat 
(Hoekstra et al., 2004).  Lee & Lip (2003) demonstrated that heavy 
or binge drinking is associated with lower fibrinolytic capacity with 
increases in PAI-1 levels. 
2.3.2.6 Blood Platelets 
The development of thrombosis, especially arterial, is greatly 
influenced by the number of circulating blood platelets.  This is 
important where vessel disease, especially atherosclerosis, is the 
underlying cause of any manifest pathological state.  Platelet 
hyperaggregability is associated with increased risk of 
cardiovascular incidence (Mammen, 1999).  This is particularly true 
for sticky platelet syndrome, where platelets show marked 
hyperaggregability with Adenosine diphosphate (ADP) and/or 
epinephrine (Mammen, 1995; Frenkel & Mammen, 2003).  These 
patients have an increased risk of developing thrombosis, even while 
on anticoagulant therapy or with no evidence of other 
hyperaggregability conditions. 
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Urbanisation and Diet as Risk Factor for raised Blood Platelet levels 
Certain aspects of blood platelet function, blood coagulability, and 
fibrinolytic activity are associated with cardiovascular risk, but 
causality has been insufficiently proven.  Challen, Branch & 
Cummings (1983) hypothesed that dietary fibre might protect against 
the development of ischaemic heart disease through an effect on 
platelet aggregation and blood clotting. Eleven healthy volunteers 
took an additional 36g of pectin per day.  The study by the above 
mentioned authors found that platelet aggregation, platelet fatty acid 
composition, dilute blood clot lysis time and bleeding times were 
unaltered during the study.  They concluded that if dietary fibre does 
protect against heart disease it is probably not through an effect on 
platelet aggregation or haemostasis. 
Aoki et al. (2006) investigated the cellular mechanism of a 
prothrombotic state in spontaneously atherogenic rodents kept on a 
Western-style high fat diet. These findings show that a high fat diet-
induced prothrombotic state, endothelial dysfunction precedes both 
the morphologically detectable lesions and the enhancement of 
platelet reactivity.   Furthermore, Mezzano et al. (2003) also found 
that a Mediterranean-type diet, high in fruit and vegetables and low 
in saturated fats had longer bleeding times as a result.  The longer 
bleeding times in individuals on the Mediterranean diet, denotes less 
interaction of platelets with the vascular wall, which could be 
beneficial from the point of view of cardiovascular risk. 
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2.3.3 Blood Lipids 
The value of abnormal blood lipids and apo-lipoprotein levels as 
predictors of CHD and mortality has been studied for decades. In 
general, research has focussed mainly on the role of circulating total 
cholesterol (TC) in relation to cardiovascular disease, but it has  shifted 
to also include the individual components and fractions that collectively 
represent circulating total cholesterol (TC).  Over the last 30 years, 
these fractions of blood cholesterol, as well as their respective carrier 
proteins, or lipoproteins, have also come to the forefront as important 
predictors of CHD risk (Krummel, 2008). 
TC is a composite measure of the cholesterol content of lipoprotein 
particles, mainly represented by low-density lipoprotein cholesterol 
(LDL-C) and high-density lipoprotein cholesterol (HDL-C) (Norman et 
al., 2007).  The Third Report of the Expert Panel on Detection and 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III, or ATPIII) reaffirms that lowering blood-TC and -
LDL-C reduces the risk of developing CHD (NCEP, 2002).  It is 
estimated that a 10% reduction in serum-TC decreases CHD incidence 
by at least 30% (CDC, 2001).  Yet, whereas TC was previously 
recommended as a screening tool, ATPIII now also recommends a 
complete lipoprotein profile for screening purposes (NCEP, 2002).  The 
dyslipidaedemic patterns of high levels of LDL-C, associated with or 
without low levels of HDL-C, have been found to impart high risk for 
developing IHD, and justify treatment to reduce the overall risk for the 
development of CHD (NCEP, 2002). 
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LDL-C is the primary cholesterol carrier in the blood, a powerful 
atherogenic lipoprotein and consequently, total cholesterol levels and 
LDL-C levels are highly correlated.  The positive relationship between 
serum cholesterol levels and the development of first or subsequent 
attacks of CHD is observed over a broad range of LDL-C levels: the 
higher the level, the greater the risk (Fletcher et al., 2005; Marcovina 
and Packard, 2006; AHA, 2006).  However, it is also believed that the 
risk associated with LDL-C is diminished when associated with high 
serum-HDL-C concentrations (Kaplan et al., 1995). Thus, high HDL-C 
levels conversely reduced risk.  Epidemiological data taken as a whole 
signify that a 1% decrease in HDL-C is associated with a 2-3% 
increase in CHD risk.  Epidemiological studies consistently show low 
HDL-C to be an independent risk factor for CHD (Assmann et al.,1996, 
NCEP, 2002)  Cooney et al. (2009) confirmed an inverse, independent, 
strong and graded relationship between HDL-C concentration and 
CHD.   A low HDL-C level correlats with elevations of serum 
triglycerides and LDL-C (Lichtenstein et al., 2006)    The LDL-C:HDL-C 
ratio therefore, also serves as a strong predictor of cardiac events 
(Hermansen et al., 2003).   
Assmann et al. (1998) and Austin, Hokanson & Edwards (1998) 
reported a positive relationship between serum triglyceride levels and 
incidence of CHD.  Lipoprotein metabolism is integrally linked, and 
elevation of serum triglycerides can be confounded by significant 
correlations with TC, LDL-C and HDL-C levels (Grundy, 1998; NCEP, 
2002).  Mazza et al. (2005) indicated that the combination of high 
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triglyceride and low HDL-C levels quadrupled the risk of CHD mortality 
in elderly women.  According to Grundy et al. (2004), raised triglyceride 
levels and low concentrations HDL-C that manifest from routine 
lipoprotein analysis, can be classified as atherogenic dyslipidaemia.  
ATP IIII defined atherogenic dyslipidaemia as one of the components of 
the metabolic syndrome (NCEP, 2002).  Since the metabolic syndrome 
comprises accepted CHD risk factors, it would be expected that the 
syndrome is a strong predictor for CHD (Alberti, Zimmet & Shaw, 
2006).     
Urbanisation and Diet as Risk Factor for abnormal Blood Lipid Profiles 
In a local study (THUSA) it was demonstrated that, although the serum-
TC levels of urban Africans are lower in comparison to other population 
groups, professional urban Africans have significantly higher serum-TC 
levels, when compared to their own rural counterparts (Vorster, 2002).  
According to Norman et al. (2007) the serum-TC levels of young black 
South Africans were more similar to that of other population groups, 
when compared to that of older black South Africans. This 
phenomenon suggests that the younger African groups have already 
adopted a fully westernised lifestyle.   In the aforementioned study it 
was reported that almost 28% of all Africans, 30 years and older of 
age, also presented with a serum-TC level that classifies them as 
hypercholesterolaemic. Vorster (2002) mentioned that it could be that 
with more urban Africans exposed to affluence and Western lifestyles 
over longer periods, dyslipidaemia and obesity may increase to such 
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an extent that the protective mechanisms against IHD are no longer 
active. 
Historically, CHD has been remarkably rare in black South Africans 
(Seftel, 1978).  This low prevalence of CHD in the rural African 
population was initially ascribed to their favourable lipid profiles (Seftel, 
Raal & Joffe, 1995), marked by low serum-TC, –LDL-C and high HDL-
C levels (Steyn et al., 1987; Vermaak et al., 1991; Oosthuizen et al., 
2002). The ratio of serum-HDL-C to -TC has generally been found to 
be higher in the black African population group, when compared to any 
other ethnic groups (Mollentze et al., 1995; Oelofse et al., 1996).  This 
suggests that the black African population group with its lower serum-
TC levels experiences additional protection against atherosclerosis and 
-related disease, by virtue of relatively higher proportions of the 
protective HDL-C fractions (Norman et al., 2007).  Seftel, Raal & Joffe, 
(1995) reported that the serum-TC of almost all black Africans 
comprise of more than 20% HDL-C, which protects them against IHD.  
However, Ntyintyane et al. (2008) reported that with slightly elevated 
TC and LDL-C levels, the urbanised black African population group 
also had lower HDL-C concentrations. 
An unfavourable lipid profile is accepted as an independent risk factor 
for the development of CHD and as reported by Oostuizen et al. 
(2002), serum lipid levels of black South Africans increase with 
urbanisation.   Urbanisation is mainly associated with the shift from a 
traditional lifestyle and prudent eating habits, to a westernised lifestyle 
and diet (McMurry et al., 1991; Bourne et al., 1993).  The traditional                                                                                            
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prudent diet is low in fat, high in unrefined carbohydrates and dietary 
fibre.  A western diet can be defined as high in animal fat and refined 
carbohydrates and low in dietary fibre (Walker, 1981; Bourne et al., 
1993; Solomons & Gross, 1995). For more than 40 years, 
epidemiologic and clinical trials have managed to show that numerous 
dietary risk factors affect the circulating components of serum lipids.  
The main elements of a prudent or anti-coronary diet include a 
reduction of saturated fat, cholesterol and energy intake, relative to the 
typical westernised intake (Berger & Marais, 2000; Giugliano, Ceriello 
& Esposito, 2008).  A Westernised diet is generally associated with 
detrimental metabolic consequences (Meisenberg & Simmons, 1998; 
Grundy et al., 2005). Saturated fats, derived mainly from animal fats, 
tend to elevate the presence of cholesterol in all lipoprotein fractions 
(i.e. both LDL-C and HDL-C) when substituted for carbohydrates or 
other fatty acids (Van Horn & Ernst, 2001).  In general, low levels of 
serum-TC, -LDL-C and -HDL-C and raised triglyceride levels are all 
associated with a carbohydrate intake of 50 to 60 % of the total energy 
intake (Hallfrisch et al., 1988; Turley et al., 1998).  Although high-
carbohydrate low-fat diets are associated with lower HDL-C levels, it 
seems as if the ratio of HDL-C:LDL-C slightly increases (Pietinen & 
Huttunen, 1987).  When carbohydrates are consumed along with high-
fibre diets, however, the rise in triglycerides or fall in HDL-C has been 
reported to reduce (Jenkins et al., 1993; Turley et al., 1998, Vuksan et 
al., 2000).  Soluble fibres, like oat bran and beans, significantly reduce 
the serum-TC and LDL-C levels (Brown et al., 1999; Anderson et al., 
38 
 
2000; Aller et al., 2004) , but have no consistent effect on HDL-C and 
serum-TG levels (Aller et al., 2004).  However, it has been reported 
that soluble dietary fibre could cause a reduction in serum-TG and an 
increase in HDL-C levels (Sing et al., 1992; Lui et al., 2000; Jenkins et 
al., 2002b). 
2.3.4 Possible Relationship between Haemostatic and Other Risk 
Markers 
CHD is a multicausal disease manifested as atherosclerosis and/or 
thrombosis (Krummel, 2008).  Besides their independent association 
with CHD, it seems as if the risk markers often co-exist (Steyn, 
Rossouw & Joubert, 1990).  In addition, the collective risk of CHD 
seems more than would be expected if the risk calculation were based 
on the sum of the contribution of individual risk markers (WHO, 1990).  
A High CHD risk is therefore, usually defined only in the presence of 
two or more CHD risk factors, and requires more vigorous intervention 
(NCEP, 2002). 
The value of plasma fibrinogen as risk marker for CHD is controversial 
and neglected. In general, a plasma fibrinogen assay is not requested 
as part of a clinical CHD risk profile assessment. Yet, both clinical and 
epidemiological data provide sufficient evidence to support the use of 
plasma fibrinogen as risk marker for the development of CHD. When 
the plasma fibrinogen concentration is added to the risk profile for 
CHD, the individual prediction of coronary risk may be markedly 
improved (Kannel et al., 1987; Heinrich et al., 1994).  High levels of 
fibrinogen clusters with most of the major coronary risk factors, such as 
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abdominal obesity (Vorster et al., 1998), dyslipidaemia (Møller & 
Kristensen, 1991; Kannel, 1997), diabetes (Haffner, 2003) and 
hypertension (Best et al., 2008).  It is suggested that fibrinogen 
represents one mechanism by which various other risk factors lead to 
CHD, based on the premise that other risk factors are able to mediate a 
fibrinogen effect (Ernst & Resch, 1993).  This hypothesis seems highly 
valid. A raised plasma fibrinogen concentration is linked to an 
unfavourable lipoprotein profile, as well as associated with the serum-
TC levels (Ernst & Resch, 1993).  Several other studies support this 
positive relationship between fibrinogen and raised plasma cholesterol 
(Cushman et al., 1996; Alikmets, Parik & Teesalu, 1996; Ridker, 2000;  
Fibrinogen Studies Collaboration, 2005). Stone & Thorp (1985) 
implicates the risk of CHD to increase six times if both elevated TC and 
plasma fibrinogen levels are present.  This relationship extends to other 
clotting proteins. Factor VII activity (Wilhelmsen et al., 1984; Prisco et 
al., 1996; Cushman et al., 1996) and factor VIIIc activity (Pan et al., 
1997) were also positively associated with TC and LDL-C. Halle et al. 
(1996) and other studies reported a significant association between 
elevated fibrinogen levels, factor VII activity and reduced HDL-C levels.  
Although Møller & Kristensen (1991) indicates that HDL-C levels are 
independently related to the plasma fibrinogen levels, both serum 
triglyceride levels and obesity act as confounders within the formula 
(Halle et al., 1996). 
Furthermore, Veldman (2008) reviewed that not only fibrinogen itself 
but also the quality of resultant fibrin networks may be a predisposing 
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risk factor for the development of cardiovascular disease.  Fibrin 
network architecture as a CHD risk is discussed earlier.  However, 
Veldman (2008) reported that changes in plasma fibrinogen 
concentrations need not be present to induce alteration in fibrin 
network architecture.   Studies confirmed that a cardiovascular risk 
reducing diet promoted the formation of ―healthier‖ fibrin networks, 
believed to be less atherogenic, without inducing a fibrinogen lowering 
effect (Veldman et al., 1997; Veldman et al., 1999). This aspect 
requires further research. 
2.3.5 Other cardiovascular risk factors 
Risk factors mediate their effect by causing change in the quality and/ 
or concentration of an established metabolic risk marker. These effects 
can then be measured experimentally. In the previous section, diet and 
urbanisation as risk factor for CHD have been reviewed. Yet, as 
mentioned earlier, CHD is a multifactorial disease. Other risk factors 
generally associated with an increased CHD risk, not discussed here in 
detail, include: 
 Smoking (Haapenen et al., 1989; Homer et al., 1991; Ingall et 
al., 1991; Lichtenstein et al., 2006; Karaolis et al., 2010; Bowen, 
2010); 
 Obesity (Lowe et al., 1988; Lee et al., 1990; Lowe et al., 1992; 
De Pergola & Pannacciulli, 2002; Bowen, 2010) ; 
 Diabetes mellitus (Colwell, 1988; Ostermann & Van de Loo, 
1996; Hu et al., 2000; Bowen, 2010);  
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 Hypertension (Kannel, 1991; Rodgers & MacMahon, 1999; Van 
den Hoogen et al., 2000; Karaolis et al., 2010); 
 Stress, or type A personality (Siltanen, 1987; Dimsdale, 1988);  
 Gender (Beard et al., 1989; Stampfer et al., 1991; Wilson et al; 
1998) ; 
 Physical inactivity (Powell, Thompson & Casperson, 1987; 
Møller & Kristensen, 1991; Kannel, 1997; Lichtenstein et al., 
2006) and  
 Age (Bush, Fried & Barrett-Connor, 1988; Witterman et al., 
1989; Barrett-Connor & Bush, 1991; Wilson et al., 1998). 
 
2.4 DIETARY FIBRE 
 
2.4.1 Introduction 
 A large quantity of material describes how a diet rich in fibre is 
beneficial to human health, including a decreased risk of CHD and 
improved laxation (Dietary Guidelines for Americans, 2005). Rimm et 
al. (1996) suggests that fibre independent of fat intake is an important 
dietary component for the prevention of CHD.  The ―Fibre Hypothesis,‖ 
first described by Dennis Burkitt & Hugh Trowell in the early 1979, 
suggests that a diet rich in fibre helps protect against certain diseases 
preventable in the affluent Western communities (Burkitt & Trowell, 
1986).  
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 Dietary fibre can affect satiety, blood glucose, lipid metabolism and 
through fermentation exert a major control on colonic function, 
including bowel habit, transit, the metabolism and balance of the 
commensal flora and large bowel health (Cummings & Stephen, 2007).  
During their transit through the alimentary tract, dietary fibres have 
many opportunities to interact with the substrates, effectors and 
products of digestion as well as a variety of other substances 
progressing towards absorption or evacuation (reviewed by Deskens, 
1996). 
 Addition of fibre for treatment of disorders such as atherosclerosis and 
colon cancer could hold therapeutic value (Wrong, 1995).  Adding 3g 
per day of soluble fibre from oat bran can reduce total cholesterol by 
0.13mmol/L (Blake & Triplett, 1995).  
 Current dietary guidelines recommend a total daily intake of at least 20 
to 30 grams for adults, with 25 percent of the fibre being soluble fibre 
(NCEP, 2002).  These levels may be attained with a proposed six or 
more daily servings of grain products and five or more daily servings of 
fruit and vegetables.  
2.4.2 Classification, chemistry and sources of dietary fibre 
Dietary fibre is defined as plant material, mainly derived from plant cell 
walls, that is resistant to digestion by human gastrointestinal enzymes 
(Englyst, Liu & Englyst, 2007).   Food chemists prefer to define fibre as 
―lignin and non-starch-polysaccharides (NSP)‖, where NSP includes 
cellulose, hemicelluloses, pectin, gums and mucilage, found in food 
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(Cummings & Stephen, 2007).  NSP is not hydrolysed by small-
intestinal enzymes and is a suitable substrate for the bacterial 
production of short chain fatty acids (SCFAs), acetate, propionate and 
butyrate in the large bowel, together with incompletely digested starch, 
lactose and proteins (Champ et al., 2003; Fuller & Perdigon, 2003).  
Soluble fibres such as pectin, gums and certain hemicelluloses, are 
almost completely fermented in the colon to SCFAs (Walker, 1993). 
2.4.3 Production of Short-Chain Fatty Acids 
Short-chain fatty acids are the final product of microbial fermentation of 
dietary fibre within the digestive tract.  SCFAs are biochemically more 
closely related to carbohydrates than fats.  Some of them are not 
constituents of natural fats, and they are not ―fatty‖, as the 
nonprofessional envisages the term, as they are completely miscible in 
water (Wrong, 1995).  SCFAs (acetate, propionate and butyrate) and 
gases (H2, CH4 & CO2) are the main products of the anaerobic 
breakdown of complex polysaccharides by colonic bacteria (Topping & 
Clifton, 2001).  SCFAs make up the predominant anions in the large 
intestine of mammals and create a slightly acidic pH level (6.0-7.0).  
SCFAs vary widely in their relative proportions, depending upon the 
fibre source in the diet.  Various population data show that SCFA 
production is in order of acetate > propionate > butyrate in a molar ratio 
of approximately 60:20:20 or 3:1:1, respectively in the proximal and 
distal colon (Cummings, 1981; Cummings et al., 1987; Topping & 
Clifton, 2001).   
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Fermentation of dietary fibre involves a variety of reactions and 
metabolic processes in the anaerobic microbial breakdown of organic 
matter, yielding metabolisable energy for microbial growth and 
maintenance and other metabolic products for host use (Hijova & 
Chmelarova, 2007).  
Carbohydrates are fermented (Fig.2.1) by saccharolytic bacteria 
primarily in the proximal colon producing linear SCFAs, CO2 and H2 
(Macfarlane & Macfarlane, 2003), and both the presence of 
carbohydrates in the colon and their fermentation can alter the colonic 
physiology.  Fermentation of proteins and amino acids by proteolytic 
bacteria yield branched SCFAs, SCFAs, CO2, CH4 and H2, phenols, and 
amines (Roberfroid, 2005).  The primary effect of SCFAs on colonic 
function is the result of their uptake and metabolism by colonocytes, 
although SCFAs are also metabolic substrates for other host tissues.  
The production of SCFAs is determined by many factors, including the 
numbers and types of micro flora present in the colon (Roberfroid, 
2005), substrate source (Cook & Sellin, 1998), and gut transit time.   
Other predominant factors that affect SCFA production from 
polysaccharides and protein by bacteria in the large intestine are as 
follows:  
 chemical composition of the fermentable substrate;  
 amount of substrate available;  
 type of bacteria present in the large gut;  
 rate of depolymerisation;  
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 colonic transit time;  
 availability of inorganic electron acceptor;  
 pH of the gut content, particularly in the proximal colon;  
 fermentation strategies of substrate-utilising bacteria;  
 substrate specificities and catabolite regulation mechanism of 
individual competitive and co-operative particle size;  
 solubility and association with indigestible complexes such as 
lignin, tannins and silica (Macfarlane & Gibson, 1995). 
 
 
 
 
Figure 2.1 SCFA production in the colon.  The basic pathway for production 
of a variety of SCFA metabolites by bacterial fermentation in the colon lumen 
(Macfarlane & Gibson, 1996). 
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2.4.4 Absorption and functions of SCFAs 
Short-chain fatty acids are rapidly absorbed in the caecum and colon 
with only 5% to 10% excreted in the faeces (Cook & Sellin, 1998).  
SCFA absorption in the large intestine involves several processes: non-
ionic diffusion, carrier-mediated mechanisms, diffusion after 
protonation, carrier mediated SCFA anion exchange with bicarbonate, 
and diffusion coupled with sodium absorption (Scheppach, Fabian & 
Kasper, 1987; Fuller & Perdigon, 2003).  It is widely believed that the 
transmural movement of SCFAs is a concentration-dependent, passive 
diffusion process, whereby SCFAs, at least in part, are transported in 
the protonated form.  Hydrogen ions are needed for SCFA protonation, 
because 99% of SCFA (pKa = 4.8) are in the ionised form for hydration 
of luminal CO2 to HCO3- and H+.  In addition, the mechanism of uptake 
into enterocytes is undoubtedly a complex process involving a number 
of factors and mechanisms (Engelhardt, 1995).  The precise 
mechanism for the absorptive process of SCFAs remains undefined, 
but all these above outlined factors seem to play a role (Brøbech-
Mortensen & Clausen, 1996).   SCFAs uptake is associated with the 
transport of water that seems to be higher in the distal than in proximal 
colon (Hijova & Chmelarova, 2007).   
The role of SCFAs has expanded to include their role as nutrients for 
the colonic epithelium, as modulators of colonic and intracellular pH, 
cell, volume, and other functions associated with ion transport, and as 
regulators of proliferation, differentiation, and gene expression (Cook & 
Sellin, 1998).  Increases in SCFAs result in decreases of pH, which 
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indirectly influence the composition of the colonic micro flora, decrease 
solubility of bile acids, increase absorption of minerals (indirectly), and 
reduce the ammonia absorption by the protonic dissociation of 
ammonia and other amines (i.e., the formation of less diffusible NH4+ 
compared with the diffusible NH3) (Vince, Kingley & Wong, 1978; 
Jenkins et al., 1987). 
2.4.5 SCFAs Metabolism 
The SCFAs that escape colonic metabolisation enter the hepatic portal 
blood, where their concentration varies over a wide range, depending 
on their intestinal production rates, and therefore on the diet.  The 
major site of SCFA metabolism is the liver; where butyrate and 
propionate are almost entirely absorbed.  However, the percentage of 
acetate uptake is lower (frequently less than 50%).  SCFA 
concentrations in the portal vein are closely dependent on digestive 
fermentation (Brøbech-Mortensen & Clausen, 1996).  The relative 
proportions of the three major acids in the portal blood reflect the 
relative proportions of those found in the intestinal contents (Bugaut & 
Bentéjac, 1993).  Portal vein concentrations of butyrate are 
approximately tenfold higher when compared to the peripheral vein 
concentration, while propionate concentrations are 20 - 40 fold higher 
and acetate concentrations only approximately fourfold higher. 
The major SCFAs, acetate, propionate and butyrate are absorbed at 
comparable rates in different regions of the colon.  Once absorbed, 
SCFAs are metabolised at three major sites in the body (Hijova & 
Chmelarova, 2007).  : 
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1. cells of the ceco-colonic epithelium that use butyrate as a major 
substrate for the maintenance of energy producing pathways; 
2. liver cells that metabolise residual butyrate with propionate used 
for gluconeogenesis; 50% to 70% of acetate is also taken up by 
the liver; 
3. muscle cells that generate energy from the oxidation of residual 
acetate (Hijova & Chmelarova, 2007).   
2.4.5.1 Acetate metabolism 
Acetate, the principal SCFA in the colon, is readily absorbed and 
transported into the liver, and therefore less metabolised in the colon 
(Hijova & Chmelarova, 2007).  The metabolic fate of acetate and its 
role in the liver is connected to the general orientation of metabolism 
towards carbohydrate or lipid utilisation (Rèmésy, Demigné & 
Morand, 1995).  Acetate is the primary substrate for cholesterol 
synthesis.  In the host, it may be absorbed and utilised by peripheral 
tissues (Pomare, Branch & Cummings, 1985), further, bacteria 
isolated from the human intestine are capable of utilising acetate for 
the production of butyrate in the colon (Duncan et al., 2002). 
Furthermore, acetate can stimulate gluconeogenesis from lactate.  A 
substantial fraction of acetate from digestive fermentation is not taken 
up by the liver.  Splanchic balance of acetate is always positive, even 
during fasting periods.  Most of the extrasplanchnic tissues can 
metabolise acetate, for example, adipose tissue, mammary gland 
(cytosolic), muscle, kidney, and the heart (mitochondrial).  The 
presence of acetyl-CoA synthesis in the cytosol of adipose and 
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mammary glands allows the use of acetate for lipogenesis once it 
enters the systemic circulation, whereas the mitochondrial localisation 
favours its utilisation for energy supply in the Krebs cycle (Rèmésy, 
Demigné & Morand, 1995; Hijova & Chmelarova, 2007). 
2.4.5.2 Butyrate metabolism 
Butyrate is an important source of energy for colonocytes and thus 
extensively metabolised by the colon (Kruh, Defer & Tichonicky, 
1995).  Butyrate is found in a lower proportion in the blood draining 
the large intestine when compared to blood draining the lumen 
(Brøbech-Mortensen & Clausen, 1996).  This reflects the fact that a 
large part of absorbed butyrate is metabolised by the mucosa (to 
carbon dioxide and ketone bodies).  Butyrate is an important fuel for 
the colonic mucosa whereas acetate and propionate are released into 
the portal blood.  Butyrate is exclusively metabolised in mitochondria 
(carnitine-independent source of acetyl-CoA) and acts as a potentially 
ketogenic substrate during the post-absorptive period.  In fed 
subjects, butyrate may represent a precursor for lipogenesis.  High 
concentrations of butyrate inhibit propionate utilisation.  Because of 
the provision of acetyl-CoA in mitochondria, butyrate is an effective 
activator of gluconeogenis from lactate, and of ureogenesis; thus 
butyrate probably thwarts some of the inhibitory effects of propionate 
on gluconeogenesis (Rèmésy, Demigné & Morand, 1995). 
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2.4.5.3 Propionate  metabolism 
Propionate can be found in portal blood, although some may be 
metabolised in the colonic epithelium and may be a differentiating 
factor, but with less power than butyrate (Champ et al., 2003).  
Propionate is produced via two main pathways (Cummings, 1981) : 
1. fixation of CO2 to form succinate, which is subsequently 
decarboxylated; 
2. from lactate and acrylate (Cummings, 1981).   
Much of the knowledge about the nutritional fate of propionate comes 
from studies of ruminants.  Intestinal glucose uptake is minimal in 
ruminants because of the presence of microbiota in their rumen for 
the digestion and fermentation of carbohydrates (Hijova & 
Chmelarova, 2007).  Production of SCFA constitutes the major 
source of ruminant energy (Hooper, Midtvedt & Gordon, 2002) where 
propionate is a primary precursor for gluconeogenesis.  Propionate 
metabolism in humans is not understood very well. 
Under normal conditions, propionate is completely metabolised by the 
liver (Rèmésy, Demigné & Morand, 1995).  This process is certainly 
favoured by facilitated diffusion, which is efficient even in the 
presence of relatively low propionate concentrations (Fafournoux, 
Rèmésy & Demigné, 1985).   
2.4.6 Biological Effects of SCFAs 
Various epidemiological and case control studies have shown that the 
intake of dietary fibre has some beneficial effects on the health of 
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human subjects (Brøbech-Mortensen & Clausen, 1996).    Colonic 
fermentation of dietary fibre results in SCFAs (Bourquin, Titgemeyer & 
Fahey, 1992).  After absorption, each of the primary SCFAs produced 
is metabolised by the body and many biological effects of SCFAs have 
been reported (Bourquin, Titgemeyer & Fahey, 1992).  SCFAs 
influence carbohydrate and lipid metabolism, and may therefore 
contribute to the protective effect of NSP against degenerative western 
diseases associated with fibre intake (Burkitt & Trowell, 1986; Wolever, 
Spadafora & Eshuis, 1991).   
Especially the cholesterol-lowering effects of dietary fibre intake have 
been the topic of many studies.  Veldman et al. (1997) found that pectin 
supplementation caused significant decreases in total cholesterol,  
LDL-C, apo A, apo B and lipoprotein (a).  Vorster et al. (1988) also 
suggested that SCFA production, which is quickly absorbed and 
transported to the liver, is one of the possible mechanisms by which 
NSP may influence the synthesis of coagulation factors.    
2.4.6.1 Acetate  
When acetate is administered through different routes, for example 
oral, rectal and intravenous, to healthy human volunteers a decrease 
in glycerol levels and a significant decrease in serum concentrations 
of free fatty acids is seen.  Acetate appears to compete with long-
chain fatty acids for oxidation in certain tissues, promote hepatic 
cholesterol synthesis and decrease lipolysis (Topping & Pant, 1995).  
Acetate is the primary substrate for cholesterol synthesis.  Veldman 
et al. (1999) postulated that acetate affected fibrin network structure 
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in a positive way.  The networks were more permeable and had lower 
tensile strength and are believed to be less atherogenic.  These 
changes are partly accounted for by the direct effect of acetate on 
fibrin network structure. 
2.4.6.2 Propionate 
Propionate supplemented diets have been shown to lower blood 
cholesterol in rats (Chen, Anderson & Jennings, 1984; Illman et al., 
1988) and pigs (Boila et al., 1981), but in humans the effects are less 
clear.  Venter, Vorster & Cummings (1990) administered 7.5g of 
propionate daily in capsule form to healthy subjects for seven weeks.  
Propionate use did not affect serum cholesterol levels but significantly 
increased HDL-C.   
Venter et al. (1997) undertook a study where baboons were fed a 
western diet with either a 2% propionate or 5% soluble dietary fibre 
concentrate supplement.  Total serum cholesterol values were 
increased in the baboons fed a non-supplemented western diet.  
Soluble fibre supplementation prevented this increase, while 
propionate did not.  However, both propionate and fibre intake 
increased the serum HDL-C concentration.  Furthermore, the liver 
cholesterol concentration was lowered with propionate and fibre 
supplementation.  Experimental studies in animals indicate that 
feeding oat bran has hypocholesterolaemic effects (Brøbech-
Mortensen & Clausen, 1996).  Concomitant to this, oat bran 
significantly increases portal vein propionate concentration.  In 
comparison, cellulose that does not lower cholesterol levels does not 
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increase the propionate concentration.  In vitro studies indicate that 
propionate at physiological concentrations, significantly decreases 
hepatic cholesterol synthesis (Anderson, 1995).  Other conflicting 
results show that propionate administered rectally, has no effect on 
either the circulating total cholesterol or the triglyceride concentration 
(Wolever, Spadafora & Eshuis, 1991).  When administered orally, 
propionate is reported to have no effect on serum cholesterol levels, 
but causes an increase in the triglyceride concentration (Brøbech-
Mortensen & Clausen, 1996).  Conflicting results show that the total 
serum cholesterol concentration is slightly decreased and the 
triglyceride concentration slightly increased when propionate is 
administered (Anderson, 1995). 
A number of mechanisms have been suggested to be responsible for 
the observed lipid lowering effect, with an increased propionate 
production being one of the possible mechanisms (Hijova & 
Chmelarova, 2007).   Increased production of propionate, through 
fermentation, may inhibit hepatic cholesterol synthesis.  It seems 
possible that one of the determinants of action of propionate in serum 
lipids is the ratio of propionate to acetate (Cheng & Lai, 2000; 
Wolever, Fernandes & Rao, 1996).     
2.4.6.3 Butyrate 
The effect of butyrate on haemostasis is not known, while the effect 
on lipid metabolism has not been extensively studied.  In cultured cell 
lines, butyrate is a well-recognised antitumor agent, whereas the 
other SCFAs are much less active in this respect (Young & Gibson, 
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1995; Brøbech-Mortensen & Clausen, 1996).  Sodium butyrate exerts 
an antiproliferative activity on many cell types that have demonstrated 
preventative effects of butyrate on colon cancer and adenoma 
development (Bornet et al., 2002).  At a molecular level, butyrate 
affects gene expressions via the phosphorylation and acylation of 
histone proteins (Archer & Hodin, 1999).  Butyrate also stimulates 
immunogenicity of cancer cells (Hijova & Chmelarova, 2007).   
 
2.5 SUMMARY 
In this chapter, the author provides a summary of the most important 
theoretical concepts that relates to this study.  Risk factors that provide 
some evidence to increase the risk of cerebrovascular and CHD and 
how these are linked to diet and urbanisation have been reviewed.    
Cerebrovascular disease and CHD are of the most important causes of 
morbidity and mortality amongst South Africans.   It is evident that 
black populations of South Africa are now migrating and adopting a 
more westernised lifestyle, which includes a diet low in fibre and high in 
fat.  This urbanisation and adoption of a westernised diet, is one of the 
reasons responsible for the rise in cardiovascular disease in the black 
population of South Africa.   
In general, it is suggested that lifestyle management should be the first 
choice when having to treat patients at risk of CHD. Diet is one of the 
controllable factors in the treatment and prevention of westernised 
diseases such as CHD.  Based on current understanding, it is apparent 
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that western diets do not contain enough dietary fibre.  Furthermore, 
research has shown that the addition of dietary fibre may have a 
beneficial effect on some known coronary risk factors.  The 
physiological effects of dietary fibre in humans are significantly 
influenced by the degree to which fibre is fermented to SCFAs, acetate, 
propionate and butyrate, in the colon.  It will be discussed how these 
SCFAs are believed to be one of the possible mechanisms through 
which dietary fibre protects against heart disease. 
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CHAPTER 3 
 
METHODOLOGY 
 
3.1 INTRODUCTION 
 
The main objective of this study was to measure the possible metabolic 
effects of the intake of different combinations of colonic release SCFA 
supplements on lipid and haemostatic risk profiles in westernised black men.  
The diet of a group of westernised African male volunteers was supplemented 
with different combinations of short-chain fatty acids, for a period of six weeks, 
in addition to supplementation with placebo for one week at the beginning and 
end of the study.  Blood was drawn at various intervals and analysed to 
assess changes in the metabolic profiles of the volunteers.  In this chapter, 
the author provides a comprehensive summary of all methods and materials 
used in this study. 
 
3.2 STUDY DESIGN 
 
The study design was that of a randomised, placebo-controlled, double 
blinded, clinical research trial (represented in Figure 3.1).  Seventy-five 
volunteers that adhered to a predetermined set of inclusion criteria (see 
section 3.6.1) were recruited from the Military Base at Tempe Defence Force,  
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RECRUITMENT 
Screening (n=120) 
75 Subjects recruited according to inclusion / exclusion criteria 
   
MEASUREMENTS AT BASELINE 1 (day 0) 
75 SUBJECTS 
 Blood sampling for metabolic parameters 
 Anthropometric measurements 
 Blood pressure 
 Food Frequency questionnaire (FFQ)  
                                              
 
MEASUREMENTS AT BASELINE 2 (day 8) 
75 SUBJECTS 
 Blood sampling for metabolic parameters 
 Anthropometric measurements 
 Blood pressure 
Group 1 (n=25) 
 
Placebo Supplement 
(SCFA free) 
Group 2 (n=25) 
 
50% acetate/ 
50% propionate 
supplement 
 
Group 3 (n=25) 
 
70% acetate/ 
15% propionate/ 
15% butyrate supplement 
   
MEASUREMENTS AFTER 4 WEEKS of continuous supplementation 
(day 36) 
Group 1 (n = 21) Group 2 (n = 23) Group 3 (n = 22) 
 Blood sampling for metabolic parameters (day 22 and day 36) 
 Anthropometric measurements 
 Blood pressure 
 Food frequency questionnaire (FFQ) 
  
 
COMPLETION OF STUDY (day 43 – washout period) 
 Blood sampling for metabolic parameters 
 Anthropometric measurements 
Figure 3.1 Schematic representation of the study design 
 
Placebo Supplementation 
Placebo Supplementation 
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Bloemfontein, and randomly assigned to three different supplementation 
groups.  Group 1 was assigned a placebo supplement filled with non-
fermentable cellulose.  Group 2 was assigned  a supplement containing short-
chain fatty acids in a ratio of 50% acetate and 50% propionate.  Group 3 was 
assigned a SCFA supplement in a ratio of 70% acetate, 15% propionate and 
15% butyrate.  Researchers, field-workers and the volunteers were unaware 
of the assignment.  It was also not possible to differentiate between 
supplements based on the capsules, or the physical  characteristics of the 
content. The study was therefore of a double-blind nature. 
For standardisation purposes, experimental supplementation followed after 
collection of two subsequent baseline samples on day 0 and 8, during which 
all subjects took placebo supplements. in order to obtain a stable reference 
baseline.   On day 8, the subjects were randomised into three different 
experimental groups of 25 subjects each. The groups  were assigned to either 
one of the two experimental SCFA combinations, or the placebo.  
Supplementation was then sustained for four weeks (days 8-36).  During this 
experimental phase, blood samples were drawn after two weeks of 
supplementation (on day 22) and again at the end of the four-week period 
(day 36).  An additional washout period followed, during which all subjects 
received the placebo supplement for an additional  period of seven days (day 
36 to day 43), after which blood was drawn to assess the recovery of 
measured variables after supplementation. 
The study was undertaken at a time specifically designed to minimise possible 
seasonal effects on human metabolism.  The dietary intake of the group was 
under strict control during the study. What was of importance, is that no major 
59 
 
changes in their intake occurred during the intervention period. All meals were 
therefore served at the same mess of the Tempe Defence Force. In addition, 
the principle investigator of this study, as a registerd dietitian, were 
responsible for working out their menue at this mess. Food Frequence 
Questionnaires were completed at the beginning and end of the study, but 
used only for control purposes and will not be discussed in this thesis.  At the 
end of the study, the subjects completed a questionnaire to report their 
experiences during the study, in addition to any side effects (Appendix D). 
 
3.3 SUBJECT SELECTION 
 
A recruitment day was scheduled at the premises of the Tempe South African 
National Defence Force base in Bloemfontein, during which blood samples 
were drawn, dietary intake, social and demographic background 
questionnaires  were completed, as well as anthropometric measurements 
taken as part of the screening process.  The inclusion criteria used for the 
selection of subjects in this study are discussed under section 3.6.1. The 
scientific value of the study and expectations of the researchers were also 
explained to the volunteers, in both English and their preferred mother tongue.  
Inclusion criteria were strictly adhered to for selection of participants.  
 
3.4 ETHICAL CONSIDERATION 
 
This study proposal was submitted to and approved by the Ethics Committee 
of the University of the Free State, reference number: ETOVS 227/98.  The 
60 
 
study was conducted according to International Good Clinical Practice 
Guidelines and adhered to the contents of the Declaration of Helsinki.  All 
subjects participating in the study received information leaflets that explained 
the relevance of the study.  Subjects were requested to give written consent 
(Appendix A). A record of patients and their appropriate assignments were 
kept at the NESTEC Research Laboratory, Lauzanne, Switzerland, for safety 
purposes, in case of an emergency. 
 
3.5 OPERATIONAL DEFINITIONS 
Variables defined to meet the objectives of this study, included the general 
health profiles, lipid profiles, haemostatic profiles, and glycometabolic 
indicators.  
3.5.1 General Health Profiles 
For the purpose of this study, health status includes the anthropometric 
measurements, a selection of biochemical parameters, and blood 
pressure as general markers of health and nutritional status. 
3.5.1.1 Anthropometric measurements 
Body mass inex (BMI), a definition of the degree of adiposity is a 
validated measure of nutritional status (see Table 3.1) (Hammond, 
2008), even though it is not very accurate in that sense.  BMI 
accounts for differences in body composition by defining the level of 
adiposity according to the relationship of weight to height, thus 
elimination dependence on frame size (Lee & Nieman, 2003; Gibson, 
2005).   
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Table 3.1  Classification of BMI (Laquatra, 2004) 
Classification BMI 
Underweight < 18.5 kg/m2 
Normal weight 18.5 – 24.9 kg/m2 
Overweight 25.0 – 29.9 kg/m2 
Obesity, class I 30.0 – 34.9 kg/m2 
Obesity, class II 35.0 – 39.9 kg/m2 
Obesity, class III >40 kg/m2 
 
Waist circumference measurements assess abdominal fat content.  
A measurement of greater than 102 cm for men is an independent 
risk factor for disease when out of proportion to total body fat (Centre 
for Disease Control and Prevention, 2002). 
3.5.1.2 Blood Pressure 
Blood pressure is dynamic and measured as an indicator of the 
physical and emotional state of the subject at the time of the 
measurement (De Bono & Boon, 1991).  A general definition of 
hypertension is a systolic blood pressure (SBP) of 140 mmHg or 
higher or a diastolic blood pressure (DBP) of 90 mmHg or higher, or 
both.  In the seventh Report of the Joint National Committee on 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 
VII) (Joint National Committee, 2004), hypertension is classified in 
stages based on the risk of developing CVD (see Table 3.2). 
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Table 3.2 Classification of Blood Pressure (Joint National 
Committee, 2004) 
Blood Pressure 
Classification 
SBP 
mmHg 
DBP 
mmHg 
Normal <120 and <80 
Prehypertension  120-139 or 80-89 
Stage 1 Hypertension 140-159 or 90-99 
Stage 2 Hypertension ≥160 or≥100 
 
 3.5.1.3 Biochemical parameters 
Serum-total protein (TP) and -albumin, have been used for decades 
now as biochemical risk markers for general health and nutritional 
status (Lindsay, 1996). 
Serum total protein is a biochemical test for measuring the total 
amount of protein in blood plasma or serum.  Protein in the plasma 
constitutes of albumin and globulin (Lindsay, 1996).  
Serum total albumin is the most abundant and most often measured 
plasma protein and a strong predictor of health (Lindsay, 1996). 
 Full blood count is one of the most commonly performed blood 
tests, which can be used as an indication of general health status.  A 
full blood count examines the different components of blood, 
including red blood cells, white blood cells and platelets (Lindsay, 
1996) and can be used to indicate the presence of infection, or even 
chronic diseases. It is important to note that in this study, the Full 
Blood Count data was analysed as part of the general health profiles 
and not as part of the haemostatic profiles. A Full Blood Count is 
used to establish the general health of patients under normal clinical 
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conditions. It was therefore used in that respect, as it was not 
expected that the intervention would affect any of these parameters. 
3.5.2 Lipid profiles 
Serum-total cholesterol (TC), serum low-density lipoprotein cholesterol 
(LDL-C), serum high-density lipoprotein cholesterol (HDL-C), serum 
triglycerides (TG) as part of the lipid profile (NCEP, 2002). 
3.5.2.1 Serum total cholesterol (TC) 
A total cholesterol measurement captures cholesterol contained in all 
lipoprotein fractions: 60% to 70% is carried on LDL, 20% to 30% on 
HDL, and 10% to 15% on very low-density lipoprotein cholesterol 
(VLDL).  There is a direct, positive relationship between total 
cholesterol and CHD (Krummel, 2008).  The clinical classification of 
serum total cholesterol is provided in Table 3.3. 
 
Table 3.3 Classification of serum Total Cholesterol (NCEP, 2002) 
Total Cholesterol mmol/L 
Desirable <5.17 
Borderline High 5.17-6.18 
High ≥6.20 
 
3.5.2.2 Serum Low-Density Lipoprotein Cholesterol (LDL-C) 
Lipoproteins are the major cholesterol carrier in the blood.  High 
levels are associated with increased risk of CHD (Krummel, 2008).  
The clinical classification of serum LDL-Cholesterol is provided in 
Table 3.4. 
 
64 
 
Table 3.4 Classification of serum LDL-Cholesterol (NCEP, 2002) 
LDL-Cholesterol mmol/L 
Optimal <2.59 
Near Optimal/ above optimal 2.59-3.34 
Borderline High 3.35-4.1 
High 4.14-4.89 
Very High ≥4.9 
 
3.5.2.3 Serum High Density Lipoprotein Cholesterol (HDL-C) 
A plasma lipoprotein containing mostly protein and less cholesterol 
and triglyceride.  High levels of HDL-cholesterol are associated with 
a decreased risk of CHD (Krummel, 2008).  The clinical classification 
of serum HDL-Cholesterol levels are provided in Table 3.5. 
Table 3.5 Classification of serum HDL-Cholesterol (NCEP, 2002) 
HDL-Cholesterol mmol/L 
Low HDL-Cholesterol <1 
High HDL-Cholesterol ≥1.55 
 
3.5.2.4 Serum Triglycerides 
Triglycerides are the most common type of glyceride in which the 
three alcohol groups in the glycerol molecule are attached to fatty 
acids.   The triglyceride-rich lipoproteins, include chylomicrons, 
VLDL and any remnants or intermediary products formed in 
catabolism (Krummel, 2008).  Many prospective epidemiological 
studies have reported a positive relationship between serum 
triglyceride levels and incidence of CHD (reviewed by NCEP, 2002).  
The classification of serum triglycerides is provided in Table 3.6. 
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Table 3.6 Classification of serum Triglycerides (NCEP, 2002) 
Triglycerides mmol/L 
Normal  <1.7 
Borderline High 1.7-2.25 
High 2.26-5.6 
Very High ≥5.6 
 
3.5.3 Haemostatic profiles 
Plasma fibrinogen, a collection of fibrin network architecture variables, 
factor VII activity and factor VIII activity, D-Dimer, c-reactive protein and 
fibrin monomers were measured as part of the haemostatic risk profile 
(see Table 3.7): 
3.5.3.1 Plasma fibrinogen 
 Raised plasma fibrinogen levels are associated with increased risk of 
cardiovascular disease (Viles-Gonzalez, Fuster & Badimon, 2004; 
Fibrinogen Studies Collaboration, 2005). 
3.5.3.2 Factor VII and VIII activity 
 Elevated FVII (Heinrich et al. 1994) and FVIII (Pan et al. 1997) are 
associated with increased risk of cardiovascular disease.  
3.5.3.3 Antithrombin III (AT III) 
 AT III is considered a natural anticoagulant; its deficiency is 
associated with thrombosis.   
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3.5.3.4 Fibrin monomer and D-Dimer 
 Both fibrin monomer and d-dimer levels are considered as potential 
risk markers for development of cardiovascular events.  D-dimer is a 
product of clotted fibrin breakdown, and is usually found in increased 
levels in patients with hypercoagulable disease states occurring 
before and after cardiovascular events.   
3.5.3.5 Fibrin network architecture 
 Three independent methods have been used in this study to 
characterise the fibrin network architecture.  The mass-length ratio 
serves as a measure of fibrin thickness (Nair et al., 1991a).  
Compaction characterises the degree of cross-linking and tensile 
properties of the fibrin network (Nair & Shats, 1997). The network 
lysis rate, which could be used to assess the overall structure of the 
fibrin network in terms of lytic rate under controlled conditions.  
Gabriel, Muga & Boothroyd (1992) have shown that thin fibrin fibres 
are lysed more slowly when compared to thick fibrin fibres. 
3.5.3.6 C-reactive protein 
 C-reactive protein (an acute phase protein) was measured to ensure 
that possible changes in other haematological parameters may not 
be due to inflammation or any other unknown acute phase response, 
and also because it is associated with CHD. 
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Table 3.7 Normal ranges for haemostatic profiles (Department 
Haematology and Cell Biology, University of the Free 
State & NHLS, 2003) 
 Normal Range 
Plasma fibrinogen  2.0 -4.0 g/L 
Favtor VII 50 – 150% 
Factor VIII 50 – 150% 
AT III 76 – 122% 
D-Dimer < 500 µg/dL 
C-reactie protein 0 – 03mg/dL 
 
3.5.4 Glycometabolic indicators 
Fasting serum glucose and -insulin levels were measured as part of the 
carbohydrate risk profile.   
3.5.4.1 Fasting Serum Glucose 
According to the Framingham Heart Study, the association between 
elevated plasma glucose and CHD risk is a continuous variable. 
Some investigators view impaired fasting glucose (IFG) to be an 
independent risk factor for cardiovascular disease (NCEP, 2002).  
According to the American Diabetes Association (ADA) (2008) IFG 
can be defined between 5.6mmol/L to 6.9 mmol/L.   
3.5.4.2 Fasting Serum Insulin 
The metabolic syndrome is closely associated with a generalised 
metabolic disorder called insulin resistance, in which tissue 
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responsiveness to the normal action of insulin is impaired (Haffner, 
1999).  According to Alberti, Ziimmet and Shaw (2006) insulin 
resistance correlates with the risk of CHD.  The mechanisms 
underlying the link between insulin resistance and CHD require 
further investigation. 
 
3.6 MATERIALS 
3.6.1 Study population 
Approximately one hundred and twenty members of the SANDF were 
screened for participation in the study.  The subjects had to be 
permanent African male staff residing at the Tempe Military base, 
Bloemfontein.  Subjects were selected based on the following inclusion 
criteria: 
 No smokers 
 No previous history of cardiovascular incidences, diagnosed 
diseases of lifestyle (diabetes, hypercholesteraemia, etc.) or 
apparent genetic disorders 
 No usage of chronic medications 
 No usage of medication or other supplementation during the 
study, without the knowledge of the principal investigator 
 No apparent lifestyle changes during study and at least six 
months prior the study 
 Subjects should have been permanent staff for at least one year 
prior the study 
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 Subjects with a plasma fibrinogen level lower than 2.5 g/L were 
excluded from the study 
 Subjects with a fasting blood glucose levels above 5.8 mmol/L 
were excluded from the study 
 No alcohol abusers (<3 drinks/day or 28g alcohol/day) 
The background diet of all subjects had to be controlled.  All subjects in 
this study received their meals from the same mess.  
3.6.2 Sample size 
Seventy-five volunteers were recruited to participate in the study.  The 
total sample size (3 x n) was prescribed by the statistical services of the 
Research Centre, NESTEC LTD PTY, Lauzanne.  A calculation based 
on the results of previous experiments was only of partial value for 
obtaining sample size, since effects of propionate supplementation on 
outcomes measured in this study are not available.  For power 
calculations a reference of 15% change in circulating blood cholesterol 
was used (Veldman, 2000).  It was estimated that a group of 25 
individuals per supplement would allow for expected drop-outs without 
a significant loss of statistical power. 
3.6.3 Supplements 
Volunteers obtained SCFA supplements in capsules equivalent to the 
fermentation of 15 grams dietary fibre.  The capsules were designed in 
such a way that their contents were released only in the large intestine.  
This simulates the generation of SCFA from soluble dietary fibre, in the 
large intestine.  The capsules were designed in such a way that they 
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Table 3.8  Ratio of SCFAs in the different supplements 
Placebo Supplement   
Sodium chloride, calcium chloride and CMC sodium carmelel DV (S), a non 
fermentable form of cellulose.  The capsules weighed approximately 
1.0288g each.  Number of capsules per day: 8 
Supplement 1: 50% acetate; 50% propionate; 0% butyrate 
50% acetate, consisting of 0.3299g sodium and 0.2135g calcium acetate; 
50% propionate, made up of 0.2328g sodium and 0.2257g calcium 
propionate. The capsules weighed 1.0019g each. Number of capsules per 
day: 8 
Supplement 2: 70% acetate; 15% propionate; 15% butyrate 
70% acetate, consisting of 0.4618g sodium and 0.2989g calcium acetate; 
15% propionate, made up of 0.0698g sodium and 0.0677g calcium 
propionate; 15% butyrate, made up of 0.0801g sodium and 0.0779g calcium 
butyrate. The capsules each weighed 1.0562g. Number of capsules per 
day: 8 
 
contained equal amounts of the sodium and calcium salts, in order to 
protect subjects against excess intake of these ions. The ratio of SCFAs 
in the different supplements is presented in Table 3.8.    
Compliance was monitored directly by the dieticians (Captains M. de 
Wet (priniciple researcher) and A. van Onselen) – who were involved in 
the study, as the entire subject group ate their meals at the same mess 
hall of Tempe Military Base, Bloemfontein. 
71 
 
3.6.4 Specimen collection 
Fasting blood samples were required from all subjects on the 
appropriate sampling days. Venepuncture was performed between 
8:00 and 10:00 am.  Subjects were requested to fast from 22:00 the 
previous night.  For the full blood count and C-reactive protein analysis, 
blood was drawn into one 5 ml EDTA tube. Two 10 ml red top serum 
tubes were drawn for analysis of biochemical markers, and an 
additional six 5 ml tri-sodium citrate (3.8%) tubes for coagulation and 
network assays. 
3.6.5 Apparatus 
All laboratory analyses were performed using commercially available 
apparatus. Relevant information with a description of the apparatus 
used for the respective laboratory analyses is provided in table form 
(Table 3.9). 
 
Table 3.9 The apparatus used for laboratory analyses of blood specimens 
Apparatus Description Brand Name Supplier  
Coagulation analyser Coagulation Timer Behring Dade Behring 
Chemical analyser Hitachi 902 Hitachi Roche Diagnostics 
Cell counter Coulter MD 18 Coulter Beckman Coulter 
Microplate reader EL 312e Biotek Biotek Instruments 
CRP analyser MICROS CRP  ABX CRP-100 ABX Diagnostics 
Spectrophotometer Shimadzu UV-1201 Shimadzu Scientific Group 
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3.6.6 Standards and controls 
The quality of all laboratory analyses was under strict control. 
Apparatus were regularly cleaned and control samples analysed 
according to the prescribed protocol of each variable. Relevant 
information with a description of the appropriate standards and controls 
used for specific laboratory analyses is provided in table form  
(Table 3.10). 
 
Table 3.10 Standards and controls used for different laboratory 
investigations 
Standard or control Catalogue 
no. 
Supplier 
Fibrinogen Standards 1-4# OWCS 11 Dade Behring, Marburg, Germany 
Standard Human Plasma# ORKL 17 Dade Behring, Marburg, Germany 
Control Plasma N# ORKE 35 Dade Behring, Marburg, Germany 
Control Plasma P# OUPZ 13 Dade Behring, Marburg, Germany 
D-Dimer Standard Plasma# OQXA 11 Dade Behring, Marburg, Germany 
D-Dimer Control Plasma I# OQKA 15 Dade Behring, Marburg, Germany 
D-Dimer Control Plasma II# OQKB 17 Dade Behring, Marburg, Germany 
S.F.A.C.* 759350 Roche Diagnostics, Mannheim, Germany 
Percinorm® U* 171735 Roche Diagnostics, Mannheim, Germany 
Percipath® U* 171760 Roche Diagnostics, Mannheim, Germany 
# the reagents used for calibration and control of coagulation assays, while * where used 
for   chemical assays. 
 
 
3.6.7 Reagents and consumables 
Relevant information with a description of the reagents used for each 
laboratory analysis is provided in table form (Table 3.11). 
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Table 3.11 Reagents and consumables used during the study 
Reagents & consumables Catalogue no. Supplier 
Trasylol®/Aprotinin H2912 Bayer-miles, Germany 
Glass beads 267 02 50 Saarchem, South Africa 
Sodium hydroxide 582 31 80 Saarchem, South Africa 
Sodium carbonate 582 20 40 Saarchem, South Africa 
Folin & Ciocalteu’s reagent 243 300 Saarchem, South Africa 
Albumin T-3379 Sigma, USA St. Louis 
Thrombin 101141 ICN, USA 
Streptokinase 10114 ICN, USA 
CRP latex reagent 7003077 ABX Diagnostics, France 
 
3.7 METHODS AND TECHNIQUES 
 
3.7.1 Metabolic risk markers 
3.7.1.1  Specimen preparation 
Full blood count analysis was performed within four hours post 
venepuncture, after which the specimen was centrifuged, plasma 
separated and stored in 1.5 ml Eppendorf vials at –70°C for CRP 
analysis.  Clotted specimens were centrifuged; serum separated and 
stored in 1.5 ml Eppendorf vials at –70°C.  Platelet free plasma 
was obtained by centrifuging citrated blood twice, which was 
aliquoted and stored in 1.5 ml Eppendorf vials at –70°C. 
3.7.1.2 Fibrin network architecture variables 
Fibrin network structure variables were performed using citrate 
plasma.  Thirty-five micro-litres of 10.000 KIU/ml Trasylol/aprotinin 
per nine volumes of citrate plasma was added, and thus used as an 
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inhibitor of fibrin(ogen)olysis.  Plasma with trasylol was used for 
analysis of fibrin network content, compaction and mass-length ratio 
from turbidity.  Permeability was not performed because of the great 
degree of variation and the complexity of the method.  Network lysis 
rate was performed on plasma without Trasylol®. 
3.7.1.2.1 Network fibrin content 
The method of Ratnoff & Menzies (1951) was used for duplicate 
determination of the network fibrin content.  For network fibrin 
content 0.9 ml plasma was pipetted into test tubes containing 1g 
glass beads and clotted by addition of 100 µL Thrombin Reagent 
(1 IU/ml Thrombin final concentration, 25 mM Ca++ final 
concentration).  Samples were left overnight for maximum 
polymerisation.  All samples were centrifuged at 1300 x g and the 
supernatants discarded.  The isolated networks were washed 
three times with saline solution.  One ml 2.5 M NaOH was 
dispensed into each test tube and the networks dissolved by 
heating the tubes for 15 minutes at 95°C.  The samples were left 
to cool at room temperature.  Seven millilitres water and  
3 ml 1.9 M sodium carbonate were dispensed into each tube, 
containing 200 µL of the NaOH-fibrin suspension.  The tubes were 
vortexed and mixed with one ml Folin-Ciocalteu's phenol reagent.  
Samples were incubated at room temperature for 20 minutes and 
the absorbance measured at 650 nm.  Different concentrations of 
albumin were dissolved in 2.5 M NaOH and used to prepare a 
75 
 
standard curve.  This standard curve was used to calculate the 
concentration of fibrin present in unknown samples. 
3.7.1.2.2 Mass-length ratio from turbidity (µT) 
The mass-length ratio from turbidity (µT) was determined in 
triplicate for each sample, using the method as described by Nair 
et al. (1991a).  Nine hundred µL of platelet-poor plasma was 
pipetted into micro-cuvettes of 1 cm path length.  The plasma was 
mixed and clotted by addition of 100 µL Thrombin Reagent 
(1 IU/ml Thrombin final concentration, 25 mM Ca++ final 
concentration).  Samples were left overnight for maximum 
polymerisation. 
The intercepts, A, in plots of c/T()3 as a function of 1/()2 were 
used to calculate µT according to the equation: 
µT = [10/1.48xA] x 1012 daltons/cm 
with c the network content, T the absorbance  2.304 and  the 
wavelength.  Turbidity (optical density) was measured at a range 
of wavelengths between 600 and 800 nm. 
3.7.1.2.3 Fibrin network compaction 
Compaction was measured in duplicate using the method as 
described by Dhall, Bryce and Dhall (1976).  Nie hundred µL of 
plasma was pipetted into 1.5 ml Eppendorf vials, pre-sprayed 
with lecithin-based aerosol (Spray-a-Cook) to render the surface 
non-adhering.  The plasma was clotted by introduction of 100 µL 
Thrombin Reagent (1 IU/ml Thrombin final concentration, 25 mM 
Ca++ final concentration).  Samples were left overnight for 
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maximum polymerisation.  After centrifugation at 8000 X g for 
45 seconds the volume of expelled sample from the fibrin 
networks was determined using a one ml syringe and expressed 
as a percentage of the initial volume.  
3.7.1.2.4 Fibrin network lysis rate 
The network lysis rate was measured in duplicate using a method 
developed at the Fibrinogen Unit, Research laboratory.  Ninety µL 
of plasma was mixed and clotted by the introduction of 10 µL 
thrombin reagent (1 IU/ml thrombin final concentration, 25 mM 
calcium final concentration) in microtiter plates. After total 
polymerisation took place, 50 µL of streptokinase with a final 
concentration of 100 U/ml was introduced to start lysis of 
networks.  The absorbance was measured with an ELISA plate 
reader at 608 nm for six hours at 10 minute intervals.  The lysis 
rate was determined by plotting the time versus change in 
absorbance. 
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3.7.1.3 Coagulation factor determinations 
All the coagulation measurements were performed on the Behring 
Coagulation Timer auto-analyser, using the methods listed in Table 
3.12. 
 
Table 3.12 Methods used for coagulation factor determinations 
Measured variable Catalogue no Brand name Principle 
Factor VII OUHP 17 Thromborel® S Clot formation 
Factor VIII OQGS 17 Pathrombin® SL Clot formation 
Antithrombin III OWWR 17 Berichrom® AT III Chromogenic 
Fibrinogen OWZG 15 Multifibrin® U Clauss' method 
Fibrin monomers OWXZ 11 Berichrom® FM Chromogenic 
D-Dimers$ OQWW 11 D-Dimer Plus Turbidimetric 
$D-Dimer analyses were performed only on samples drawn on day 8 and 36.  These 
reagents were all provided by Dade Behring, Marburg, Germany 
 
 
3.7.1.4 Blood Chemistry analyses 
All the chemical analyses were performed on the Hitachi 902, 
automatic analyser, using the methods as listed in Table 3.13. 
 
Table 3.13 Methods used for chemical variables determination 
Variables Cat. no. Principle Supplier 
Total cholesterol 1489323 Enzymatic colorimetric Roche Diagnostics 
LDL-Cholesterol 1985604 Enzymatic colorimetric Roche Diagnostics 
HDL-Cholesterol 1930672 Enzymatic colorimetric Roche Diagnostics 
Triglycerides 1488872 Enzymatic colorimetric Roche Diagnostics 
Free fatty acids FA115 Enzymatic colorimetric Randox Laboratories Ltd 
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3.7.1.5 Full blood counts and C–reactive protein measurements 
A full blood count was performed on the Coulter® MicroDiff 18, 
automatic cell counter. CRP is determined using the CRP Latex 
Reagent, Cat. No. 7003077 (ABX Diagnostics, France). 
3.7.2 Anthropometric Measurements 
Anthropometric variables included body mass index (BMI) and waist 
circumference.  All the anthropometric measurements were performed 
by a paid field-worker, for standardisation purposes. The researcher 
trained the field-worker. The field-worker was a student in Dietetics at 
the University of the Free State and had prior experience taking 
anthropometric measurements. 
BMI refers to a relationship of weight in kilogram to the square of the 
height in meter (Lee & Nieman, 2003)  
BMI = Weight (kg) ÷ Height (m)2 
Weight: Body weight was measured according to standard method 
described by Lee & Nieman (2003) using a calibrated Seca digital 
electronic scale which weighs to the nearest  
0.1 kg.  The weight of the subjects wearing light clothing and no shoes 
was measured before blood samples were collected prior to breakfast, 
and after the subjects went to the bathroom.  The weight was 
measured at baseline and after four weeks of supplementation. 
Height: Standing height of subjects wearing light clothing and no shoes 
was measured to the nearest 0.5 cm using a stadiometer as described 
by Lee & Nieman (2003).  The subjects stood with their feet together, 
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heels against the measuring board.  They stood erect, neither slumped 
nor stretching, looking straight ahead, without tipping the head up or 
down.  The top of the ear and outer corner of the eye were in a line 
parallel to the floor (―Frankfort plane‖).  The top of the stadiometer was 
lowered to rest flat on the top of the head. 
Waist Circumference is obtained by measuring the distance around 
the smallest area below the rib cage and above the umbilicus with the 
use of a non-stretchable tape measure (Gibson, 2005).    
3.7.3 Blood Pressure 
Blood pressure was recorded by a qualified nurse using a 
sphygmomanometer and a stethoscope, before blood sampling, using 
the method as described by De Bono and Boon (1991).  The subjects 
were seated with their back supported.  The cuff was applied to the 
right upper arm, with the bag over the branchial artery and connected 
to a mercury or aneroid manometer.  The stethoscope was placed over 
the brachial artery and the cuff was inflated to a level well above that 
which abolishes the Korothov sounds.  The pressure in the cuff was 
then allowed to drop slowly and the point of return of the sounds was 
taken as the systolic pressure.  As the pressure drops further, the 
sounds become louder and then usually suddenly becomes muffled 
and later disappears, at which stage the diastolic pressure is 
measured.  Three intermittent readings were taken at two-minute 
intervals, and the lowest value was recorded.  
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3.7.4 Questionnaires 
It is important to acknowledge that this study was performed on exactly 
the same study population as a previous study, during which the 
principal investigator of this study was also involved, as a Masters 
student in Dietetics. The questionnaires used in this present study, are 
very similar to those used as part of the previous study. Yet, none of 
them are exactly the same and were the current questionnaires 
adapted for this study. 
Questionnaires used in this study included: 
i) a screening /recruitment questionnaire (Appendix B),  
ii) a food frequency questionnaire (Appendix C) and 
iii)  a tolerance questionnaire (Appendix D).  
Questionnaires were designed in collaboration with the University Free 
State and NESTEC PTY LTD. The questionnaires were tested during a 
pilot study (see section 3.10), on a group of random individuals from 
the study population, during which the average time to take each 
questionnaire was measured, as well as its clarity.  All the 
questionnaires were completed during an interview by the main 
researcher and four trained, qualified dieticians. 
3.7.4.1 Screening / recruitment questionnaire 
The screening questionnaire was developed to select subjects with 
specific characteristics according to the inclusion and exclusion 
criteria of the study.   Answers to questions regarding age, activity 
level, smoking habits, alcohol intake and a medical history were 
recorded.  All the volunteers were from exactly the same socio-
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economic background (based on income, where they live, working 
environment, etc.). The socio-demographic status of the 
respondents was therefore not a variable or considered relevant for 
the purpose of this study. All questions relating to socio-
demographic information, were therefore included as part of the 
screening questionnaire.   
3.7.4.2 Food Frequency Questionnaire (FFQ) 
  Nelson (2000) states that the purpose of dietary assessment is to 
estimate food consumption of dietary intake in individuals or groups 
of people.  The dietary intake of the subjects in this study was 
measured by means of a FFQ adopted from the THUSA study 
(North-West University) and standardised  for use in the  African 
population in the Free State Province (Hatting, 2000). This FFQ was 
adjusted to include cultural food preferences and habits of the study 
population (Macintyre, Venter & Vorster, 2000).  According to Dwyer 
(1998), the FFQ provides an overall picture of food intake. The FFQ 
were completed during and interview by the trained fieldworkers.  In 
this study, the FFQ (Appendix C) was used exclusively to control for 
the homogeneity of the study population. No detailed analyses of the 
FFQ were performed, or related to any of the blood parameters, as it 
was not within the scope of this study. It is important here to 
acknowledge that all volunteers followed exactly the same meal 
plan, which was developed by the principal investigator of this study. 
A short discussion of the dietary intake of the study group will be 
provided in Chapter 4. 
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3.7.4.3 Tolerance questionnaire 
The tolerance questionnaire (Appendix D) was completed  at the end 
of the study to determine whether any of the subjects experienced 
any possible side effects or discomfort during the intervention period,  
whether suspected to be related to the supplements or not.  Subjects 
were asked whether they experienced any of the following 
symptoms during the study: nausea, constipation, diarrhoea, 
decrease or increase in appetite, and whether the number of 
capsules was acceptable. 
 
3.8 FIELDWORKERS AND STANDARDISATION OF TECHNIQUES 
 
3.8.1 Pilot Study 
A pilot study was conducted on a group of 20 volunteers chosen 
randomly from the study population.  However, all measurements 
where simulated and no blood samples were taken from any of the 
volunteers.  The FFQ was tested on five members of the 20 volunteers 
in order to ensure the clarity of quetsions. This simulation was 
performed in order to give the research team a clear indication of 
possible problem areas and identify time- and other practical limitations 
and implications. Based on the results of this study, the research group 
could assess how much time is required for each volunteer to progress 
through each separate assessment of the study. It was then also 
possible to establish the total number of subjects that could be 
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assessed on a daily basis. The pilot study was performed one month 
prior the actual study. 
3.8.2 Fieldworkers  
The fieldworkers used in the study included: 
 A qualified nurse (registered with the South African Health 
Professions Council). The nurse worked within a general clinic 
setting, so required additional training to deal with the large number 
of blood samples taken from each volunteer, in addition to those 
samples that were specifically prepared for the study (and not part 
of general clinical investigations). The time limitations for blood 
sampling were also strictly adhered to (all samples were taken 
before 10 a.m. in order to minimise the impact of daily variation on 
the measured variables. 
 A group of four trained medical personnel of the SANDF who were 
also responsible for taking the blood samples and measuring blood 
pressure. The group was trained with the study nurse. 
 Four qualified dieticians (fourth-year students from the University of 
the Free State, Department of Human Nutrition) who were trained 
by the principal investigator of this study, to use the validated FFQ. 
 A bilingual primary health care worker of the SANDF who helped 
with the translation of the questionnaires, when necessary. All 
questionnaires were thoroughly discussed with the Principal 
Investigator of this study, before starting the actual study. 
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 A post-graduate dietetics student trained specifically to take 
anthropometric measurements (for standardisation purposes the 
anthropometric data were collected only by one single individual). 
 A full-time medical team on the premises of the SANDF. The 
subjects had 24 hour access to the medical team. The team itself 
did not participate in the study itself, but were aware that it is taking 
place and that any of the subjects could develop side-effects that 
require medical attention. 
 
3.9 VALIDITY AND RELIABILITY OF MEASUREMENTS 
Validity refers to the degree to which a research procedure or tool 
measures what it is supposed to measure (Mosdøl & Brunner, 2005; 
Gibson, 2005; Koh & Owen, 2000). Reliability refers to the degree to 
which the same results can be reproduced after repeating the 
measurement (Gibson, 2005). The validity and reliability of all 
laboratory analyses were discussed with their appropriate 
methodology, which include the use of commercially available 
standards (validity) and controls (reliability).  
3.9.1 Anthropometric measurements 
As discussed under section 3.7.2., anthropometric measurements were 
taken by a trained fieldworker in order to perform measurement 
technique correctly, and to ensure validity and reliability.  
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3.9.1.1 Validity 
The validity of a test or instrument refers to its ability to measure the 
phenomenon it intends to measure (Monsen, 1992). To ensure 
validity in this study the appropriate measuring tools and techniques 
were used as recommended in the literature and discussed under 
section 3.7.2. The student was trained beforehand by a trained 
research biokineticist. 
3.9.1.2 Reliability 
The reliability of a test or instrument is determined by its consistency 
of results when applying to the same specimen repeatedly, 
administered by either the same or different persons.  The reliability 
of physical examinations can be assessed by comparing the data 
from the same subjects gathered by two or more observers 
(Monsen, 1992). To ensure reliability in this study the fieldworkers 
used the same, standardised techniques as recommended by Lee & 
Nieman (2003). It was required of the fieldworker to repeat each 
measurement three time, after which an average was used as a final 
value.  
3.9.2 Questionnaires 
Dietary methods designed to characterise usual intakes of individuals 
are the most difficult to validate because the ―truth‖ is never known with 
absolute certainty. There is no guarantee that a subject‘s true usual 
food intake can be assessed with precision (Gibson, 2005). 
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A dietary assessment method is considered precise (i.e. 
reliable/reproducible) if it gives very similar results when repeated in 
the same situation (Koh & Owen, 2000).    
3.9.2.1 Validity  
The performance of any dietary assessment method is markedly 
influenced by the motivation and compliance of the respondents 
(Gibson, 2005).  Careful attention must be given to the choice of 
foods, the clarity of the questions and the format of the frequency 
response section, when constructing the FFQ (Koh & Owen, 2000).  
In this study, a FFQ was used that was adjusted specifically for 
African population groups, based on results from the THUSA survey. 
This FFQ lists commonly consumed foods of the target population. 
Yet, it is important to acknowledge that the food given to the study 
population at the mess, classify as westernised, and not traditional. 
The FFQ were tested during the pilot study on five individuals from 
the same group at the SANDF and who did not participate in the 
study (but came from the same population). For the purpose of this 
study, the FFQ was only used as a measure of control. 
3.9.2.2 Reliability 
A FFQ is not sensitive to day-to-day variations in intake, because it 
is designed to assess the usual food intake of an individual over an 
extended period of time. Gibson (2005) suggests that the 
reproducibility of the FFQ is good.  Reliability is influenced by the 
method of administration. Interviewer administration is likely to 
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appear more reliable than self-administration (Koh & Owen, 2000).  
The FFQ in the present study was completed by trained dieticians, 
but the principal researcher interpreted and coded the 
questionnaires.  The portion sizes used in the FFQ were compared 
to the portion sizes used in the mess and three dimentional food 
models, portion sizes, cups, plates and spoons usually used in the 
mess were used to estimate and calculate exact portion sizes. The 
results from the FFQ could be compared to the actual intake of the 
population group. It is important to acknowledge that it is only the 
energy distribution of the macronutrients (including the dietary fibre 
intake) that is of importance here. 
 
3.10 MANAGEMENT OF THE STUDY AND ROLE OF THE RESEARCHER 
 
This study formed part of a commercial endeavour, funded by the NESTEC 
PTY LTD Research group, Lausanne, Switzerland. The study was performed 
by a group of individuals, headed by Prof. FJ Veldman, the then Director of 
the Fibrinogen Unit, School of Health Technology, Central University of 
Technology. The researcher of this study, as a registered dietitian with the 
South African Health Professions Council, working on the premises of the 
SANDF where this study was performed, was responsible for all activities at 
the premises of the SANDF (letters of permission, handing out the 
supplements, recruitment of volunteers, activities at the mess, etc.). Yet, is is 
important to acknowledge that this was a large study and required the 
assistance of other research personnel and field workers. In addition, the 
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Principle Investigator of this thesis actively participated in the laboratory 
analyses of biological material. Yet, it should also be appreciated that most of 
the analyses were performed using automated equipment, and that in such 
case, the investigator of this study was assisted by trained Biomedical 
Technology students from the School of Health Technology, Central 
University of Technology. 
Daily management is an essential component of quality assurance (Dennis & 
Kris-Etherton, 1992).  A strong, capable investigative team is the key to 
avoiding problems that might prejudice the study.  Good management 
includes: organisation, communication, clear delineation and coverage of 
duties and responsibilities, contingency plans, and procedures for dealing with 
problems (Dennis & Kris-Etherton, 1992).  The following management 
measures were taken to ensure that the objectives of the study were met: 
 Volunteers were informed of the content of the study, the importance of 
their roles, as well as the practical arrangements that might help the flow 
of the study. 
 A placebo group was included in the study to exclude the effect of other 
factors such as seasonal changes, etc. on the measured metabolic 
variables; 
 A late breakfast was arranged at the mess after the blood samples were 
drawn to make sure that volunteers attended the sample collection in a 
fasting state; 
 The Department of Biostatistics at the UFS randomly divided the subjects 
into the experimental and placebo groups; 
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 The capsules were counted beforehand by an outside party that neither 
participated in the project, nor in the execution of any aspects of the 
project.  All capsules looked similar.  Packages were numbered by an 
outsider and kept off-site.  The blind information was made available once 
all the results were supplied to the statistician in charge.  This ensured 
that both participants and researchers were blinded for the duration of the 
study.   
 The SANDF section head of the members ensured that the capsules were 
taken daily.  Capsules were kept in separate bags, clearly marked with 
individual numbers. 
 If was crucial that the subjects be continuously motivated throughout the 
study.  The following measures were taken by the researcher in order to 
keep the subjects motivated: 
 The researcher encouraged the members with each visit to take 
their supplements daily.  The researcher gave the subjects 
supplements on a daily basis when they had their meals at the 
mess.  This was also a measure of compliance. The bags were 
transparent and were marked clearly with each participant number.  
All capsules were exactly similar in shape and colour.  Capsules 
were counted beforehand and the exact number of capsules was 
given to each participant on a daily basis.  
 Informal social functions for volunteers were arranged at regular 
intervals. 
 The subjects were followed up weekly by the researcher.  This 
helped with the evaluation of the progress of the study, as well as 
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with the participation of the subjects; and also identified any 
unwanted but inevitable problems. 
 At the end of the study, each subject received a gift in 
acknowledgement for taking part in the study. 
 
3.11 STATISTICAL ANALYSES 
 
Results were analysed by the Research Centre, NESTEC PTY LTD., 
Lauzanne. Results were summarised using means and standard deviations 
(SD), and frequencies and percentages (categorical variables).  Changes 
within groups, from baseline one (day 0) to baseline two (day 8); and from 
baseline 2 (day 8) to the end of the intervention period (day 36), were 
compared using paired-t-tests, using a p-level of <0.05 as significant.  Level of 
significance: The chosen level of significance sets the likelihood of detecting a 
treatment effect when no effect exists (leading to a so-called "false-positive" 
result) and defines the threshold "P value". Results with a P value above the 
threshold lead to the conclusion that an observed difference may be due to 
chance alone, while those with a P value below the threshold lead to rejecting 
chance and concluding that the intervention has a real effect. The level of 
significance in this study was set at 5% (that is, P = 0.05). This means the 
investigator is prepared to accept a 5% chance of erroneously reporting a 
significant effect.Between-group differences were compared using the student 
t-test, also using a p-level of <0.05 as significant. Power calculations were 
performed to establish the minimum number of volunteers required to 
participate in each study group. Calculations indicated that 15 individuals are 
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required for each of the three intervention groups. The power of a study is its 
ability to detect a true difference in outcome between the standard or control 
arm and the intervention arm. This is usually chosen to be 80%. By definition, 
a study power set at 80% accepts a likelihood of one in five (that is, 20%) of 
missing such a real difference. Thus, the power for large trials is occasionally 
set at 90% to reduce to 10% the possibility of a so-called "false-negative" 
result. The effect of treatment in a trial can be expressed as an absolute 
difference. That is, the difference between the rate of the event in the 
control group and the rate in the intervention group, or as a relative 
reduction, that is, the proportional change in the event rate with 
treatment. If the rate in the control group is 6.3% and the rate in the 
intervention arm is 4.2%, the absolute difference is 2.1%; the relative 
reduction with intervention is 2.1%/6.3%, or 33%. In this study, the 
effect of treatment was fixed at 15%. From these components, sample 
size can be calculated. Based on these calculations, it was decided to 
recruit 25 volunteers for each group, taking into consideration that not all 
volunteers will complete the study. 
In this chapter, the author provides a concise summary of all methods, 
procedures and materials used throughout the study. In the next Chapter, the 
results of the different analyses will be provided, followed by a discussion 
thereof in chapter 5. 
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CHAPTER 4 
 
RESULTS 
 
4.1 INTRODUCTION 
 
Chapter 3 was used to describe the experimental procedures of a 
clinical intervention trial during which the metabolic effects of the long-
term intake of two different combinations of short-chain fatty acid 
supplements were tested on westernised black male volunteers.  The 
results of this randomised clinical intervention trial will be presented in 
this chapter.  The aim is now to describe the baseline characteristics of 
the subject group as a whole, as well as the metabolic changes 
measured in physical- and metabolic risk markers, during different 
intervals after intake of the respective supplements. 
 
A summary of the baseline measurements (day 0 and 8) for the entire 
study group will be presented, followed by the results of the individual 
supplements, measured at the separate intervals.  The results are 
summarised as follows: (i) general health profiles, (ii) haemostatic 
profiles, (iii) lipid profiles, and (iv) glycometabolic profiles. 
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4.2 BASELINE RESULTS OF THE ENTIRE STUDY GROUP 
 
Two baseline measurements were performed for each volunteer.  Each 
measurement was separated by a time-interval of seven days, during 
which subjects consumed placebo supplements for standardisation 
purposes.  The results of the two baseline measurements will be 
presented in order to provide information regarding the health status of 
the study population as a whole (Tale 4.1).  The reference ranges of 
the different variables are included as an aid to judging the results. 
 
4.2.1 Demographic characteristics of the study group as a whole 
All the volunteers of this study were members of the South African 
National Defence Force (SANDF), Tempe, having been based in 
Bloemfontein for at least one year prior the study.  The subjects all 
lived on the premises of the SANDF, and followed exactly the same 
basic diet, supplied at the same mess on the premise of the SANDF.  
The researcher monitored the food intake of the study group in order to 
limit any major changes of dietary intake during the study, as well as for 
general control purposes. 
 
4.2.2 Dietary intake of the entire study group 
 
The dietary intake of the study group was determined by means of a 
FFQ  at the start of the study (day 0) and at the end of the intervention 
washout period (day 36) as a measure of control.  It is important to 
acknowledge that what is of importance here, is not the dietary intake 
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of the respective supplementation groups, but rather that of the group 
as a whole. The random selection of individuals allocated to specific 
supplementation groups, would also imply that a change of dietary 
intake within the group as a whole, would be equally distributed 
between the respective supplementation groups. All subjects followed 
exactly the same meal plan during the entire study.  It was therefore 
important to evaluate whether the dietary intake of the study group 
remained constant throughout the study.  
 
The results of the FFQ showed that at baseline the mean energy intake 
of the subjects was ~16 570kJ per day, with the total mean 
carbohydrate intake below 50% of the total energy intake.  The dietary 
protein intake contributed to approximately 16% of the total daily 
energy intake.  The total mean fat intake of the group was higher than 
30% of their total energy intake.  The mean dietary fibre intake of the 
study group was reported as 32.5g per day.  A tendency was therefore 
observed towards a high fat (>30% of total energy) and low 
carbohydrate intake (< 50% of total energy), which is characteristics of 
an atherogenic, westernised diet. Assessment of the dietary intake at 
the end of the study showed that there was no significant change in 
dietary intake during the study. The results indicated that the usual 
dietary intake of the subjects did not differ significantly and remained 
somewhat similar from baseline (day 0) to the end of supplementation 
(day 36), with an almost similar energy intake of approximately 16 
000kJ per day.  
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4.2.3 General health profiles of the entire study group for both baseline 
1 and 2 (Table 4.1) 
All subjects were male, between the ages of 18 and 45 years.  The 
mean age of the study group was 27 years.  None of the subjects used 
any chronic medication, had a history of previous lifestyle illness (such 
as coronary heart disease, diabetes) or had known or visible physical 
disabilities prior to the study.  A total of 66 suject were include in the 
results 
No overweight or obese subjects were included (see section 3.6.1) in 
the study group.   Anthropometric measurements, blood cell counts and 
CRP concentrations of the two baseline visits for most of the study 
group were within the normal reference range, except for a few 
individual outliers.  However, none of these outliers could be classified 
as clinically abnormal and there was no reason to exclude them from 
the study. The results of baseline one were comparable to those of 
baseline two, with no statistically significant differences between the 
two visits, for any variable (Table 4.1). 
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Table 4.1 General health profiles of the entire study group for both baseline 1 and 2  
 
VARIABLE Normal Range Baseline 1 (Day 0) 
n= 66 
Baseline 2 (Day 8) 
n = 66 
  X SD Min Max X SD Min Max 
Length (cm)  170.0 6.5 157.0 189.0     
Weight (cm)  66.3 8.9 51.4 87.5 67.2 8.9 52.3 86.9 
BMI (kg/m2)  22.8 2.3 17.3 29.0 23.0 2.4 18.0 29.5 
Waist circumference 
(cm) 
 77.2 6.9 66.0 94.0 77.7 7.1 66.0 94.0 
Hip circumference 
(cm) 
 95.4 5.9 74.0 110.0 95.9 6.2 74.0 110.0 
SBP (mmHg) 125±13.6a 118 11 90 160 118 12 91 162 
DBP (mmHg) 78±9.9 a 81 16 60 130 83 12 60 130 
TP (g/L) 60-82 80.5 6.30   79.9 5.60   
Albumin (g/L) 34-48 45.20 3.80   44.80 2.60   
WBC (x103/µL) 2.5-8.5b 5.95 2.05 3.20 12.00 5.66 1.51 2.90 9.00 
RBC (x103/µL) 4.5-5.9 b 5.16 0.53 4.31 6.77 5.17 0.57 4.25 6.93 
Hb (g/dL) 13.7-17.8 b 15.9 1.1 13.0 18.1 15.8 1.5 12.8 22.6 
Haematocrit (%) 41-52 b 45.8 4.1 37.9 60.2 45.2 4.1 35.7 61.0 
PLT (x103/µL) 50-400 b 281 56 182 396 297 67 149 498 
CRP (mg/dL) 0 - 0.3c 0.22 0.29 0.01 1.35 0.27 0.33 0.01 1.91 
(X = mean; SD = standard deviation; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; TP = Total 
Protein; WBC = White Blood Cell Count; RBC = Red Blood Cell Count; CRP = C-reactive protein; Hb = Haemoglobin; PLT = Platelet 
count). 
a = Solomon, Schmidt & Adragna, 1990; b = Department Haematology and Cell Biology, University of the Free State & NHLS, 2003; c = 
Department of Chemical Pathology, University of the Free State & NHLS, 2003. 
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4.2.4 Haemostatic profiles of the entire study group for both baseline 1 
and 2 (Table 4.2) 
Haemostatic profiles for both baseline visits of the group as a whole fell 
within the normal reference range.  No clinical reference values for 
markers of fibrin network architecture are available. Due to cost 
implications, D-Dimer concentrations were only measured from 
baseline two. The results of baseline one was comparable to that of 
baseline two, with no statistically significant changes that took place 
within any variable between the two visits. 
 
Table 4.2 Haemostatic profiles of the study group as a whole for both 
baseline 1 and 2  
 
VARIABLE Normal 
Range 
Baseline 1 (Day 0) 
n = 66 
Baseline 2 (Day 8) 
n = 66 
  X SD Max Min X SD Max Min 
FVII (%) 50-150 b 101 8 121 82 103 10 122 85 
FVIII (%) 50-150 b 88 8 108 73 92 11 116 76 
Fibrinogen 
(g/L) 
2.0-4.0 b 2.77 0.91 4.93 1.80 3.28 1.26 6.72 1.56 
ATIII (%) 76-122 b 113 12 132 78 113 13 133 83 
DDimer 
(g/dL) 
<500 b     98 70 271 26 
Fibrin 
Monomer 
(mg/L) 
 13.6 1.8 19.2 10.5 13.7 2.4 20.5 9.2 
Compaction 
(%) 
 16 6 26 8 14 5 23 7 
µT  
x1012Da/cm 
 11.8 6.3 32.3 2.7 7.2 5.6 28.1 2.0 
Network Fibrin 
Content (g/L) 
  
2.0 
 
0.5 
 
1.0 
 
3.8 
 
2.9 
 
1.3 
 
5.8 
 
1.0 
(X = mean; SD = standard deviation; FVII = blood clotting factor VII; FVIII = blood clotting 
factor FVIII; ATIII= antithrombin III; µT = mass/length-ratio of fibrin strands in fibrin networks) 
b = Department Haematology and Cell Biology, University of the Free State & NHLS, 
2003. 
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A graphic presentation of the changes that occurED during fibrin 
network lysis, as measured by means of turbidimetry, for both baseline 
1 and 2 of the group as a whole, is provided in Figure 4.1.  Similar rates 
of network lysis were measured up until 10 minutes, after which the 
curves both plateau at 180 minutes.  However, in comparison with 
baseline one, baseline two plateaus at a higher absorbance. 
 
 
Figure 4.1 A turbidimetric presentation of the mean fibrin network 
lysis rate of the entire study group at baseline one and 
two (Day 0 and 8) 
 
4.2.5 Lipid profiles of the entire study group for both baseline 1 and 2 
(Day 0 and 8) 
Mean lipid measurements of the two baseline visits for the entire group 
fell within the normal reference range.  Subjects with outlier values 
were not considered clinically abnormal, and therefore not excluded 
from the study.  The results of baseline one was comparable to those 
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of baseline two, with no statistically significant differences measured 
between the two visits (Table 4.3). 
 
Table 4.3 Blood lipid profiles of the study group as a whole for both 
baseline 1 and 2  
VARIABLE Normal 
Range 
Baseline 1 (Day 0) 
n = 66 
Baseline 2 (Day 8) 
n = 66 
  X SD Max Min X SD Max Min 
TC  
(mmol/L) 
2.10-5.32 4.36 0.88 6.3 2.3 4.46 0.84 7.2 2.6 
TG 
(mmol/L) 
0.30-1.70 c 1.17 0.50 2.21 0.50 1.17 0.61 2.72 0.53 
HDL-C 
(mmol/L) 
0.75-1.9 c 1.41 0.47 3.6 0.7 1.24 0.28 2.0 0.7 
LDL-C 
(mmol/L) 
2.24-4.6 c 2.35 0.83 4.51 0.8 2.67 0.78 3.64 1.24 
% HDL-C 
(%)  
 33.7 9.5 65.5 16.4 28.5 7.3 47.1 14.8 
NEFA 
(mmol/L) 
 4.78 2.74 9.10 1.40 3.68 1.70 9.10 1.20 
(X = mean; SD = standard deviation; TC = serum-Total Cholesterol; TG = serum-
Triglycerides; HDL-C = serum-High-Density Lipoprotein Cholesterol; LDL-C = serum-Low-
Density Lipoprotein Cholesterol; %HDL-C = HDL-C/TC * 100; NEFA = Non-Esterified Fatty 
Acids, The measurement unit for all the lipid variables was mmol/L except for % HDL-C which 
was percentage)  c = Department of Chemical Pathology, University of the Free State & 
NHLS, 2003. 
 
 
4.2.6 Glycometabolic profiles of the entire study group for both 
baseline 1 and 2 (Day 0 and 8) 
The fasting serum-glucose levels and fasting serum-insulin levels of the 
study group as a whole fell within the normal healthy reference range 
(Table 4.4).  
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Table 4.4 Glycometabolic indicators of the study group as a whole for both 
baseline 1 and 2 
VARIABLE Normal 
Range 
Baseline 1 (Day 0) 
n =66 
Baseline 2 (Day 8) 
n = 66 
  X SD Max Min X SD Max Min 
Glucose 
(mmol/L) 
4.1-5.9 c 5.32 0.83 6.12 3.25 5.47 0.88 6.30 3.88 
Insulin 
(IU/mL) 
6-27c 10.7 16.6 28.0 4.8 13.7 21.3 5.20 40.2 
(X = mean; SD = standard deviation;) 
c = Department of Chemical Pathology, University of the Free State & NHLS, 2003. 
 
 
4.3 RESULTS OF THE INTERVENTION STUDY 
 
This section will be used to present the results measured in metabolic 
risk markers after supplementation with the placebo and two different 
short-chain fatty acid supplements.  Results for short-term changes 
(after 14 days of supplementation), at the end of supplementation 
changes (after 28 days of supplementation) and an additional washout 
period of one week will be reported, for each supplement.  Attention will 
mainly be given to the differences between day 8 (baseline 2; start of 
supplementation) and day 36 (at the end of 4 weeks supplementation). 
A full-time medical team on the premises of the SANDF monitored any 
apparent changes in the health of the subjects.  Subjects had access to 
this team both during and after the study.   
Any drugs, medication or supplements taken during the intervention 
phase were reported on the individual subject files.  Subjects were 
examined for any possible side effects that may have been directly or 
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indirectly caused by the respective supplements (allergic reactions, 
abdominal iscomfort, nausea, etc.).  In addition, subjects were asked to 
report side effects, observations, or anything out of the ordinary. 
Records were kept of these reports on the tolerance questionnaire 
(Appendix D).   
 
4.3.1 The Placebo Supplement Study Group Results 
 
The group consumed a placebo for the entire study period.  The group 
composed of 25 volunteers, of which only 21 completed the study. 
4.3.1.1 Changes in the general health profiles within the placebo supplement 
study group 
No significant changes were measured in any of the general health 
indicators from day 8 (start of supplementation phase) to day 36 (end 
of supplementation phase) within the placebo supplement group 
(Table 4.5). 
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Table 4.5 Changes in the general health profiles within the placebo 
supplement study group (n = 21) 
VARIABLE 
 
 Day 1 Day 8 Day 22 Day 36 Day 43 
Length 
(cm) 
X 
SD 
171.0 
6.6 
    
Weight 
(kg) 
X 
SD 
69.0 
10.6 
70.0 
10.2 
70.3 
11.3 
9.8 
10.4 
70.0 
10.5 
BMI 
(kg/m2) 
X 
SD 
23.5 
3.1 
23.8 
3.0 
24.0 
3.2 
23.8 
2.9 
23.9 
3.0 
Waist 
(cm) 
X 
SD 
79.8 
8.6 
80.7 
8.5 
79.1 
8.1 
79.11 
8.3 
79.1 
8.0 
Hip 
(cm) 
X 
SD 
96.2 
8.4 
96.8 
8.7 
97.9 
6.3 
97.5 
6.2 
98.2 
6.7 
SBP 
(mmHg) 
X 
SD 
120 
14 
124 
14 
122 
13 
116 
11 
116 
10 
DBP 
(mmHg) 
X 
SD 
85 
15 
87 
15 
85 
15 
83 
10 
83 
11 
TP  X 76.8 79.8 77.5 77.0 79.7 
(g/L) SD 4.7 3.4 6.6 4.4 4.9 
Albumin X 43.9 45.1 43.9 43.9 45.8 
(g/L) SD 2.1 2.8 3.4 2.3 1.7 
WBC 
(x103/µL) 
X 
SD 
6.24 
2.06 
5.91 
1.62 
5.27 
1.52 
5.29 
1.24 
5.82 
1.79 
RBC 
(x103/µL) 
X 
SD 
5.25 
0.44 
5.10 
0.50 
5.00 
0.52 
5.00 
0.42 
5.19 
0.62 
Hb 
(g/dL) 
X 
SD 
16.1 
1.1 
15.3 
1.0 
15.2 
1.3 
15.6 
1.2 
15.8 
1.2 
Haematocrit 
(%) 
X 
SD 
46.4 
3.6 
44.2 
3.0 
43.3 
3.1 
43.6 
3.2 
44.9 
3.6 
Platelets 
(x103/µL) 
X 
SD 
307 
58 
304 
66 
296 
61 
300 
56 
348 
52 
CRP 
(mg/dL) 
X 
SD 
0.17 
0.17 
0.24 
0.15 
0.21 
0.14 
0.11 
0.12 
0.16 
0.23 
(X = mean; SD = standard deviation; BMI = Body Mass Index; SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure; TP = Total Protein WBC = White Blood 
Cell Count; RBC = Red Blood Cell Count; Hb = Haemoglobin; CRP = C-reactive 
protein) 
 
4.3.1.2 Changes in the haemostatic profiles within the placebo supplement 
study group  
A statistically significant decrease (p = 0.047) in the circulating plasma 
fibrinogen concentration was measured from the start of 
supplementation (day 8) to the end of supplementation (day 36) within 
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the placebo supplement group (Table 4.6).  No other significant 
changes in any of the other haemostatic variables were measured. 
Table 4.6 Changes in the haemostatic profiles within the placebo 
supplement study group (n=21) 
VARIABLE 
 
 Day 1 Day 8 Day 22 Day 36 Day 43 
FVII activity 
(%) 
X 
SD 
102.3 
9 
104 
8 
99 
12 
100 
7 
99 
10 
FVIII activity 
(%) 
X 
SD 
89 
10 
94 
10 
87 
8 
89 
7 
90 
10 
Fibrinogen 
(g/L) 
X 
SD 
2.80 
0.88 
3.39* 
1.17 
2.80 
0.71 
2.79* 
0.76 
2.90 
1.24 
Albumin/ 
Fibrinogen 
X 
SD 
17.2 
4.7 
15.5 
5.2 
16.8 
4.9 
16.8 
4.1 
19.2 
7.2 
ATIII 
(%) 
X 
SD 
114 
10 
114 
10 
109 
9 
108 
11 
110 
10 
D-Dimer 
(g/dL) 
X 
SD 
 89.9 
64.2 
 138.7 
126.0 
 
Fibrin 
Monomer 
(mg/L) 
X 
SD 
13.2 
1.4 
13.4 
3.0 
12.3 
2.5 
12.2 
3.1 
12.4 
3.7 
Compaction 
(%) 
X 
SD 
18 
7 
14 
6 
15 
5 
14 
4 
15 
5 
µT (x1012 
Da/cm) 
X 
SD 
11.8 
5.6 
7.4 
5.1 
5.5 
2.5 
5.0 
2.0 
5.8 
2.9 
Network Fibrin 
Content (g/L) 
X 
SD 
2.6 
0.9 
2.9 
1.4 
2.0 
0.6 
2.7 
1.6 
2.6 
1.9 
(X = mean; SD = standard deviation; FVII = blood clotting factor VII; FVIII = blood clotting 
factor FVIII; ATIII= antithrombin III; CRP = C-reactive Protein; FM = Fibrin Monomer; µT = 
mass/length-ratio of fibrin strands in fibrin networks; NFC = Fibrin Content of Fibrin 
Networks; * = differs significantly with p<0.05; ** = differs significantly with p<0.01) 
 
A graphic presentation (Figure 4.2) of the turbidimetric changes that 
occured during fibrin network lysis, for all visits for the placebo 
supplemented group, followed more or less the same pattern.  Similar 
rates of lysis were initially measured up until 20 minutes, after which 
the graphs all reached a plateau at 190 minutes.  However, in 
comparison to all the other study periods, day 22 (after 2 weeks of 
experimental placebo supplementation) reached the plateau phase at 
a much lower absorbance. 
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Figure 4.2 A turbidimetric presentation of the mean fibrin network lysis rates 
of the placebo group for the entire study period 
 
 
4.3.1.3 Changes in the lipid profiles within the placebo supplement study 
group 
Compared to baseline (day 8) no significant changes in any of the 
lipid variables were measured at the end of supplementation (day 36) 
within the placebo supplemented study group (Table 4.7). 
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Table 4.7 Changes in the lipid profiles within the placebo supplement study 
group (n = 21) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
TC 
(mmol/L) 
X 
SD 
4.21 
0.95 
4.31 
0.70 
4.29 
0.97 
4.32 
0.47 
4.43 
0.89 
TG 
(mmol/L) 
X 
SD 
1.26 
0.40 
1.30 
0.84 
1.12 
0.47 
1.27 
0.41 
1.18 
0.75 
HDL-C 
(mmol/L) 
X 
SD 
1.22 
0.27 
1.18 
0.27 
1.34 
0.27 
1.26 
0.25 
1.44 
0.31 
LDL-C 
(mmol/L) 
X 
SD 
2.27 
0.73 
2.47 
0.65 
2.42 
0.76 
2.47 
0.50 
2.55 
0.79 
%HDL-C 
(%) 
X 
SD 
31.3 
7.1 
28.1 
7.8 
32.3 
7.1 
29.6 
6.5 
32.9 
8.8 
NEFA 
(mmol/L) 
X 
SD 
4.99 
1.94 
3.83 
1.62 
3.68 
1.99 
3.59 
2.16 
3.66 
2.44 
(X = mean; SD = standard deviation; TC = serum-Total Cholesterol; TG = serum-
Triglycerides; HDL-C = serum-High-Density Lipoprotein Cholesterol; LDL-C = serum-
Low-Density Lipoprotein Cholesterol; %HDL-C = HDL-C/TC * 100; NEFA = Non-
Esterified Fatty Acids) 
 
4.3.1.4 Changes in the glycometabolic profiles within the placebo supplement 
study group 
No significant changes in any of the glycometabolic parameters of the 
placebo group were measured during the entire intervention period. 
The measured decrease in serum-insulin levels from day 8 to day 22 
was not significant (Table 4.8).   
 
 
Table 4.8 Changes in the glycometabolic profiles within the placebo 
supplement study group (n = 21) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
Glucose 
(mmol/L) 
X 
SD 
5.08 
0.57 
5.65 
1.16 
5.12 
0.93 
5.15 
1.21 
5.52 
1.07 
Insulin 
(IU/mL) 
X 
SD 
8.30 
8.90 
10.10 
14.90 
21.60 
20.70 
9.10 
15.30 
14.5 
9.70 
(X = mean; SD = standard deviation) 
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4.3.2 The Acetate-Propionate (50%/50%) Supplement Study Group 
Results 
 
This study group consisted of 25 volunteers that consumed placebo 
supplement for a period of one week, followed by four weeks of 
experimental supplementation, which composed of 50% acetate and 
50% propionate salts, after which an additional one week of 
supplementation with placebo followed.  Two volunteers dropped out, 
bringing the number to 23 participants. 
 
4.3.2.1 Changes in the general health profiles within the acetate-propionate 
supplement study group 
No significant changes were observed in any of the general health 
indicators between start of supplementation (day 8) and end of 
supplementation (day 36) for the acetate-propionate supplement 
group (Table 4.9). 
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Table 4.9 Changes in the general health profiles within the acetate-
propionate (50%-50%) supplement group (n = 23) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
Length 
(cm) 
X 
SD 
170.0 
6.2 
    
Weight 
(kg) 
X 
SD 
65.1 
7.4 
66.1 
8.2 
65.3 
8.1 
65.7 
7.8 
66.6 
7.5 
BMI 
(kg/m2) 
X 
SD 
22.6 
1.9 
22.9 
2.1 
22.8 
2.1 
22.8 
2.1 
23.0 
1.9 
Waist 
(cm) 
X 
SD 
75.5 
5.2 
76.4 
5.1 
75.9 
5.5 
76.5 
4.9 
75.6 
4.8 
Hip 
(cm) 
X 
SD 
95.5 
4.3 
96.5 
5.1 
96.2 
5.1 
96.4 
4.7 
96.0 
4.8 
SBP 
(mmHg) 
X 
SD 
120 
10 
116 
12 
117 
7 
116 
8 
118 
8 
DBP 
(mmHg) 
X 
SD 
81 
9 
81 
9 
79 
7 
79 
8 
83 
9 
TP X 82.10 78.90 79.90 77.80 77.40 
(g/L) SD 6.30 6.10 7.40 9.50 8.10 
Albumin X 44.80 43.90 44.70 46.46 43.50 
(g/L) SD 3.20 2.50 3.90 3.30 2.40 
WBC 
(x103/µL) 
X 
SD 
5.96 
2.47 
5.78 
1.42 
5.89 
1.30 
5.88 
1.63 
5.65 
1.43 
RBC 
(x103/µL) 
X 
SD 
5.33 
0.65 
5.32 
0.63 
5.17 
0.49 
5.33 
0.54 
5.23 
0.56 
Hb 
(g/dL) 
X 
SD 
16.2 
1.2 
16.1 
1.9 
15.5 
1.3 
15.7 
1.2 
15.6 
1.5 
Haematocrit 
(%) 
X 
SD 
47.3 
5.0 
46.1 
5.4 
44.4 
4.3 
45.6 
4.4 
44.8 
4.5 
Platelets 
(x103/µL) 
X 
SD 
264 
50 
301 
79 
282 
85 
331 
83 
340 
90 
CRP 
(mg/dL) 
X 
SD 
0.23 
0.29 
0.25 
0.28 
0.28 
0.24 
0.27 
0.49 
0.15 
0.18 
(X = mean; SD = standard deviation; BMI = Body Mass Index; SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure; WBC = White Blood Cell Count; RBC = 
Red Blood Cell Count; Hb = Haemoglobin; CRP = C-reactive protein) 
 
 
4.3.2.2 Changes in the haemostatic profiles within the acetate-propionate 
supplement study group 
A statistically significant decrease in plasma factor VII activity 
(p=0.016), antithrombin III (p<0.001), an increase in plasma fibrinogen 
concentration (p=0.048), and a decrease in the albumin/fibrinogen 
ratio (p=0.044), was measured from day 8 to day 36 within the 
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acetate-propionate supplementation group (Table 4.10).  No other 
changes in any of the other haemostatic variables were significant. 
 
Table 4.10 Changes in the haemostatic profiles within the acetate-
propionate (50%-50%) study group (n = 23) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
FVII activity 
(%) 
X 
SD 
101 
7 
102* 
7 
99 
7 
97* 
7 
98 
8 
FVIII activity 
(%) 
X 
SD 
89 
6 
91 
11 
90 
11 
91 
8 
89 
8 
Fibrinogen 
(g/L) 
X 
SD 
2.90 
1.15 
2.98* 
0.96 
2.58 
0.61 
3.04* 
0.89 
2.69 
0.70 
Albumin/ 
Fibrinogen 
X 
SD 
17.8 
5.7 
17.4* 
5.9 
17.9 
3.9 
15.7* 
4.7 
18.6 
5.5 
ATIII 
(%) 
X 
SD 
113 
13 
114** 
13 
107 
7 
108** 
10 
109.1 
8 
D-Dimer 
(g/dL) 
X 
SD 
 118.6 
89.3 
 121.2 
75.7 
 
FM 
(mg/L) 
X 
SD 
13.5 
1.3 
13.7 
2.1 
12.4 
2.3 
12.0 
2.2 
12.6 
2.6 
Compaction 
(%) 
X 
SD 
16 
6 
14 
5 
15 
4 
14 
4 
15 
4 
µT 
(x1012 Da/cm) 
X 
SD 
13.0 
7.4 
8.5 
7.5 
8.0 
5.7 
6.7 
2.3 
5.7 
3.3 
Network Fibrin 
Content (g/L) 
X 
SD 
1.8 
0.6 
3.0 
1.1 
2.5 
0.8 
2.6 
1.3 
2.7 
1.5 
(X = mean; SD = standard deviation; FVII = blood clotting factor VII; FVIII = blood 
clotting factor FVIII; ATIII= antithrombin III; CRP = C-reactive Protein; FM = Fibrin 
Monomer; µT = mass/length-ratio of fibrin strands in fibrin networks; NFC = Fibrin 
Content of Fibrin Networks; * = differs significantly with p<0.05; ** = differs significantly 
with p<0.01) 
 
A turbidimetric presentation of the changes in the network lysis rate of 
all the study periods, for the acetate-propionate study group, showed 
a sharp rise in optical density for the first 40 minutes and reaching a 
plateau phase at approximately 190 minutes, except for day 22, 
where the maximum plateau phase was reached at 240 minutes 
(Figure 4.3).  In comparison with the other study periods day 1 
reached a much lower maximum absorbance, while day 43 reached 
the highest maximum absorbance. 
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Figure 4.3 A turbidimetric presentation of the mean fibrin network lysis rate 
of the acetate-propionate group for the entire study period 
 
 
4.3.2.3 Changes in the lipid profiles within the acetate-propionate supplement 
group 
A slight decrease in the LDL-C from day 8 to day 36 within the 
acetate-propionate supplement group was measured. The serum-TC 
levels of this group remained unchanged. However, a statistically 
significant increase in HDL-C (p<0.05) accompanied by a statistically 
significant decrease in NEFA (p<0.01) were found during the same 
period for this group of subjects (Table 4.11).     
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Table 4.11 Changes in the lipid profiles within the acetate-propionate (50%-
50%) supplement group (n = 23) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
TC 
(mmol/L) 
X 
SD 
4.37 
0.96 
4.14 
0.81 
4.82 
1.00 
4.25 
1.77 
3.92 
0.80 
TG 
(mmol/L) 
X 
SD 
1.05 
0.4 
1.01 
0.39 
1.10 
0.42 
1.09 
0.36 
0.98 
0.27 
HDL-C 
(mmol/L) 
X 
SD 
1.39 
0.36 
1.21* 
0.24 
1.37 
0.32 
1.35* 
0.34 
1.37 
0.31 
LDL-C 
(mmol/L) 
X 
SD 
2.43 
0.90 
2.37 
0.58 
2.37 
0.32 
2.31 
0.71 
2.10 
0.71 
%HDL-C 
(%) 
X 
SD 
33.70 
9.40 
30.56 
6.14 
30.10 
7.90 
33.53 
6.38 
35.80 
8.70 
NEFA 
(mmol/L) 
X 
SD 
5.01 
2.23 
5.02** 
1.72 
4.06 
2.38 
4.14** 
3.43 
2.43 
1.18 
(X = mean; SD = standard deviation;TC = serum-Total Cholesterol; TG = serum-
Triglycerides; HDL-C = serum-High-Density Lipoprotein Cholesterol; LDL-C = serum-
Low-Density Lipoprotein Cholesterol; %HDL-C = HDL-C/TC * 100; NEFA = Non-
Esterified Fatty Acids;* = differs significantly with p<0.05; ** = differs significantly with 
p<0.01) 
 
4.3.2.4 Changes in the glycometabolic profiles within the acetate-propionate 
supplement group 
The fasting serum-glucose levels of this group decreased significantly 
(p < 0.05) from baseline (day 8) to the end of the experimental 
supplementation (day 36) (Table 4.12). 
 
Table 4.12  Changes in the glycometabolic indicators of the acetate-
propionate (50%-50%) supplement group (n = 23) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
Glucose 
(mmol/L) 
X 
SD 
5.87 
0.60 
6.65* 
0.98 
5.77 
0.94 
5.65* 
0.42 
5.03 
0.53 
Insulin 
(IU/mL) 
X 
SD 
7.90 
4.60 
12.62 
22.61 
7.10 
5.50 
14.01 
24.83 
13.80 
9.70 
(X = mean; SD = standard deviation; * = differs significantly with p<0.05) 
4.3.3 The High Acetate Supplement Group Results 
 
The baseline results of this group were comparable to the results of the 
other two groups.  Three members of this group dropped out of the 
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study.  This group of volunteers also consumed placebo supplements 
for a period of one week, followed by four weeks of supplementation 
with 70% acetate, 15% propionate and 15% butyrate, concluded by 
one additional week of placebo supplementation. 
 
4.3.3.1 Mean changes in the general health indicators of the high acetate 
supplement study group 
 
Table 4.13 Changes in the general health profiles within the high acetate 
supplement group (n = 22) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
Length 
(cm) 
X 
SD 
170.6 
7.2 
    
Weight 
(kg) 
X 
SD 
65.0 
8.2 
65.6 
8.3 
66.6 
8.2 
65.9 
8.6 
66.9 
7.5 
BMI 
(kg/m2) 
X 
SD 
22.3 
1.8 
22.5 
1.8 
22.6 
1.9 
22.6 
1.8 
22.7 
1.5 
Waist 
(cm) 
X 
SD 
76.4 
5.9 
76.1 
6.7 
75.6 
8.5 
75.7 
6.6 
77.4 
6.3 
Hip 
(cm) 
X 
SD 
94.6 
4.4 
94.2 
4.0 
93.9 
8.0 
94.1 
4.3 
95.2 
4.5 
SBP 
(mmHg) 
X 
SD 
115 
7 
115 
8 
118 
9 
116 
8 
116 
6 
DBP 
(mmHg) 
X 
SD 
81 
8 
80 
8 
80 
10 
82 
7 
81 
7 
TP X 81.9* 81.1** 79.7 75.9** 78.2 
(g/L) SD 6.5 6.2 6.4 8.4 5.2 
Albumin X 46.8* 45.3* 44.7 43.8** 45.4 
(g/L) SD 4.7 4.4 3.9 3.1 2.4 
WBC 
(x103/µL) 
X 
SD 
5.68 
1.61 
5.27 
1.6 
6.08 
2.17 
5.09 
1.70 
5.34 
1.51 
RBC 
(x103/µL) 
X 
SD 
4.90 
0.39 
5.05 
0.58 
5.10 
0.52 
5.25 
0.60 
5.19 
0.82 
Hb 
(g/dL) 
X 
SD 
15.5 
0.9 
16.0 
1.3 
16.1 
1.6 
16.1 
1.3 
15.9 
1.8 
Haematocrit 
(%) 
X 
SD 
43.7 
2.7 
45.1 
4.4 
45.0 
4.0 
46.0 
4.0 
45.9 
4.6 
Platelets 
(x103/µL) 
X 
SD 
273 
53 
285 
60 
299 
45 
297 
67 
298 
81 
CRP (mg/dL) X 
SD 
0.28 
0.42 
0.32 
0.50 
0.21 
0.23 
0.24 
0.36 
0.21 
0.28 
(X = mean; SD = standard deviation; BMI = Body Mass Index; SBP = Systolic 
Blood Pressure; DBP = Diastolic Blood Pressure; WBC = White Blood Cell Count; 
RBC = Red Blood Cell Count; CRP = C-reactive protein, * = differs significantly 
with p<0.05; ** = differs significantly with p<0.01) 
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No significant changes were measured in most of the general health 
indicators between day 8 (start of supplementation) and day 36 (end 
of supplementation) within the high acetate supplement group.  Total 
Protein and albumin levels decresed significantly (Table 4.13). 
 
4.3.3.2 Changes in the haemostatic profiles within the high acetate 
supplement study group 
A statistically significant decrease in plasma factor VII activity 
(p=0.018), factor VIII activity (p=0.011), antithrombin III (p<0.001), 
fibrin monomer concentration (p=0.002) and percentage compaction 
of the fibrin networks (p=0.008) was measured between the start of  
 
Table 4.14 Changes in the haemostatic profiles within the high acetate 
supplement group (n = 22) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
FVII activity 
(%) 
X 
SD 
101 
8 
103* 
14 
101 
7 
101* 
6 
99 
8 
FVIII activity  
(%) 
X 
SD 
86 
8 
93* 
13 
90 
10 
88* 
6 
86 
6 
Fibrinogen 
(g/L) 
X 
SD 
2.59 
0.57 
3.48 
1.61 
3.16 
1.20 
2.80 
0.84 
2.71 
0.84 
Albumin/ 
Fibrinogen 
X 
SD 
18.0 
3.8 
15.2 
6.4 
16.3 
4.3 
16.9 
4.7 
16.2 
5.0 
ATIII 
(%) 
X 
SD 
110.6 
12.4 
109.2** 
16.0 
104.3 
8.6 
103** 
10 
105 
13 
D-Dimer 
(g/dL) 
X 
SD 
 82.5 
46.4 
 111.8 
75.0 
 
Fibrin 
Monomer 
(mg/L) 
X 
SD 
14.3 
2.6 
13.9** 
2.2 
12.7 
2.7 
12.1** 
3.6 
12.9 
3.9 
Compaction 
(%) 
X 
SD 
14.4 
5 
14.2** 
5 
14.1 
4 
13.7** 
4 
13.7 
5 
µT 
(x1012 Da/cm) 
X 
SD 
10.4 
5.5 
5.9 
3.7 
8.7 
5.1 
7.2 
2.6 
5.9 
2.2 
Network Fibrin 
Content 
(g/L) 
X 
SD 
2.0 
0.4 
3.1 
1.2 
2.3 
1.3 
2.3 
0.7 
3.2 
2.2 
(X = mean; SD = standard deviation; FVII = blood clotting factor VII; FVIII = blood clotting 
factor FVIII; ATIII= antithrombin III; FM = Fibrin Monomer; µT = mass/length-ratio of fibrin 
strands in fibrin networks; NFC = Fibrin Content of Fibrin Networks; * = differs significantly 
with p<0.05; ** = differs significantly with p<0.01) 
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supplementation (day 8) and end of supplementation (day 36) within 
the high acetate supplementation group.  No other changes in any of 
the other haemostatic variables were significant (Table 4.14). 
Figure 4.4 represents a graphic comparison between the changes in 
the fibrin network lysis rate during each study period, within the high 
acetate group.  Turbidimetric changes showed a sharp increase in 
absorbance for the first 80 minutes and reached the plateau phase at 
180 minutes, except for day 22 which reached it by 240 minutes.  In 
comparison to the others, day 43 reached a much higher absorbance.  
The rate of lysis of day 8 and day 36 did not differ significantly. 
 
 
Figure 4.4 A turbidimetric presentation of the mean fibrin network lysis rate 
of the high acetate group for the entire study period 
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4.3.3.3 Changes in the lipid profiles within the high acetate supplement group 
A marginal decrease in TC was measured from day 8 to day 36 within 
the high acetate supplement group. This group showed a statistically 
significant decrease in LDL-C (p< 0.05).  HDL-C increased, however 
not significant and was accompanied by a statistical significant 
increase in the %HDL-C (p=0.017).  NEFA decreaed signficanly (p < 
0.01) (Table 4.15). 
 
Table 4.15 Changes in the lipid profiles within the high acetate supplement 
study group (n = 22) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
TC 
(mmol/L) 
X 
SD 
4.70 
0.75 
4.95 
0.81 
4.96 
1.24 
4.57 
0.87 
4.74 
0.90 
TG 
(mmol/L) 
X 
SD 
1.04 
0.39 
1.16 
0.53 
1.07 
0.31 
1.26 
0.56 
1.04 
0.51 
HDL-C 
(mmol/L) 
X 
SD 
1.56 
0.65 
1.27 
0.28 
1.66 
0.70 
1.46 
0.66 
1.69 
0.83 
LDL-C 
(mmol/L) 
X 
SD 
2.39 
0.85 
3.10* 
0.78 
2.91 
1.27 
2.61* 
0.94 
2.61 
0.94 
%HDL-C 
(%) 
X 
SD 
34.90 
11.90 
26.30* 
6.50 
33.50 
13.40 
32.30* 
12.40 
34.9 
14.00 
NEFA 
(mmol/L) 
X 
SD 
3.60* 
1.90 
3.58 
1.85 
3.83 
2.18 
2.87** 
1.46 
3.10 
1.70 
(X = mean; SD = standard deviation;TC = serum-Total Cholesterol; TG = serum-
Triglycerides; HDL-C = serum-High-Density Lipoprotein Cholesterol; LDL-C = serum-
Low-Density Lipoprotein Cholesterol; %HDL-C = HDL-C/TC * 100; NEFA = Non-
Esterified Fatty Acids; * = differs significantly with p<0.05; ** = differs significantly with 
p<0.01) 
 
4.3.3.4 Mean changes in the glycometabolic profiles within the high acetate 
supplement group 
The mean fasting serum-glucose levels decreased significantly during 
supplementation (from day 8 – day 36). The circulating serum-insulin 
levels also showed a concomitant decrease during the 
supplementation (p<0.001) (Table 4.16). 
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Table 4.16 Mean changes in the glycometabolic profiles within the high 
acetate supplement study group (n = 22) 
VARIABLE  Day 1 Day 8 Day 22 Day 36 Day 43 
Glucose 
(mmol/L) 
X 
SD 
5.43 
1.37 
5.41* 
0.52 
5.46 
0.96 
4.96* 
0.85 
5.72 
0.73 
Insulin 
(IU/mL) 
X 
SD 
6.70 
3.60 
5.80* 
0.77 
10.90 
4.90 
1.70* 
0.36 
15.80 
9.90 
(X = mean; SD = standard deviation; * = differs significantly with p<0.05) 
 
4.4 COLLECTIVE SUMMARY 
The group of individuals used for this study were exposed to almost 
identical environmental conditions for the duration of the study. They 
followed exactly the same diet, as they were eating at the same mess, 
performed the same physical activities and in some cases, even shared 
a living space. The general health profile indicates that the group of 
volunteers experienced no apparent health threat. The aim of this study 
was to measure the effect of two different combinations of short-chain 
fatty acids on metabolic risk markers in the group of volunteers. An 
additional placebo supplement was used for control purposes. 
Laboratory analyses show that during the study there are variations in 
the metabolic risk markers of the subjects. It is safe to assume that the 
changes in metabolic risk markers in these volunteers are at least in 
part related to the intake of the respective supplements. In Chapter 5 
these changes will be discussed and also compared to the results 
reported in available literature that could lead towards the elucidation of 
possible mechanisms to better understand the proposed effects of 
short-chain fatty acids on human health. 
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CHAPTER 5 
 
DISCUSSION 
 
5.1 INTRODUCTION 
 
The aim of the study was to determine the possible effects of different 
combinations of SCFAs on coronary risk factors of westernised black men.  
Coronary heart disease (CHD) and stroke are considered as degenerative 
western diseases which in most cases can be prevented by a change in 
lifestyle, for example diet, physical activity and psychological well being.  In 
this study, a group of westernised African male volunteers were recruited and 
supplemented with either one of two different combinations of short-chain fatty 
acids (SCFAs), as well as a placebo supplement, for an uninterrupted period 
of six weeks, with an additional one week placebo supplementation before 
and after the actual experimenetal phase.  The main goal was to establish 
whether the specific combinations of SCFAs affect the coronary risk profiles of 
the respective study groups in a different manner.  Distinction will be made 
between the following metabolic profiles: 
 haemostatic, 
 lipid, and 
 glycometabolic. 
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The discussion of the baseline results of the entire study group will be 
presented first, followed by a discussion of the results of the separate intervals 
of the intervention study.  These findings will then be compared to the results 
of other relevant studies.  A short discussion on the limitations of the study is 
also included at the end of this chapter. 
 
5.2 BASELINE RESULTS OF THE ENTIRE STUDY GROUP 
 
It is important to provide a general summary of the baseline results of the 
study group as a whole. The section is used to identify the characteristics of 
the study population and possible factors that may affect the way in which 
they respond to the experimental intervention. 
5.2.1 Baseline general health indicators of the entire study group 
The strict criteria used for selection of the study group ensured that the 
makeup of the group was of a homogeneous nature.  All the subjects 
were living on the same military base, where they received the same 
controlled westernised diet at a central mess. They also participated in 
exactly the same physical activities.  Members of the study group had 
no history of previous or current cardiovascular events, diabetes, 
hypertension or a history of any other apparent familial diseases.  
A comprehensive profile of metabolic markers, all of which reflect the 
general health status of the individuals, was analysed.  It was therefore, 
not expected that the supplements should have an effect on all of the 
measured variables and will only those of significant interest be 
highlighted and discussed in this chapter. 
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Both the Red and White Blood Cell counts fell within the normal healthy 
range.  It is important to mention that anaemic subjects or subjects with 
low platelets or white cell counts, which could be indicative of a wide 
variety of different pathological states, were excluded from the study.  
The blood cell count reference ranges used in this study were 
established for African males in the Free State region (unpublished 
data of the Department of Haematology and Cell Biology, University of 
the Free State, Bloemfontein, 1990), and thus very specific for the 
population.  In general, the African population tends to have slightly 
lower red cell and white blood cell counts, compared to the local 
Caucasian population (Bain, 1995). 
Serum albumin is acknowledged as an important indicator of nutritional 
status and longevity (Carlson, 2004).  The serum-albumin levels of the 
study group fell within the normal reference range of between 35-52g/L 
for healthy adult males (Painter, Cope & Smith, 1999).  Supported by 
this and other measured variables it is safe to conclude that the study 
population of this study presented no apparent metabolic abnormalities 
at the time of the study and could be classified as healthy. 
Elevated plasma C-reactive protein (CRP) concentration has been 
reported in the majority of patients with unstable angina, myocardial 
infarction, and a history of unstable angina (Ford, Giles & Dietz, 2002; 
Devaraj, Rosenson & Jialal, 2004).  CRP (an acute phase protein) in 
this study was measured to ensure that possible changes in other 
haematological parameters might not be due to inflammation or any 
other unknown acute phase response, including its association with 
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CHD and CVD.  Ridker et al. (1997) suggested that the baseline 
plasma concentration of CRP in apparently healthy men could predict 
the risk of first myocardial infarction and ischemic stroke, independent 
of other risk factors. 
There were no statistically significant changes in any of the general 
health indicators for both baseline one (day 1) and baseline two (day 8) 
of the entire study group.  This indicates that the run-in phase with the 
placebo supplement managed to establish a stable baseline. 
5.2.2 Dietary intake of the entire study group 
Results from the dietary analysis show that there was no major change 
in die eating habits of the study population, as a whole, during the 
period of intervention, or supplementation with SCFAs. The diet of the 
group included higher intakes of total fat and dietary fibre. Protein 
intake of the group was in the recommended range and the total 
carbohydrate intake fell in the lower range. This is typical of a 
Westernised diet, which is high in fat and lower in carbohydrates.  
Other studies conducted on urban African men in the Free State 
(Mollentze et al., 1995; Slabber et al., 1997) confirm that this is a 
general trend within the South African, African population and also 
believed to expose them to metabolic changes that promote the onset 
of CHD and CVD.  The use of a FFQ was restricted to the purpose of 
control and no other analyses were performed in relation to diet, as part 
of this study. It can therefore be concluded that it is improbable that the 
measured metabolic changes can be ascribed to a change in dietary 
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intake, but rather that it is suggested to be the direct consequence of 
the respective SCFA supplements.   
5.2.3 Anthropometric measurements of the entire study group 
No overweight or obese subjects were included for the purpose of this 
study.  This could also be ascribed to the strict inclusion criteria, and 
most importantly, the fact that the subjects were involved with physical 
activities most of the day, due to the nature of their occupation.  The 
BMI and blood pressure measurements were similar to those reported 
by epidemiological studies performed on African population groups in 
South Africa, including Durban (Seedat et al., 1992), the Cape 
Peninsula (Oelofse et al., 1996), the Free State (De Wet, 2000) and 
North West Province (James et al., 2000). 
5.2.4 Haemostatic profile of the entire study group at baseline 
Haemostatic risk factors associated with the development of CVD 
include plasma fibrinogen concentration, plasminogen activator 
inhibitor-1 (PAI-1), factor VII (Kannel, 2005) and factor VIII (Pan et al., 
1997) activities. Even though certain haemostatic risk markers are 
elevated in persons at risk of future cardiovascular events, data that 
assess the link between haemostatic risk markers and race/ethnicity is 
limited (Albert et al., 2007).  Fibrinogen seems the most fundamental 
haemostatic risk factor for CVD.  Fibrinogen was reported to increase 
with age, smoking, the waist/hip ratio and LDL-C levels.  Fibrinogen 
concentration decreases in relation to the level of education, physical 
activity, alcohol intake and HDL-C concentrations.  Fibrinogen may also 
directly increase CVD risk because of its role in platelet aggregation, 
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plasma viscosity, and fibrin formation (Kannel, 2005). Normal values for 
plasma fibrinogen concentration in the African population group are a 
point of argument.  The main reason for this being the different views 
regarding the strength of plasma fibrinogen as a predictor of stroke, 
compared to CVD and the prevalence of these two diseases within the 
different population groups.  
The factor VII and VIII activities of the current study group were similar 
to those reported by De Wet (2000).  The fibrinogen concentration of 
this study group was slightly lower when compared to that reported by 
James et al. (2000).   
Both fibrin monomer and D-dimer levels are considered as potential 
risk markers for development of cardiovascular events.  The thrombin-
catalysed released of the fibrinopeptides from fibrinogen results in the 
formation of a transient intermediate, termed fibrin monomer.  
Increased fibrin monomer levels are present in patients with 
hypercoagulable disease states, especially after a cardiovascular 
event.  The fibrin monomer concentrations in this study were higher 
than those reported by De Wet (2000).  D-dimer is a product of clotted 
fibrin breakdown, and is usually found in increased levels in patients 
with hypercoagulable disease states occurring before and after 
cardiovascular events.  It is an indication that fibrinolysis has occurred 
and therefore, it is increased in disseminated intravascular coagulation 
(Laffan & Manning, 2001). 
Fibrin network architecture is believed to serve as a marker of the risk 
of developing coronary heart disease (Mills et al., 2002).  The variables 
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included in such an analysis include the mass-length ratio from turbidity 
(as a measures of the thickness of the fibrin fibres in relation to its 
length), fibrin network compaction (as a measure of the degree of 
cross-linking of fibres within the overall network), as well as the network 
lysis rate.  The fibrin network content reported in this study was similar 
to those reported by Pieters, Jerling & Weisel (2002) and Veldman et 
al. (1999). In relation, the mass-length ratio was lower, and the 
compaction higher in this study.  Due to the lack of standardised control 
samples, it is impossible to conclude whether these differences are a 
result of variations in laboratory practice or an actual difference in 
metabolic profiles of our study group.  
Gabriel, Muga & Boothroyd (1992) suggested that fibrin network 
architecture contributes to the regulation of the fibrinolytic rate.  The 
fibrin network lysis rates of the two baseline measurements were very 
similar.  Yet, the end-point absorbance of baseline one was lower when 
compared to that of baseline two.  The network fibrin content at 
baseline two was slightly higher when compared to that of baseline one 
and may serve as an appropriate explanation for this phenomenon.  
The fibrin network content is a measure of the total amount of fibrin that 
is incorporated into the fibrin network. 
There were no statistically significant changes in any of the 
haemostatic risk markers from baseline one (day 1) to baseline two 
(day 8).  This indicates that the run-in phase with placebo managed to 
establish a stable baseline. 
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5.2.5 Baseline lipid variables of the entire study group 
The predictive value of abnormal blood lipids has been studied for 
decades, with the focus shifting from the initial study of total-cholesterol 
(TC) alone, to that of the constituent components of TC (Norman et al., 
2007).  In general, the dyslipidaemic patterns of concomitant high 
levels of LDL-C and low levels of HDL-C have been found to represent 
a high risk for developing CHD (NCEP, 2002).   Total cholesterol and 
LDL-C levels are directly and HDL-C levels inversely related to CHD 
(NCEP, 2002). Only subjects with healthy lipid profiles were recruited 
for this study, which included individuals with TC levels in the higher 
range of the normal (4.10 – 5.50 mmol/L).  Due to the nature of the 
study, it would be very difficult to show any metabolic response unless 
the risk marker in question is at a changeable level. 
Mollentze et al. (1995) reported mean TC levels between  
4.7  1.2 mmol/L for black men in the age range 25-34 years, living in 
Mangaung, Free State Province.  The authors also reported a 
concerning increased number of subjects in the moderate-risk 
hypercholesterolaemic category in this population.  Subjects in the 
younger age groups had a higher prevalence of hypercholesterolaemia.  
This could possibly reflect the more powerful impact of urbanisation on 
the younger generation.  Younger people may adopt a westernised diet 
to a greater extent than their elders (Mollentze et al., 1995).  Most of 
the subjects of the current study originally come from a urban aea, 
Mangaung.  Total cholesterol on its own is not an accurate predictor of 
cardiovascular events, and should be evaluated together with the three 
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other main serum-lipid fractions; namely High-Density Lipoprotein 
Cholesterol (HDL-C); Low-Density Lipoprotein Cholesterol (LDL-C) and 
Triglcerides (TG).  The measured concentrations of these combined 
fractions predicted that the individuals used for this study were not at 
immediate high riks of cardiovascular events.    The baseline serum-
TC, -TG, -HDL-C & -LDL-C measured in this study are all comparable 
to those reported by James et al. (2000), Oelofse et al. (1996) and 
Seedat et al. (1992). 
The measured HDL-C level of the group is high, when expressed as a 
percentage of the TC. Seftel, Raal & Joffe (1995) mentioned that 
almost all blacks have HDL-C levels above 20% of the TC, indicative of 
a protective effect against IHD.  Oosthuizen et al. (2002) confirms that 
black Africans tend to have fasting lipid profiles that are less 
atherogenic when compared to that of the white population group, with 
lower TC and LDL-C levels and higher HDL-C concentrations. 
However, in comparison with the HDL-C, concomitant high LDL-C 
levels (up to 54% of the TC) were measured.  In general, this is very 
common within the specific target group.  According to Packard (2006) 
increased LDL-C levels appear to be a primary CHD risk factor. Even 
though the HDL-C level of our study group is high, it is also suggested 
that the high LDL-C levels put them at risk of future CHD events. The 
fasting baseline TG levels of the group fell below the high-risk cut-off 
level of 1.7 mmol/L (NCEP, 2002). Consequently, at first glance, the 
lipid profiles seem healthy.  
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No statistically significant changes were measured in any of the lipid 
variables from baseline one (day 1) to baseline two (day 8) of the study 
for the entire study group. 
5.2.6 Glycometabolic indicators of the entire study group 
Measures of obesity, hypertension, dyslipidaemia, and hyperglycaemia, 
together form what is known as the metabolic syndrome (MS), a well-
recognised constellation of risk factors for type 2 diabetes mellitus and 
CVD in adults (NCEP, 2002). None of these clinical manifestations are 
expected to be present in the study group, as they formed part of the 
exclusion criteria (see section 3.6.1). 
Furthermore, it is also suggested that the high level of physical activity, 
age and absence of obesity may further benefit glycometabolic control 
of the subjects used in this study.  Neither did the actual fasting serum-
glucose and -insulin levels of the entire study group reflect the 
presence of any apparent glycometabolic disorders.  In general, 
glucose of healthy individuals are below 5.6 mmol/L (ADA, 2008). With 
a fasting mean of 5.32 ± 0.83 mmol/L at baseline one, and 5.47 ± 0.88 
mmol/L at baseline two, for serum-glucose levels, the study group 
seems to have an apparently healthy glycometabolic state. In addition, 
insulin levels of healthy individuals should vary between 0-17 IU/mL, 
depending on the time of day and the state of fasting (Painter et al., 
1999). 
No significant changes were measured in any of the glycometabolic 
indicators from baseline one (day 1) to baseline two (day 8) of the 
entire study group. 
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5.3 INTERVENTION STUDY 
 
Attention will now be given to the results of the intervention study and 
the individual supplements. Attention will mainly be given to the 
changes in metabolic profiles that occured between day 8 (start of 
experimental SCFA supplementation) and day 36 (end of experimental 
SCFA supplementation).  
Studies show that the clinical effects of SCFA administration may be 
influenced by the method of administration (oral, rectal or intravenous) 
(Wolever et al. 1995).  The capsules used for this study were coated 
with a thin layer of complex edible polymer, which prevented the acidity 
of the stomach from dissolving the capsules. The capsules were 
designed to release their contents only in the small gut. This ensured 
that maximum distribution of the supplements took place within the 
colon, resembling the SCFA distribution that takes place after dietary 
fibre fermentation.   
5.3.1 The Placebo Supplement Study group 
This group consumed placebo supplements for the entire period of the 
study. 
5.3.1.1 Anthropometric and general health changes of the placebo 
supplement study group 
No statistically significant changes in any of the anthropometric and 
general health indicators within the placebo group were measured 
during the study.  It was not expected that the placebo supplement 
should cause any changes to the anthropometric and general health 
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indicators of this group.  It is interesting to note that the plasma CRP 
concentration of day 8 was higher when compared to that of any of 
the other visits, even though not statistically significant. The change 
was of no clinical significance. 
5.3.1.2 The haemostatic profiles of the placebo supplement study group 
A statistically significant decrease was measured in the plasma 
fibrinogen concentration, for the period from day 8 to day 36. Yet, the 
change seems to be of no clinical significance. No statistically 
significant change were measured in any of the other haemostatic 
variables, between any of the study intervals.  
Fibrin network lysis rate of day 1, 8, 36 and 43 showed the same 
pattern and similar lysis rates, with only day 22 that reached a lower 
end-point absorbance.  It is important to note that the network fibrin 
content of day 22 was lower when compared to all the other visits, 
which could explain the difference in network lysis rate.  Most 
importantly, there were no significant changes observed between any 
of the haemostatic risk markers measured on day 8 and 36. 
5.3.1.3 The lipid profiles of the placebo supplement study group 
No significant changes were measured in any of the lipid variables of 
the placebo group from baseline to the end of the experimental phase. 
5.3.1.4 The glycometabolic indicators of the placebo supplement study group 
 No significant differences in any of the glycometabolic parameters of 
the placebo group were measured during the intervention period. 
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5.3.2 The Acetate/Propionate (50/50) Supplement Group 
This study group was supplemented with placebo from day 1 to day 8, 
followed by supplementation with acetate-propionate (in the ratio of 
50% to 50%) up to day 36, after which an additional one week 
supplementation with placebo followed. 
5.3.2.1 Changes in anthropometric and general health indicators of the 
acetate-propionate (50/50) supplement study group 
No significant changes were observed in any of the anthropometric 
and general health indicators of the acetate/propionate (50/50) 
supplemented group over the duration of the study. 
5.3.2.2 The haemostatic profiles of the acetate-propionate (50/50) 
supplement study group 
A statistically significant decrease in factor VII activity, antithrombin III 
and an associated increase in the plasma fibrinogen concentration 
were measured within this group from baseline to the end of 
supplementation (day 8 and day 36).  This group also showed a slight 
non-significant decrease in fibrin monomers.    Yet, even though of 
statistical significance, the changes were clinically insignificant. No 
statistically significant changes in any of the other haemostatic 
variables were measured.   
In general, a decrease in factor VII activity is beneficial, because 
some studies have suggested that a low factor VII activity is 
associated with an increased risk of CHD (Meade et al., 1980; Vorster 
et al., 1988; Buzzard et al., 1996).  The small decrease in AT III and 
increase in plasma fibrinogen concentration could render the blood 
 129 
more coagulable and the individual at higher risk of development of 
cardiovascular complications.   
No significant changes were measured in any of the fibrin network 
architecture variables, as reported by Veldman et al. (1999).  Yet, in 
the current study, the amount of acetate in the supplements were 
significantly less. In addition, Veldman et al. (1999) did not employ 
propionate in their supplements. 
The network lysis rates of day 8, 22, and 36 showed similar rates of 
lysis. 
5.3.2.3 The lipid profiles of the acetate-propionate (50/50) supplement study 
group 
A combination of acetate and propionate salts resulted in a significant 
increase in HDL-C from baseline two (day 8) to the end of the 
supplementation phase (day 36).  LDL-C showed a marginal decrease 
during the supplemental phase.  Todesco et al. (1991) reported that 
when sodium propionate is administered orally to healthy subjects, the 
LDL-C and HDL-C levels decreased without any effect on the TC 
concentration.  In a study performed by Venter, Vorster & Cummings 
(1989) a sodium propionate supplement also increased circulating 
HDL-C in human subjects.  Previous rectal infusion studies performed 
by Wolever et al. (1995) showed that colonic acetate was incorporated 
into TC and TG, and acutely raised the concentrations of serum lipids, 
and that these effects are blocked by propionate.   
NEFA concentration in this group also decreased significantly during 
supplementation.  As explained earlier, a decrease in NEFA levels is 
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associated with an increase in SCFA concentration and therefore  
serves as an indication that the SCFAs within the supplements were 
absorbed and had reached the peripheral circulation (Crouse et al., 
1968; Scheppach et al., 1988, Veldman et al., 1999). 
5.3.2.4 The glycometabolic indicators of the acetate-propionate (50/50) 
supplement group 
A significant decrease in the fasting serum-glucose levels, with no 
change in the serum-insulin concentrations was measured from 
baseline to end of supplementation with a mixture of acetate-
propionate (50/50).  Berggren et al. (1996) also reported that when 
propionate was fed orally to hyperinsulinaemic rats, that the fasting 
plasma glucose levels decreased markedly, with no effects on the 
fasting insulin levels. Venter, Vorster & Cummings (1990) reported 
similar results for human subjects. 
The U.S. Department of Agriculture (USDA) recommends dietary 
fibre intake of 14g fibre per 1000 kcal to reduce the risk of type 2 
diabetes mellitus.  It is suggested that the blood glucose lowering 
effect of soluble dietary fibres may be related, in part, to the metabolic 
effects of SCFAs generated during their fermentation (Thacker et al., 
1981).  However, the physical characteristics of the fibre itself, also 
play a role and should not be neglected. 
Akanji & Sacks (1991) demonstrated a rise in blood acetate levels 
and an associated decrease in the fasting serum-glucose levels of 
diabetic patients after a high-fibre diet.  It is suggested that acetate 
could reduce blood glucose levels in the long-term by reducing the 
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non-esterified fatty acid concentrations (Crouse et al., 1968), but 
propionate may have exactly the opposite effect. Propionate is an 
important gluconeogenic substrate in ruminants and horses (Judson 
et al., 1968).  Yet, Venter, Vorster & Cummings (1989) reported that a 
propionate supplement significantly decreased the fasting glucose 
levels as well as the maximum insulin increments during glucose 
tolerance tests.  These authors conclude that the beneficial effects of 
dietary fibre may at least be partially mediated by propionate and its 
effect on hepatic carbohydrate metabolism.  
 
5.3.3 The High Acetate Supplement Study Group Results 
This study group was supplemented with placebo from day 1 to day 8, 
followed by supplementation with acetate-propionate (in the ratio of 
70% acetate, 15% propionate and 15% butyrate) up to day 36, after 
which an additional one-week supplementation with placebo followed. 
5.3.3.1 Anthropometric and general health indicators of the high acetate 
supplement study group 
No significant differences in any of the anthropometric and general 
health indicators of the high acetate supplemented study group were 
measured, between any of the sampling intervals.  
5.3.3.2 Haemostatic profiles of the high acetate supplement study group 
A beneficial decrease in factor VII activity, factor VIII activity, ATIII, 
compaction and fibrin monomer concentration were measured during 
the experimental period (day 8 to 36).   The decrease in factor VII and 
factor VIII activity may affect the CVD risk profile positively, while a 
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decrease in ATIII is unknown, compaction‘s decrease affects the risk 
profile negatively. 
Highly compact networks have a high degree of cross-linking.  A more 
compact the network would have a high degree of cross-linking, this 
will not allow easy access for fibrinolytic enzymes (Nair & Shats, 
1997; Blombäck et al., 1992). A high degree of cross-linking renders 
the clot more rigid and less lysable. It is believed that these structures 
are more atherogenic in nature, when compared to the soft, less rigid 
networks (Collet et al., 2000). The clinical significance of these 
changes is difficult to interpret, since not all changes are in the same 
direction. Yet, it is evident that the supplement had little or no effect 
on the overall structure of the fibrin networks.  In contrast with the 
results from this study, De Wet (2000) and Veldman et al. (1999) 
reported beneficial changes in fibrin network structure after SCFA 
supplementation. It is important to note that the supplement of this 
study is a different combination of SCFAs than used by De Wet 
(2000) and pectin used by Veldman et al. (1999).   
Network lysis rate of all the visits showed a similar rate of lysis with no 
statistically significant changes amongst them.  The change in 
compaction was small and therefore was not reflected in the network 
lysis rate. 
The significant results within haemostatic variables of this group 
receiving a higher percentage of acetate, less propionate and added 
butyrate are difficult to interpret. Some changes were beneficial (such 
as the decrease in the circulating Fibrin Monomer levels), and others 
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less beneficial (such as the decrease in the fibrin network 
compaction).   After supplementation with SCFAs (65% acetate, 19% 
propionate and 16% butyrate) De Wet (2000) also reported a 
decrease in factor VII and VIII activity, and Fibrin Monomer 
concentration.  However, the higher acetate group in the present 
study showed more changes in the haemostatic variables when 
compared to that of the acetate-propionate supplement group.  
5.3.3.3 Lipid profiles of the high acetate supplement study group 
The SCFA combination of acetate, propionate and butyrate 
significantly decreased serum LDL-C levels with 16% during the four-
week supplementation.  The TC levels also decreased slightly in this 
group.  However, this decrease of TC levels was a small non-
significant change and it may be due to the decrease in LDL-C levels.  
Added to the beneficial decrease of LDL-C levels , this group also had 
a significant increase in % HDL-C levels.   
The dyslipidaedemic patterns of high levels of LDL-C associated with 
or without low levels of HDL-C, have been found to impart high risk for 
developing IHD (NCEP, 2002).   The CDC (2001) estimated that a 
10% reduction in serum-TC decreased CHD incidence by at least 
30%.  The approximately 8% decrease in serum-TC levels seen in this 
group could therefore, although of no significance, and together with 
the significant decrease of LDL-C and increase in %HDL-C levels as 
beneficial in decreasing the risk of CHD.   
The specific effect of acetate intake on cholesterol metabolism is 
controversial.  Wolever et al. (1989) suggest that acetate may reduce 
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cholesterol synthesis by reducing the circulating free fatty acid (NEFA) 
concentration.  In this study group, circulating NEFA concentrations 
decreased significantly.  In general, a decrease in NEFA levels is 
associated with an increase in circulating blood short-chain fatty acid 
concentrations and often used as a confirmation that a given oral 
SCFAs supplement was absorbed successfully (Scheppach et al., 
1988; Akanji & Sacks, 1991).  
Previous studies performed on humans and animals have shown a 
definite relation between propionate and acetate and cholesterol 
metabolism. It is known that both acetate and propionate influence 
cholesterol synthesis (Chen, Anderson & Jennings, 1984; Nishina & 
Freeland, 1990; Wright, Anderson & Bridges, 1990).   
Several studies reported that consumption of propionate could reduce 
serum cholesterol in both animal and human models (Thacker et al., 
1981; Illman et al., 1988; Stephan, 1994).  Yet, Venter, Vorster & 
Cummings (1990) showed that dietary supplementation with 
propionate increased the serum HDL-C concentrations in baboons, 
whereas no effects were observed on TC concentrations. 
However, the collective metabolic effect of a combination of acetate 
and propionate is not well documented and requires further research.  
Very little information is available on the effect of butyrate on 
cholesterol metabolism in human subjects (Topping & Pant, 1995). 
5.3.3.4 Glycometabolic profiles of the high acetate supplement study group 
The combination of acetate, propionate and butyrate caused a 
beneficial and statistically significant decrease in the serum-glucose 
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levels of the study group.  A concomitant significant decrease in the 
circulating insulin levels was also measured.  This change indicates 
that the body requires less insulin to keep the glucose levels in 
circulation at a constant concentration.  Limited data is available on 
the effect of a combination of acetate, propionate and butyrate on 
glucose metabolism.  De Wet (2000) also found that when taken orally 
a combination of acetate, propionate and butyrate orally that glucose 
levels decrease significantly.  Although other authors (Anderson & 
Bridges, 1984; Jenkins et al., 1990) found that SCFA might influence 
glucose levels, Alamowitch et al. (1996) reported that acute ileal 
perfusion of a combination of acetate, propionate and butyrate did not 
significantly reduce serum-glucose levels in human subjects.   Yet, 
when propionate was consumed with bread, postprandial blood 
glucose and insulin responses were significantly reduced in healthy 
subjects (Todesco et al., 1991; Liljeberg, Lonner & Bjorck, 1995).   
 
5.4 COLLECTIVE DISCUSSION 
 
It is well known that the consumption of dietary fibre may introduce 
metabolic changes that reduce the risk of cardiovascular disease 
(Anderson & Hanna, 1999; Krummel, 2008). It is proposed that the 
SCFAs (acetate, propionate and butyrate), produced from colonic 
fermentation of dietary fibre, may at least in part, be responsible for 
these changes (Anderson & Bridges, 1984; Wright, Anderson & 
Bridges, 1990; Krummel, 2008).  Results from the present study 
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confirm the findings that SCFAs may influence risk factors for 
cardiovascular disease.  However, the findings from this study indicate 
that there was a definite and clear difference in response to the 
different SCFA mixtures. For this study, one of the supplements 
contained a mixture of acetate (70%), propionate (15%) and butyrate 
(15%) and the other supplement contained a mixture of acetate (50%) 
and propionate (50%) only. In order to explain these differences, it was 
necessary to focus on the different contents of the two experimental 
supplements.  Only those differences that are of clinical significance 
will be discussed. 
It is important to mention that literature available on the long-term effect 
of short-chain fatty acids is limited.  It should also be noted that most 
other studies applied either rectal infusions or intravenous injections of 
SCFAs, which differ from the encapsulated supplements used in this 
study.  It is widely reported in the literature that a definite difference 
exists in response to the different routes of administration when 
supplementing humans with combinations of SCFAs (Wolever, et al., 
1995). 
Both experimental groups experienced statistically significant changes 
in their haemostatic risk profiles, from the beginning to the end of the 
study. In both groups, factor VII activity and the ATIII concentration 
decreased significantly, while in the high acetate group a decrease was 
also measured in the factor VIII activity and fibrin monomer 
concentration.  Although the high acetate group showed little or no 
effect on the overall structure of the fibrin networks, some other 
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beneficial changes, such as a decrease in the circulating fibrin 
monomer concentration, were measured.  In contrast, authors such as 
Veldman et al. (1999) reported beneficial effects after oral acetate 
supplementation.  De Wet (2000) also reported that supplementation 
with SCFAs (65% acetate, 19% propionate and 16% butyrate) caused 
a significant beneficial decrease in both the fibrin monomer 
concentration and factor VII activity.  In all the above instances, SCFA 
supplements were given to human subjects to investigate the possibility 
that some of the beneficial effects associated with the intake of dietary 
fibre, may at least in part, be mediated by the production of SCFAs in 
the large gut. It is very important to realize that not all dietary fibres 
result in the production of the same combination of SFCAs. 
The supplement in this study is of a unique combination of SCFAs and 
cannot be compared to the supplements used by other authors, such 
as Veldman et al. (1999).  Yet, the beneficial haemostatic changes 
observed in the high acetate supplement group, agrees with the results 
from another study by De Wet (2000), where exactly the same SCFAs 
were used in a different ratio.  Although no other studies are available 
to support this finding, it is suggested that the presence of butyrate in 
the high-acetate supplement may also evoke a response on the 
haemostatic risk profiles. The addition of butyrate to SCFA 
supplements requires further investigation. 
The present study confirms the favourable and independent effect of 
the oral consumption of different combinations of SCFAs on lipid 
profiles.  The work of Cummings & Macfairlane (1991) support these 
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results.  The precise metabolic mechanism of the action of SCFAs in 
reducing plasma cholesterol concentrations is unknown (Wolever et al., 
1995).   Yet, it is also known that the physical structure of the fibre itself 
may exert certain physiological changes that reflect in the chemical 
composition of blood, such as its beneficial effect on the total 
cholesterol content.  All of the subjects in this study were 
normolipidaemic.  The acetate-propionate (50/50) supplement had a 
small albeit favourable, effect on the lipid profiles of the group. Yet, it 
seems as if the high-acetate group, with the addition of butyrate, had 
an even more favourable effect on lipid metabolism, when compared to 
that of the acetate-propionate (50/50) supplement.  This suggests that 
either increased acetate production relative to propionate production, or 
reduced propionate production relative to acetate production, may 
directly affect cholesterol production (Wolever et al., 1995). The 
concomitant decrease in TC concentration and increase in the %HDL-
C in the high-acetate group are in congruence with a study performed 
by Veldman et al. (1999) during which acetate supplementation alone 
caused a significant increase in %HDL-C, as well as a statistically 
significant decrease in the serum-TC concentration.  A study performed 
by Venter, Vorster & Cummings, (1990) supports our findings in the 
acetate/propionate group where the supplementation resulted in 
increased HDL-C levels.  Venter, Vorster & Cummings (1990) also 
reported an increase in the HDL-C concentration after oral 
administration of propionate for seven weeks.  
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In this study, both the acetate-propionate (50/50) and the high-acetate 
supplement resulted in favourable changes to the glycometabolic 
indicators.  Glucose levels decreased in both groups, while the serum-
insulin levels did not change in the acetate-propionate group, but did 
decrease in the high-acetate supplement group.  De Wet (2000) also 
reported a decrease in the serum-glucose concentrations of 
westernised black men, after four weeks of supplementation with a 
combination of acetate, propionate and butyrate.  Available information 
also suggests long-term metabolic effects in humans, and dietary 
supplementation with propionate for 7 weeks decreased fasting serum-
glucose and reduced maximum insulin increments during a subsequent 
oral glucose tolerance test (Venter, Vorster & Cummings, 1990). 
Considering the results from the present study, it is important to 
acknowledge that the study group was of a healthy nature, with no 
apparent clinical manifestations of cardiovascular disease.  Previous 
studies by Molentze et al. (1995) and Slabber et al. (1997) 
demonstrated a trend towards the adoption of a westernised diet 
amongst this population group in the Free State Province. Although the 
subjects from this study were physically healthy, active and 
normolipidaemic, adoption of a westernised lifestyle would increase 
their risk for the development of cardiovascular disease.  The current 
study provides evidence to show that improvements in the haemostatic, 
lipid and glycometabolic risk profiles are possible, and that it would be 
to their own benefit to sustain such a healthy lifestyle, which could be 
improved even further by the intake of SCFA supplements.  
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It is well documented that dietary fibre plays a protective role against 
the development of CHD. It is suggested that one possible mechanism 
through which the intake of dietary fibre benefits health, is based on the 
metabolic effect of the SCFAs produced during fermentation in the 
colon (Krummel, 2008).  From the results presented in the present 
study it is clear that different combinations of SCFAs may evoke 
different metabolic responses.  From this study, it seems highly likely 
that the intake of a combination of acetate, propionate and butyrate 
induces metabolic changes that are more beneficial when compared to 
that of a supplement that contains only acetate and propionate.  This 
effct may also be a consequence of the higer acetate alone.  The 
acetate/propionate/butyrate supplement induced a significant and 
beneficial decrease in the factor VII and VIII activity, ATIII and fibrin 
monomer concentration, LDL-C concentration, as well as the serum-
glucose and -insulin levels.  Added to these beneficial effects the 
%HDL-C also increased significantly.  The acetate/propionate 
supplement induced only beneficial effects on the factor VII activity, 
ATIII concentration, as well as HDL-C and serum-glucose levels. It is 
possible that both the addition of butyrate and higher acetate content to 
this supplement may collectively alter the physiological response, but it 
cannot be said with certainty.  De Wet (2000) showed similar overall 
results with a SCFA supplement that also contained a higher 
percentage of acetate, as well as butyrate. SCFAs produced during 
fermentation do not exist in isolation, and the proportion of acetate 
produced is always greater when compared to that of propionate 
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(Mortensen, Holtug, Rasmussen, 1988).  The production of butyrate 
during the fermentation of dietary fibre may then also have additional 
beneficial metabolic effects, even though studies suggest that butyrate 
has only a limited metabolic importance.  Wolever et al. (1996) reported 
that there was no definite relationship between butyrate and lipid 
production in the fasting state. 
It is concluded that the results from this study show that 
supplementation with different combinations of SCFAs affect human 
metabolism, and more specific, the metabolism of those markers that 
are generally associated with the development of cardiovascular 
disease, even though it is clear that the changes are small. Yet, it is 
important to acknowledge that within a clinical environment we 
investigate each marker separately, but that in reality the 
cardiovascular risk depends on the collective risk all these markers.  It 
is evident though that the specific combination (and respective ratios) 
in which these SCFAs as a supplement were used, plays a significant 
role in the way it affects human metabolism. It therefore becomes clear 
that it is not only the presence of a single one of the SCFAs that 
mediate the overall metabolic effects of dietary fibre on human 
metabolism, but rather the ratio in which they occur relative to each 
other, that collectively affect human metabolism. 
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5.5 LIMITATIONS OF THE STUDY 
 
The healthy nature of the study population made it very difficult to show 
any improvements in those metabolic risk markers that we generally 
associate with CHD.  It is unknown whether the metabolic effect of the 
supplements would be different in those that do suffer from a raised 
risk for the development of CHD.  In addition, the long-term effects of 
SCFAs on the risk factors associated with CHD may differ from the 
short-term effects.  Even though a four-week trial is considered long-
term, when compared relative to acute effects, it is not sure whether 
the short-chain fatty acids may indice effects that are only metabolically 
visible after a much longer time of intervention.  
 
In the following chapter 6, the author provides a conclusion, based on 
the findings of this study. 
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CHAPTER 6 
 
CONCLUSION 
 
6.1 INTRODUCTION 
 
Urbanisation is accompanied by a rise in the rate of CHD and stroke.  
Mortality rates from CVD indicate that in urban black South Africans, stroke 
represents the highest mortality rate (Vorster, 2002).  This epidemiological 
trend goes hand in hand with changes in lifestyle, especially an increase in 
consumption of processed, energy-dense food, which are high in saturated fat 
and low in fibre, and a concomitant decrease in physical activity. CHD and 
stroke are degenerative western diseases, which in most cases can be 
prevented by a change in lifestyle. Abundant data since World War II shows 
how dietary intervention can significantly reduce the risk of CHD and stroke. 
Especially a prudent low-fat, high fibre diet plays an important role in the 
prevention of CHD.  It is postulated that dietary fibre plays a central role within 
the mechanism, but the exact action is unknown. It is suggested that the 
production of SCFAs as a result of fibre digestion in the large gut, may 
mediate some of the beneficial effects associated with fibre intake. Dietary 
fibre is fermented in the large gut to the short-chain fatty acids acetate, 
propionate and butyrate. These SCFA are absorbed and enter the hepatic 
blood circulation, where it is finally metabolised in the liver. A small 
percentage of these acids may reach the peripheral circulation. In the liver, 
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acetate, propionate and butyrate are used as a source for many different 
metabolic pathways, such as that of cholesterol production. 
The aim of this study was to test the possible metabolic effects associated 
with the intake of different combinations of SCFAs on haemostatic and other 
metabolic risk markers associated with the development of CHD in 
westernised African men. A group of westernised African male volunteers 
were recruited and supplementedwith two different combinations of short-
chain fatty acids, as well as a placebo for an experimental  period of six 
weeks, with an additional one week placebo supplementation before and after 
this period.  Blood was drawn at different intervals and analysed to assess 
metabolic changes induced by the different supplements.  Focus was mainly 
on the differences between start of supplementation (day 8) and end of 
supplementation (day 36). The conclusion of the baseline results of the entire 
study group will be presented first, followed by the intervention study results, 
where the conclusion of the different study groups will be presented. The 
chapter will be concluded with recommendations. 
 
6.2 BASELINE CHARACTERISTICS OF THE ENTIRE STUDY GROUP 
 
The characteristics of this group of subjects reflect a group of apparently 
healthy individuals without any current metabolic abnormalities. This could be 
ascribed to the strict inclusion criteria adhered to during the recruitment of 
subjects.  The anthropometrical measurements reflect that this group of 
subjects were physically healthy.  Both the blood pressure, lipid profile and full 
blood count measurements support this finding.  
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The more specific haemostatic profiles were also within the normal reference 
ranges for the specific subject group.  In addition, the lipid profile of this group 
reflected that of a normolipidaemic group with a slight change to the 
westernised lipid profile, though not pronounced. 
It is therefore safe to conclude that the overall characteristics of this study 
group reflect that of an assumingly healthy population. Yet, this by no means 
implies that they could not benefit from intervention, or that it is impossible to 
show the benefit of such intervention on their risk of developing CHD in the  
future. 
There were no significant changes, statistical or clinical, observed between 
the two baselines measurements during which all subjects consumed placebo 
supplements. The placebo supplement therefore, was successful in 
establishing a stable baseline. 
 
6.3  INTERVENTION STUDY 
 
6.3.1 The Placebo Supplement Study group 
No significant changes occurred in any of the measured variables of 
this group of subjects, apart from a significant decrease in the plasma 
fibrinogen levels from baseline two (Day 8) to the end of experimental 
supplementation (Day 36). Yet, this decrease is of no clinical 
significance. Plasma fibrinogen levels of Day 1 and 36 were almost 
identical and remained so for the duration of the study. 
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6.3.2 The Acetate-Propionate (50/50) Supplement Study Group 
This group received a supplement containing a mixture of acetate and 
propionate in a ratio of 50% acetate and 50% propionate.  As expected 
the general health indicators, which were only used as a measure of 
general health, were not affected by the supplements. As for the 
haemostatic variables a beneficial decrease in the factor VIII activity 
was measured, with a concomitant increase in the fibrinogen 
concentration, perceived as a detrimental change. Though statistically 
significant, these changes were so small that they are of no clinical 
significance.   
The supplement had no effect on the fibrin network architecture.  The 
acetate-propionate supplement induced a slight non-significant 
decrease in LDL-C combined with a statistically significant increase in 
HDL-C.   
The supplement showed benefit in terms of glycometabolic control of 
the subjects, with a statistically significant decrease in the blood 
glucose levels of the study group, from Day 8 to 36. 
 
6.3.3 The High Acetate Supplement Study Group 
This supplement contained a mixture of acetate, propionate and 
butyrate in a ratio of 70% acetate, 15% propionate and 15% butyrate.  
As with the acetate-propionate supplement group, the general health 
indicators were not affected by the supplement. A statistically 
significant decrease in the factor VII and VIII activity and fibrin 
monomer concentration lower the individual risk of developing CHD. 
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The concomitant small decrease in fibrin network compaction is 
believed to be of no clinical significance. In addition, it is uncertain what 
the exact clinical value of fibrin network compaction is, due to a lack of 
both evidence and research in this regard. The high-acetate 
supplement induced a beneficial, significant decrease in the LDL-C 
concentration and significant increase in %HDL-C.  The combination of 
acetate, propionate and butyrate  caused  a  statistically significant    
decrease in serum-glucose levels, with a concomitant significant 
decrease in the circulating insulin levels.     
 
 
6.3.4 Conclusion  
It is evident from this study that the intake SCFAs exert some metabolic 
effects on those risk markers that we associate with the development of 
CHD. It is believed that these same acids, as a by-product of microbial 
fermentation of dietary fibre in the large gut, does contribute, in part, to 
the metabolic changes associated with the intake of dietary fibre.  Yet, 
results from this study could not confirm this, even though small 
metabolic changes were induced as a result of the different SCFA 
supplements. However, what this study does show is that the metabolic 
effects of SCFAs depend on the specific combination of SCFAs, which 
could also be the reason why different types of fibre induce different 
metabolic responses.  Fermentation of dietary fibre in the large gut 
produces SCFAs of a specific quantity, but the ratios in which the 
different acids are produced are not the same for all fibres.  It is very 
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important to acknowledge that the use of SCFA supplements should, 
based on the results of this study, not replace the intake of dietary fibre, 
as the physical characteristics of any dietary fibre also exert an 
additional effect independent of that of its metabolic by-products, which 
is lost when giving short-chain fatty acid supplements. At this stage it 
seems highly likely that the physical characteristics contribute 
significantly towards its metabolic effects.   
In terms of the original hypothesis of this study, it is concluded that the 
addition of propionate and butyrate in different quantities to colonic 
release acetate supplements significantly alters the effect of the 
supplement on haemostatic, lipid and glycomatebolic profiles of 
westernised African men. It is therefore suggested from this study that 
the ratio in which short-chain fatty acids are produced, as a result of 
microbial fermentation in the large gut, could partially explain why not 
all dietary fibres exert exactly the same metabolic response in human 
subjects, and requires further investigation. 
 
6.4 RECOMMENDATIONS 
 
6.4.1 General recommendations 
This study show that the long-term intake of two specific combinations 
of SCFA supplements exert metabolic effects that can be measured in 
the lipid, carbohydrate and haemostatic profiles of human subjects.  
Yet, it is very important to acknowledge that the use of SCFA 
supplements should not be promoted as a replacement for fibre in the 
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diet. The physical characteristics of any dietary fibre also exert an 
effect over and above that of its metabolic SCFA by-products.  People 
should therefore, primarily be educated to eat fruit and vegetables, 
oats, legumes, psyllium seeds and other foods high in fibre to 
experience the full benefit from the products just mentioned. An 
increased intake of fruit, vegetables and high fibre foods provide 
additional benefits to health, such as micronutrients, which also include 
antioxidant vitamins and minerals. Migration from a rural to urban 
environment is associated with a change in lifestyle that includes the 
adoption of westernised eating habits. In addition, over nutrition 
becomes the burden of an affluent lifestyle. In contrast to a prudent 
diet, the westernised diet provides little protection against those 
diseases that are associated, in general, with lifestyle: obesity, insulin 
resistance, hypercholesterolaemia, hypertension, etc. Several studies 
report that urbanisation is associated with metabolic profiles, which are 
believed to promote the development of CHD and CVD. Diet stays the 
sure way to counteract these changes. Public health intervention 
should therefore, address these issues by means of appropriate health 
education interventionprograms. 
6.4.2 Further research 
Results from this study show that the intake of SCFAs exerts a 
metabolic effect that can alter the level of those markers that are used 
to predict the risk for development of CHD. In general, lifestyle 
influences the development of CHD. Raised CHD risk associated with 
the Metabolic Syndrome, a by-product of our modern lifestyle, 
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constitutes a growing problem worldwide.  In this study, the study 
population was apparently healthy. Clinical trials are required to 
investigate the possible additional beneficial effects, if any, of SCFA 
supplementation on subjects diagnosed with the Metabolic Syndrome 
(abdominal obesity, dyslipidaemia, hypertension, insulin resistance or 
glucose intolerance, etc.). 
It s clear from this study that different combinations of SCFAs exerts 
different metabolic effects in human subjects. Additional research is 
therefore required to establish the appropriate ratio in which these 
SCFAs should be present in any given supplement. It is suggested that 
the supplement that contained a ratio of acetate, propionate and 
butyrate, similar to the ratio of SCFAs produced during natural 
fermentation of fibre in the large gut, benefits health more so than an 
acetate- and propionate-containing supplement.  Furthermore, previous 
studies also showed how the route or method of administration might 
influence the metabolic outcome of SCFA supplementation. The route 
or method of administration determines the location of the gastro-
intestinal tract where absorption will take place, which in turn, 
determines the site where these acids are metabolised. SCFAs 
released in the colon enter the hepatic circulation, where it can take 
part in lipid and carbohydrate metabolism in the liver. Intravenous 
injections of SCFAs reach the cells of the periphery, where it can 
partake in cellular metabolism of other body tissue. SCFAs derived 
from the microbial fermentation of dietary fibre enter the hepatic blood 
circulation via the colon. It is important to know whether the beneficial 
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effects associated with the intake of dietary fibre are related to the 
specific region of SCFA absorption. 
Before making available supplements that contain acetate, propionate 
and butyrate, it would be necessary to evaluate the degree to which the 
most appropriate combination of SCFAs can contribute to the 
prevention and onset of CHD. The results of this study open new 
possibilities that could be used to the benefit of understanding the 
relationship between food and disease and ―hopefully‖ stimulate further 
research. 
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